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Sulforaphane (SFN) is an electrophilic isothiocyanate which can adduct cysteine 
thiols within proteins. Protein targets of SFN were immunoprecipitated from 
cardiac tissue of wildtype (WT) mice following in vivo treatment with the 
electrophile using a validated polyclonal antibody developed in-house to pan-
specifically detect SFN adducted to cysteines. Combined with quantitative 
proteomics, this confirmed the non-receptor protein-tyrosine phosphatase, 
SHP2, as a target of SFN. SFN is intrinsically unstable at room temperature, 
therefore, a chemically stabilised variant developed by Evgen Pharmaceuticals 
(UK) known as Sulforadex (SFX-01), was used in subsequent experiments. 
Using a commercially available phosphatase activity assay, SFX-01 was shown 
to inhibit recombinant SHP2 in vitro, as well as that in cardiac tissue of mice 
administered SFX-01 in their drinking water for 4 days. We speculated that SFX-
01 may be therapeutic in diseases where SHP2 is hyperactive, such as Noonan 
syndrome (NS). Indeed, using an NS mouse model, Ptpn11D61G/+, a mutation 
resulting in hyperactivity of the phosphatase, SFX-01 time-dependently inhibited 
cardiac SHP2 activity. 
100 % of homozygous and ~50 % of heterozygous Ptpn11D61G/+ mice die mid-
gestation due to severe skeletal or cardiac defects, with the remaining ~50 % 
surviving to adulthood where they show non-cardiac features of NS. To assess if 
SFN-induced inhibition of SHP2 in the homozygous or heterozygous foetus could 
improve embryonic development, breeding pairs consisting of WT only or NS 
only parents were administered SFX-01 before conception and continued during 
pregnancy. SFX-01 treatment induced SFN-protein labelling of foetal tissue but 
also reduced litter sizes born from NS breeding pairs and genotyping showed 
only WT mice were born. This adverse effect may be due to SFN increasing the 
phospho-activation of ERK, which is deleterious in embryonic development of NS 
foeti. However, SFX-01 had no adverse impact on the pregnancies of WT mice. 
Adult NS mice develop splenomegaly and myeloproliferative disease which can 
further develop into leukaemia. With this in mind, adult WT or NS mice were 
administered SFX-01 for 10 weeks to assess if prolonged treatment with the drug 
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would inhibit SHP2 activity and reduce the incidence of myeloproliferative 
disease in the NS mouse model. Using whole blood cell staining, ultrasound and 
flow cytometry, lower total white blood cell count, spleen size and myeloid cell 
count in the blood, bone marrow and spleen of NS mice by SFX-01 was seen 
compared to water only controls. SHP2 activity was also attenuated in the spleen 
of both WT and NS mice, strongly suggesting this therapeutic action of SFX-01 
was mediated by inhibition of SHP2 phosphatase activity. 
Unexpectedly, even though phosphatase activity was inhibited following 4-day or 
10-week treatment with SFX-01, this occurred without evidence of an SHP2-SFN 
adduct in the tissue of WT or NS mice. Data from biochemical analyses involving 
biotinylated iodoacetamide (BIAM) labelling, the polyethylene glycol (PEG)-
switch method or phenylarsinic acid (PAA)-binding, showed that SFN induced an 
inhibitory modification within SHP2 between two vicinal thiols within the active 
domain of the phosphatase, which to reiterate was not stable SFN adducts. Data 
from complementary studies using site-directed mutagenesis of cysteines 
supported the concept that SFN adducts to SHP2 and inhibits it, which is followed 
by a proximal cysteine thiol mediating its removal or truncation, with the resulting 
modification maintaining inhibition of the phosphatase. This SFN-induced 
inhibitory modification may be the formation of an intramolecular disulfide bond 
or perhaps the chemical modification of the SFN adduct to a dithiolethione. 
Additional data has also shown that an SFN adduct can transfer from one thiol to 
another, so-called ‘trans-thiolation’. Using bovine serum albumin with an SFN 
adduct, which had been purified by large-format gel filtration on a protein 
chromatograph, transfer of the adduct to other cysteine-containing molecules 
such as haemoglobin or glutathione was observed. 
SFX-01, a stabilised SFN variant in phase 2 clinical trials, inhibits WT SHP2 as 
well as a hyperactive Ptpn11D61G/+ mutant form expressed in many patients with 
NS. Consistent with this, SFX-01 significantly corrects the myeloproliferative 
disease found in Ptpn11D61G/+ NS mice. Thus, in conclusion, SFX-01 has 
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1 General introduction   
1.1 Overview 
The following introduction provides background information to the studies 
conducted in this research project, which explored the potential for the 
electrophilic isothiocyanate (ITC) sulforaphane (SFN) to adduct and inhibit src 
homology 2 (SH2)-domain containing tyrosine phosphatase 2 (SHP2). First, an 
overview of how changes in the oxidation-reduction (redox) state of cells can 
induce a variety of oxidative post-translational modifications of protein cysteine 
thiols. How such modifications, as well as adduction of the protein by SFN, may 
impact on the structure and function of SHP2, which is also known as protein-
tyrosine phosphatase (PTP) non-receptor type 11 (Ptpn11), is then considered 
in detail. SHP2 is hyperactivated in humans with Noonan syndrome (NS), a 
disorder that presents with an array of debilitating symptoms for which there is 
an unmet therapeutic need. A transgenic mouse model of NS that was 
engineered to express a single gain-of-function mutation in SHP2, Ptpn11D61G/+, 
was studied in the context that SFN may be therapeutic by attenuating the activity 
of this phosphatase.  
1.2 Biochemistry of cysteine thiol oxidation 
Post-translational modifications, such as phosphorylation and methylation, can 
alter protein structure and function and are fundamental processes in regulating 
cellular homeostasis or in response to internal or external stimuli. More recently, 
oxidation and reduction of proteins by cellular oxidants and reductants 
respectively has been recognised as a mediator of cellular communications. 
Amino acids most susceptible to oxidation are those containing sulfur or aromatic 
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side chain groups 1. Their oxidation by reactive oxygen species (ROS), reactive 
nitrogen species (RNS) or hydrogen sulphide (H2S) allows changes in cellular 
oxidant status to be relayed into regulatory responses, which has led to these 
species being classified as signalling mediators in their own right. ROS form 
following the addition of electrons to O2. This can occur either spontaneously or 
be mediated by enzymes such as myeloperoxidase, xanthine oxidase, 
nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase, cytochrome 
p450, uncoupled nitric oxide (NO) synthase, as well as electrons formed by the 
mitochondria 2 3. The addition of a single electron to O2 generates a superoxide 
anion (O2˙-). Following the addition of a second electron, the functionally efficient 
secondary messenger H2O2 is produced. If a third electron is accepted, a highly 
reactive hydroxyl radical is formed (OH˙). The production of NO leads to the 
subsequent formation of RNS, including nitroxyl (HNO), nitrite (NO2-), dinitrogen 
trioxide (N2O3) and peroxynitrite (OONO-).  
Thiol groups (-SH) within cysteines are considered the amino acid side chain 
most vulnerable to oxidative modification. However, reaction with oxidants 
predominantly occurs when this thiol group resides in a deprotonated (loss of H+) 
thiolate state (-S-). The ability for a thiol to reside as a thiolate depends on its acid 
disassociation constant (pKa), which is defined as the pH at which the thiolate 
and thiol form of a certain cysteine is equal 4. A lower pKa value corresponds to 
increased susceptibility for the thiol to become deprotonated at cellular pH and 
therefore is considered more reactive towards oxidants. Most cellular thiols hold 
a pKa of ~8.3 and are therefore mainly in their protonated, unreactive state at a 
typical cellular pH of 7.0-7.4. The microenvironment of proteins can, however, 
alter the pKa of a thiol 5. For example, if the cysteine resides near positively 
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charged side chains of an arginine residue then electrostatic interactions 
between these amino acids will stabilise the negatively charged thiolate and help 
maintain a low pKa. Negatively charged side chains of aspartate and glutamate, 
on the other hand, will increase the pKa by destabilising the negatively-charged 
cysteine side chain 6.  
Thiolates can undergo a range of oxidative modifications as shown in figure 1.1. 
Whilst RNS can induce protein nitrosylation or nitrothiol formation, H2O2 can 
modify a thiolate to form a sulfenic acid intermediate (-SOH). If this sulfenic acid 
intermediate is not rapidly reduced, hyperoxidation can occur to generate a 
sulfinic (-SO2H) and then a sulfonic acid (-SO3H), each with increasing 
irreversibility. The modifications induced by oxidants can either evoke a signalling 
event on their own or act as an intermediate step leading to further, perhaps more 
stable alterations that mediate any associated functional alteration. For example, 
the generation of a sulfenic acid intermediate in close proximity to a vicinal thiol 
may facilitate intramolecular disulfide bond formation with the generation of H2O 
as a condensation product as shown in figure 1.2. All these considerations 
contribute to the intricate and selective signalling that can be orchestrated by 
alterations in the abundance of cellular oxidants. Oxidation of protein thiolates 
may also induce homo- or heterodimers via intermolecular disulfide bond 
formation between proteins of the same or different species respectively (figure 
1.2). Disulfide bonds can then be reduced by cellular antioxidants such as 
disulfide reductases including thioredoxin (Trx) and glutaredoxin 1 (GRX1), 
whose mechanisms of action are outlined in chapter 4 7. Dysregulation of cellular 
oxidant and antioxidant levels can result in altered protein oxidation states, which 
has been identified in a range of pathological scenarios 8–15. Understanding more 
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about these mechanisms of protein oxidation and why their alterations lead to 





























1.3 Sulforaphane   
As well as oxidants, negatively charged moieties such as cysteine thiolates can 
also react and so adduct with electrophilic compounds such as SFN, as shown 
in figure 1.3. SFN is an ITC, which are characterised by an N=C=S functional 
group. Donation of electrons by the carbon atom across the double bonds results 













1.3.1 SFN from naturally derived sources  
Whilst this research project used chemically synthesised derivatives of SFN, 
SFX-01 or L-SFN, naturally, ITCs are derived from cruciferous vegetables, such 
as broccoli, cabbage, kale and Brussels sprouts 16. ITCs themselves are not 
present within these plants but form following enzymatic cleavage of parent 
phytochemicals named glucosinolates. Chewing releases β-thioglucosidase 
myrosinase enzymes from extracellular vesicles, which are then free to hydrolyse 
the thioglucosidic bond of glucosinolates yielding glucose and thiohydroxamate-
O-sulfonate, an unstable aglycone 17. The latter then undergoes spontaneous 
rearrangement into different bioactive molecules including ITCs, thiocyanates 
and nitriles (figure 1.4) 17.  
Figure 1.3. SFN can adduct protein cysteine thiolates. 
Following electrophilic attack of the positively charged carbon within its ITC functional 














Hydrolysis of glucosinolate not only occurs in the mouth cavity but also by β-
thioglucosidase found in gut microflora 18. The abundance and occurrence of 
different glucosinolates vary between members of the cruciferous vegetable 
family and their hydrolysis products therefore also differ 19. The predominant 
glucosinolate within broccoli is glucoraphanin whose hydrolysis produces SFN 
(figure 1.5) 20. Naive broccoli sprouts are a particularly good source of 
glucoraphanin, found at concentrations 20-50-fold higher than the mature form 
of the plant 21.  
 
 
Figure 1.4. A diagram showing hydrolysis of glucosinolate and subsequent 















1.3.2 SFN metabolism   
The antioxidant tripeptide glutathione (GSH) can conjugate with free 
electrophiles such as SFN, with this adduction often the first stage of metabolism 
for such xenobiotic compounds 22. Most ingested SFN passively enters small 
intestine epithelial cells where it is adducted by GSH, which is shown in figure 
1.6. GSH-SFN then effluxes back into the lumen through the unidirectional efflux 
transporters multidrug resistance-associated protein 1 (MRP1) or P glycoprotein 
1 (Pgp1). Both function as multispecific organic anion transporters and are 
expressed and distributed ubiquitously or in the intestinal epithelium respectively 
23. A proportion of unconjugated SFN bypasses the tripeptide and passes into 
Figure 1.5. Generation of SFN by enzymatic hydrolysis of glucoraphanin. 
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the systemic circulation, where it may become conjugated to GSH or alternatively 
passively enter tissue cells 23. Once inside the cell, SFN can adduct nucleophilic 
moieties and regulate protein function, or again is liable to encounter and adduct 
with GSH that is abundant in the cytosol 23. Conjugation of SFN to GSH may 
even occur following trans-thiolation from a cysteine-containing protein, a 
concept discussed in greater detail in chapter 4. GSH-SFN is transported from 
the cell into the systemic circulation where it is metabolised sequentially by ƴ-
glutamyl-transpeptidase (GTP), cysteinyl-glycinease (CGase) and N-
acetyltransferase (NAT) to form SFN-cysteine-glycine and SFN-N-acetylcysteine 
respectively (SFN-NAC) as shown in figure 1.6, which undergo urinary excretion 



















Figure 1.6. Pathway for SFN metabolism.   
Following absorption from the small intestines into enterocytes, SFN may rapidly conjugate 
GSH which passes back to the small intestinal lumen through Pgp1 or MRP1 transporters. 
Alternatively, passive movement of free SFN into the blood may conjugate free GSH or 
continue into tissue cells. This simplified schematic shows conjugation to cellular GSH, 
which is discussed in greater detail in chapter 4, which is transported back to the blood 
through Pgp1 or MRP1 transporters. Sequential metabolism of GSH-SFN to SFN-cysteine-
glycine and SFN-NAC occurs enzymatically by GTP and CGase NAT respectively with 




1.3.3 Modulation of signalling pathways by SFN  
This introduction has outlined that SFN can adduct nucleophilic cysteine thiols. 
This interaction may alter the biological function of a protein and potentially 
regulate downstream signalling pathways. The two most studied and 
characterised cellular events which can be altered by protein adduction of SFN 
are nuclear factor-кB (NF-кB) and KEAP1/nuclear factor erythroid 2-related factor 
2 (Nrf2) signalling pathways which are detailed below.  
1.3.3.1 Modulation of the NF-кB signalling pathway by SFN 
NF-кB is a transcription factor whose adduction by lipopolysaccharides during 
chronic inflammation causes translocation into the nucleus and upregulation of 
proinflammatory enzymes including inducible NO synthase (iNOS) and 
cyclooxygenase 2 (COX2). Subsequent elevation of cellular levels of NO and 
prostaglandins respectively can lead to DNA damage through nitrosative 
deamination of DNA bases, facilitating cancer initiation and progression 25 and 
enhance proliferation and invasiveness of cancer cells as well as inhibit apoptosis 
26.  
SFN is a negative regulator of this signalling event by adducting cysteine thiols 
within NF-кB which impairs DNA binding of the transcription factor 27. Further to 
this, SFN adducts Trx and GSH which are also required for NF-кB function 27. 
Such anti-inflammatory effects of SFN can, therefore, prevent an inflammatory 
response from occurring which may prevent the progression of certain cancers.  
1.3.3.2 Modulation of the KEAP1/Nrf2 signalling pathway by SFN 
Under homeostatic conditions, KEAP1 forms a homo-dimer within the cytosol and 
is part of a protein complex with the E3 ubiquitin ligase RING-box protein 1 
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(RBX1) as well as the RBX1 scaffold protein Cullin 3 (CUL3), as shown in figure 
1.7. The function of this complex is to retain the transcription factor Nrf2 in the 
cytosol and target it for degradation, so acting as a negative regulator to prevent 
its translocation into the nucleus. Nrf2 initially interacts with KEAP1 at the 
proteins N-terminal ETGE motifs 28. Secondary interactions with a KEAP1 DLG 
motif position the transcription factor for ubiquitination by RBX1, targeting Nrf2 
for proteasomal degradation. The reaction of an oxidant at one or multiple 
cysteines within KEAP1 induces structural changes with the resultant release of 
Nrf2 from the complex 29 30. The transcription factor then stabilises and 
accumulates within the cytosol with subsequent translocation to the nucleus. Nrf2 
then binds the antioxidant response element (ARE) DNA-promoter binding region 
found in the 5’-flanking region of phase 2 and antioxidant genes, upregulating 
multiple antioxidant enzymes which act to attenuate pathological damage caused 
by ROS, RNS and electrophiles as outlined in figure 1.7. Examples of these 
enzymes include the ubiquitous disulfide reductases Trx and GRX1 whose 
mechanisms of action are outlined in chapter 4. Gamma-glutamylcysteine 
synthetase (GCS) expression is also increased, an enzyme which catalyzes the 
rate-limiting step in GSH synthesis 31. This results in increased production of 
GSH, a key player in GRX1-mediated disulfide reduction. 
It is now well established SFN adducts KEAP1 at Cys151, and modification of this 
cysteine by oxidants is shown to induce the structural change which leads to the 
release of Nrf2 from the cytosolic KEAP1/RBX1/CUL3 complex 32. Adduction of 
SFN at this cysteine induces the same structural modification (figure 1.7) and the 

















Figure 1.7. Modulation of antioxidant and xenobiotic detoxification enzymes by the 
KEAP1/Nrf2 signalling pathway.  
Nrf2 is sequestered in the cytosol via interaction with a KEAP1/RBX1/CUL3 complex. 
Upon ubiquitination by RBX1, Nrf2 is degraded following targeting to proteasomes. 
Adduction of ROS or SFN to essential cysteines upon KEAP1 drive a conformational 
change allowing release of Nrf2. Following its translocation into the nucleus, the 
transcription factor adducts ARE along with small musculoaponeurotic 
fibrosarcoma (sMAF) and CREB-binding protein/p300 (CBP/p300). This drives 
upregulation of antioxidant and xenobiotic detoxification enzymes. GST = glutathione S-
transferase. Trx1 = thioredoxin 1. UGT = UDP glucuronosyltransferase Family 1 Member 
A1. HO1 = heme oxygenase 1. GR = glucocorticoid receptor. GCS = glutamate-cysteine 
ligase. NQO1 = NAD(P)H quinone dehydrogenase 1. 
14 
 
1.3.4 Protein targets of SFN 
As outlined above, the most studied protein-SFN interactions are its adduction to 
KEAP1 or NF-кB. However, a wide range of proteomic studies have identified 
hundreds of protein targets of SFN in a variety of cell lines exposed to this 
electrophile 36–41. The reactive nature of SFN, together with is relatively simple 
structure, underlies a lack of selectively in the targets it interacts with and 
potentially covalently adducts to. Whilst Angeloni et al have documented cardiac 
protein targets of SFN following treatment of isolated neonatal Wistar rat 
cardiomyocytes in vitro 42, in vivo targets after oral consumption of SFN are 
largely unknown.  
This issue was addressed using quantitative mass spectrometry (MS) conducted 
by Dr Ewald Schroder from our research group. This proteomic analysis was 
carried out following immunoprecipitation of SFN-adducted proteins from cardiac 
tissue of mice using a polyclonal rabbit antibody developed in our laboratory 
which detects SFN adducted to protein cysteines. This methodology, therefore, 
allowed identification of proteins containing a reactive cysteine which may be 
altered or functionally important in adaptive mechanisms that occur during 
pathological conditions, whereby adduction by SFN regulates their activity. The 
analysis of biological replicates of wildtype (WT) mice orally gavaged with SFN, 
which were statistically compared to untreated controls, showed 40 significant 
cardiac protein targets of the electrophile under the conditions tested, which are 
shown in table 1.1. Notably, a high proportion of the targets identified were 
mitochondrial proteins. If SFN were to adduct and inhibit these proteins, perhaps 
the transport of pyruvate into the mitochondria or its subsequent conversion 
inside the organelle may be altered. Investigated changes in metabolites and 
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ROS production following treatment with SFN may therefore warrant further 
investigation.   
Nevertheless, another significant protein target of SFN in cardiac tissue was 
Ptpn11, commonly named SHP2, which is highlighted in red in table 1.1. The 



















Protein name Abbreviation 
2-oxoglutarate dehydrogenase, mitochondrial ODO1_MOUSE 
3-ketoacyl-CoA thiolase, mitochondrial THIM_MOUSE 
Acetyl-CoA acetyltransferase, mitochondrial   THIL_MOUSE 
ADP/ ATP translocase 2 ADT2_MOUSE 
ATP synthase subunit alpha, mitochondrial ATPA_MOUSE 
ATP synthase subunit gamma, mitochondrial ATPG_MOUSE 
Carnitine O-palmitoyltransferase 1, muscle isoform CPT1B_MOUSE 
Cytochrome b-c1 complex subunit 1, mitochondrial QCR1_MOUSE 
Cytochrome b-c1 complex subunit 2, mitochondrial QCR2_MOUSE 
Dihydrolipoyl dehydrogenase, mitochondrial DLDH_MOUSE 
E3 ubiquitin-protein ligase  NEDD4_MOUSE 
Electron transfer flavoprotein oxidoreductase, mitochondrial ETFD_MOUSE 
Electron transfer flavoprotein subunit alpha, mitochondrial ETFA_MOUSE 
Elongation factor TU, mitochondrial EFTU_MOUSE 
Enoyl-CoA delta isomerase 1, mitochondrial  ECI1_MOUSE 
Fructose-bisphosphate aldolase A  ALDOA_MOUSE 
Fumarate hydratase, mitochondrial FUMH_MOUSE 
Isocitrate dehydrogenase (NADP), mitochondrial IDHP_MOUSE 
Isovaleryl CoA dehydrogenase, mitochondrial IVD_MOUSE 
LIM domain-binding protein 3 LDB3_MOUSE 
L-lactate dehydrogenase B chain LDHB_MOUSE 
Malate dehydrogenase, mitochondrial MDHM_MOUSE 




Myosin-binding protein C, cardiac-type MYPC3_MOUSE 




Phosphate carrier protein, mitochondrial MPCP_MOUSE 
Phosphoglycerate kinase 1 PGK1_MOUSE 
Protein-tyrosine phosphatase non-receptor type 11 PTPN11_MOUSE 
Pyruvate dehydrogenase E1 component subunit alpha, somatic 
form, mitochondrial  
ODPA_MOUSE 
Pyruvate kinase PKM KPYM_MOUSE 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  AT2A2_MOUSE 
Short-chain specific acyl-CoA dehydrogenase, mitochondrial  ACADS_MOUSE 
Succinate dehydrogenase flavoprotein subunit, mitochondrial  DHSA_MOUSE 
Trifunctional enzyme subunit alpha, mitochondrial ECHA_MOUSE 
Trifunctional enzyme subunit beta, mitochondrial ECHB_MOUSE 
Voltage-dependent anion-selective channel protein 2 VDAC2_MOUSE 
 
Table 1.1. Protein targets of SFN in cardiac tissue of WT mice identified by 
quantitative mass spectrometry following oral gavage with SFN.  
These studies were conducted by Dr Ewald Schroder at King’s College London.  
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1.4 An introduction to SHP2 
SHP2 is a ubiquitously expressed non-receptor protein-tyrosine phosphatase. 
Like oxidative modifications, phosphorylation of proteins can influence their 
activity, complex association and/or localisation and protein phosphorylation 
status is orchestrated by the balanced actions of kinases and phosphatases. To 
analyse the chemical adduction of SFN to SHP2 and understand the biological 
consequences of this interaction it is important to consider how the phosphatase 
is regulated as well as the signalling events that this protein controls.  
1.4.1 SHP2 structure and regulation 
SHP2 is a 68 kDa protein with two tandem SH2 domains, a central PTP catalytic 
domain and a C-terminal domain containing two tyrosine phosphorylation sites 
at residues 542 and 580, as well as a proline-rich motif. Biochemical analysis and 
crystallographic studies showed when SHP2 is in an inactive state the backside 
loops of the N-terminal SH2 domains of SHP2 fold across its PTP catalytic site 
where it is maintained by H bonding as shown in figure 1.8 43. The phosphatase 
domain is therefore physically inaccessible and SHP2 is biologically inactive due 
to phosphorylated substrates having limited access to the catalytic site. Binding 
of these N-terminal SH2 domains to phospho-tyrosine residues upon receptor 
tyrosine kinases (RTKs) (e.g. growth factor receptor (GFR) and ephrin receptors 
(EphR)), cytokine receptors or scaffold proteins (e.g. insulin receptor substrate 1 
(IRS1), focal adhesion kinase (FAK), GFR-bound protein 2-associated–binding 
protein 1 (GAB1)) induces a conformational change that relieves auto-inhibition 
of the catalytic domain as depicted in figure 1.8 44 45. The same can be achieved 
following docking of the N-terminal SH2 domains to phospho-tyrosine residues 
542 and 580 in its own C-terminal domain following phosphorylation by cytosolic 
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kinases protein kinase C (PKC) or zeta chain of T-cell receptor-associated 
protein kinase 70 (ZAP70), or by membrane-bound RTKs such as EphA2, for 
example 46 47 48. This unfolding relieves autoinhibition and allows access of 
phosphorylated substrates to the active domain containing a catalytic cysteine, 
Cys459, which is fundamental to the phosphatase activity of SHP2. Incorporated 
within Cys459 is a low pKa thiol which means that at physiological pH it 
predominantly exists as an ionised thiolate, which enables nucleophilic attack of 
the sulfur towards a phosphate group, which is crucial for dephosphorylation of 
target proteins. As well as structural inhibition by N-terminal SH2 domains, further 
modulation of the phosphatase’s activity can occur via oxidative modification of 
Cys459. The catalytic domain of the phosphatase and mechanism of substrate 

















1.4.2 Cell signalling pathways regulated by SHP2   
The dephosphorylation of RTKs, cytokine receptors, associated scaffold proteins 
and other cytosolic substrates by SHP2 regulates a wide variety of downstream 









Figure 1.8. SHP2 structure and mechanism of activation by docking phospho-
tyrosine residues.  
In the inactive state, N-terminal SH2 domains of SHP2 sterically hinder access of 
phospho-tyrosine substrates to the catalytic domain and blocks phosphatase activity (1). 
Binding of N-terminal SH2 domains by specific phospho-tyrosine-containing motifs 
releases this inhibition. These phospho-tyrosine residues may be an activated receptor 
(2), a protein which forms part of a scaffold complex (3) or tyrosine-phosphorylated C-







cycle progression and apoptosis. Regulation of such signalling pathways often 
has significant biological consequences including in embryonic development and 
white blood cell production, which have been a focus of these studies. Ras/ERK 
and janus kinase (JAK)/signal transducer and activator of transcription (STAT) 
are the most studied signalling pathways regulated by SHP2 and are outlined in 
detail in chapter 3. Nevertheless, a simple overview of SHP2’s involvement in 
other key signalling events illustrates its importance in multiple biological 
functions.  
1.4.2.1 Regulation of integrin signalling by SHP2 
Heterodimerization of α and β integrin receptor subunits occurs following binding 
of their extracellular domains to extracellular-matrix proteins. This dimerization 
increases the affinity of the receptors intracellular domains towards ligands 
including protein-tyrosine kinases focal adhesion kinase (FAK) and Src family 
kinase (SFK) 49. FAK firstly docks to the cytoplasmic tail of the integrin β subunit 
along with focal adhesion proteins talin and paxillin. Upon activation, FAK auto-
phosphorylates itself, creating a docking site for SFK, which in turn becomes 
phosphorylated by FAK. Phospho-tyrosines within SFK provide docking sites for 
the N-terminal SH2 domains of SHP2, as shown in figure 1.9. Upon binding, 
SHP2 positively regulates integrin signalling by dephosphorylating inhibitory 
phospho-tyrosines within FAK, stimulating downstream events which are 
essential to embryonic development, tissue maintenance and repair, host 
defence and haemostasis 50. Downstream, SHP2 also dephosphorylates p190 
Ras homolog gene family member A (RhoA) guanine triphosphate (GTP)ase-
activating protein (p190RhoAGAP). This facilitates the exchange of RhoA 
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guanine diphosphate (GDP) for GTP, activating Rho-associated protein kinase 
(ROCK) to further stimulate cell proliferation and migration 51.  
1.4.2.2 Regulation of insulin signalling by SHP2 
Binding of insulin to extracellular α subunits of insulin homodimer receptors 
induces a conformational change which facilitates transphosphorylation of 
tyrosine residues within intracellular β subunits 52. Pleckstrin homology (PH) 
domains of insulin receptor substrate 1 (IRS1) subsequently dock these 
phospho-tyrosine residues and the substrate itself becomes phosphorylated by 
the activated receptor. This allows association of IRS1 with the regulatory subunit 
of phosphoinositide 3-kinase (PI3K), p85, through the substrates SH2 domains 
which brings the kinase in proximity to the cell membrane as shown in figure 1.9. 
The catalytic subunit of PI3K, p110, then phosphorylates phosphatidylinositol-
4,5-bisphosphate (PIP2) leading to the formation of PIP3. A key downstream 
effector, Akt (otherwise known as protein kinase B) is recruited and 
phosphorylated by PI3K-dependent protein kinase 1 (PDK1), which stimulates 
downstream glycogen synthesis, promoting cell survival and growth 53. As well 
as binding p85, phospho-tyrosine residues of IRS1 also bind N-terminal SH2 
domains of SHP2, and the phosphatase is a negative regulator of insulin 
















1.5 Dysregulation of SHP2 in pathologies 
As SHP2 is a regulator of multiple signalling events which modulate a number of 
cellular processes, it is unsurprising that dysregulation of its phosphatase activity 
due to somatic or germline mutations can initiate and/or maintain a variety of 
pathogenic outcomes.  
SHP2 acts upstream as well as downstream of different proto-oncogenes. A 
detailed review of how the phosphatase functions in certain cancer cell lines is 
not in the scope of this thesis, but an essential and relevant message in the 
Figure 1.9. Regulation of integrin and insulin signalling by SHP2.  
Following activation of integrin receptors, SHP2 dephosphorylates inhibitory phospho-
tyrosines of FAK and p190RhoAGAP, leading to activation of RhoA/ROCK signalling 
and promoting cell proliferation and migration (left pathway). Dephosphorylation of IRS 
by SHP2 negatively regulates insulin signalling following insulin receptor activation, 
providing a negative feedback mechanism for PI3K/Akt signalling and controlling cell 
survival and growth (right pathway). 
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context of this project is that somatic mutations of Ptpn11, the gene encoding 
SHP2, drive initiation and progression of hematologic malignancies. These 
include juvenile myelomonocytic leukaemia (JMML) and solid tumours 
associated with breast, colon, lung, brain and thyroid cancer, among others 56 57 
58 59. Germline mutations in Ptpn11 have also been identified in two 
multisymptomatic developmental disorders named NS, which is the main focus 
of this thesis, and NS with multiple lentigines (formerly termed LEOPARD 
syndrome). Both are characterised by multiple, almost identical, congenital 
defects. However, remarkably 50 % of NS patients are genetically characterised 
by gain-of-function mutations of SHP2 60 61, whilst NS with multiple lentigines is 
commonly driven by loss-of-function 62 63, highlighting the complexity that results 
from dysregulation of this phosphatase.  
1.5.1 Noonan syndrome  
NS is an autosomal dominant and genetically heterogeneous condition with an 
estimated prevalence of 1 in 1000-2500 live births. The clinical diagnosis of NS 
is established on the basis of distinctive features, including facial dysmorphism 
(high forehead, hypertelorism, down-slanting palpebral fissures, epicanthal folds, 
ptosis, low-set ears), reduced growth, spinal abnormalities, intellectual 
impairment, feeding difficulties in infancy, bleeding tendencies and hearing loss 
64 65. Other common phenotypic characteristics include a broad or webbed neck, 
unusual chest shape with increased coagulation defects, lymphatic dysplasia, 
cryptorchidism and ocular abnormalities. With the exception of Down’s 
syndrome, NS is the most common syndromic cause of congenital heart defects, 
occurring in around 50-80 % of patients 66 67. Pulmonary valve stenosis, often 
with dysplasia, is the most common cardiac manifestation, resulting from 
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dysplastic valve leaflets. Other cardiac structural deformities include atrial and 
ventricular septal defects, mitral valve stenosis, branch pulmonary artery stenosis 
and hypertrophic cardiomyopathy. Infants with NS are also predisposed to 
developing myeloproliferative disease, which may regress without the need for 
treatment, but has been shown to escalate to JMML in a cohort of these patients 
68 69. 
In ~50 % of NS patients, these manifestations occur due to gain-of-function 
heterozygous germline mutations in Ptpn11 60 61. The remaining 50 % of patients 
have mutations in one of the 6 following genes; Son of Sevenless 1 (SOS1), 
Rapidly accelerated fibrosarcoma 1 (Raf1), BRaf, KRas, NRas or mitogen-
activated protein kinase kinase 1 (MAP2K1) 70 71. All 7 genes encode 
components or regulators of the Ras/mitogen-activated protein kinase (MAPK) 
pathway and therefore places NS in a group of developmental disorders termed 
RASopathies.  
1.5.1.1 Ptpn11 mutations associated with NS 
Currently, 12 germline, missense mutations in Ptpn11 have been identified in NS 
patients. Energetic-based structural and biochemical analysis has identified that 
all of these are gain-of-function alterations, causing hyperactivation of SHP2. As 
shown in figure 1.10 the majority of these mutations occur in or around regions 
of SHP2 that form interactions between the proteins N-SH2 and PTP domains 72 
73 74. As discussed previously, interactions between these two domains form an 
autoinhibitory mechanism, preventing access of phosphorylated proteins to the 
catalytic cysteine of the phosphatase. Mutations in these areas, therefore, disrupt 
the intermolecular interactions, relieving the autoinhibited conformation which 
results in constitutive SHP2 activation and enhanced downstream signalling. In 
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rare cases, mutations occur within the C-SH2 domain or within the peptide linking 
the N-SH2 and C-SH2 domains, although with the same effect of relieving the 
autoinhibited structure conformation of the protein 75. In contrast, SHP2 
mutations identified in NS with multiple lentigines typically only effect residues 
within the PTP domain of the protein, resulting in decreased catalytic activity, 
highlighting that positioning of the mutation within the Ptpn11 gene drives the 
subsequent effect on SHP2 activity 76.  
SHP2 is a regulator of multiple stages of white blood cell production as well as 
embryonic development, including of the heart, which I outline in detail in the 
introduction of chapter 5. With this in mind, it is perhaps unsurprising that 10 of 
the 12 missense, gain-of-function mutations in Ptpn11 identified in NS patients 
are correlated with one or multiple congenital heart and skeletal defects as well 




Figure 1.10. Location of 12 known NS-associated SHP2 mutations.  
The majority of germline, missense mutations identified in NS patients occur in or around 
the N- or C-SH2 domains of SHP2, preventing autoinhibitory interactions with the PTP 
domain of the phosphatase. The mutation highlighted in red, D61G, causes the most 
hyperactive form of SHP2.  
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1.5.1.2 NS mouse model with a Ptpn11D61G/+ mutation 
The D61 residue within the N-SH2 domain of SHP2, which is highlighted in red 
in figure 1.10, participates in an H bond network between the N-SH2 domain and 
water molecules within the PTP domain of the phosphatase, forming a major 
component in maintaining the proteins autoinhibited conformation. Replacement 
of this negatively charged aspartic acid for an uncharged glycine residue (D61G) 
is a commonly occurring NS-associated mutation. This charge change prevents 
the formation of the inhibitory N-SH2/PTP domain interface. This opens up the 
structure of the protein, allowing access of phosphorylated substrates to the 
catalytic cysteine of SHP2 and increases the basal activity of the phosphatase 
77. Using a gene-targeting vector, the Neel group generated a heterozygous 
knock-in Ptpn11D61G/+ mouse model with a C57BL/6J/129S4/SvEv hybrid genetic 
background 78. To do so a D61G mutation was introduced into J1 embryonic stem 
cells of 129S4/SvEv background. Correctly mutated embryonic stem cells were 
transfected with a plasmid expressing Cre recombinase to excise the neo 
cassette and two properly excised clones were injected into C57BL/6J 
blastocysts. Characterisation showed these mice exhibit many of the phenotypes 
that characterise NS patients such as short stature, facial dysmorphia, severe 
cardiac defects, myeloproliferative disease and splenomegaly.  
As with human NS patients who have a Ptpn11 mutation, not all offspring of the 
D61G/+ mouse model exhibit the same phenotypes. Phenotypes associated with 
NS are therefore defined as variably penetrant i.e. they may be present in some 
patients and not others. Further to this, two mice who have the same phenotype 
may present them with different severity. Whilst haematopoietic, craniofacial and 
growth defects are completely penetrant, occurring in all heterozygous mice, the 
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severity of these phenotypes differ between mice. On the other hand, cardiac 
defects are incompletely penetrant, with 50 % of heterozygous embryos dying 
prematurely with a spectrum of cardiac defects, whilst the rest exhibit mild 
valvular hyperplasia during embryogenesis which resolves before birth. As 
homozygous Ptpn11D61G+/+ is embryonic lethal it is evident gene dosage and 
expressivity of the mutant correlate with the severity of the defects. Cell- and 
pathway-specific differences in sensitivity to D61G also likely account for 
exacerbation of some phenotypes over others. The Neel group conclude 
incomplete penetrance is reflected by the amount of strain-specific genetic 
modifiers present within each mouse which is reflected by their 129S4/SvEv 
and/or C57BL/6J background, and therefore the degree to which they affect 
certain modifier genes 73. However genomic scans using single nucleotide 
polymorphism panels have failed to identify strong modifier loci 73.  
Regardless of severity and penetrance, this single gain-of-function mutation of 
D61 to G61 results in the greatest activation of SHP2 associated with NS and 
evokes all major phenotypes seen in human patients. The Ptpn11D61G/+ mouse 
is, therefore, an optimal animal model for delineating the potential therapeutic 
benefit of SHP2 inhibitors.  
1.6 SHP2 inhibitors 
As hyperactivation of SHP2 is causative of clinical manifestations present in 50 
% of NS patients 60 61 as well as the initiation and progression of many cancers 
56 57 58 59, it is rational to assume that inhibition of the phosphatase’s activity would 
be beneficial in these pathologies. The identification of inhibitors of its 
phosphatase activity has therefore been a major research goal. However, 
structural homology between many PTPs, as well as the charged active site of 
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the phosphatase have made the development of an inhibitor selective of SHP2 
challenging.  
Studies have identified compounds which are potent inhibitors of SHP2 
phosphatase activity in cultured cell lines as well as recombinant protein. For 
example, the commercially available phenylhydrazonopyrazolone sulfonate 
(PHPS1) is a phospho-tyrosine mimetic with a half maximal inhibitory 
concentration (IC50) value for SHP2 of 2.1 µM. At these low concentrations, 
PHPS1 is selective for SHP2 in cultured epithelial cells, however, adducts other 
PTPs at higher concentrations including SHP1 and PTP1B 79. The compound 
has low cell-membrane permeability which reduces the bioavailability of the drug 
in vivo. The Zhang group demonstrated naphthyl and polyaromatic salicylic acid-
based compounds exhibit enhanced affinity for PTPs 80 81. Using a library of 
salicylic acid-based compounds, they identified II-BO8 as an inhibitor of SHP2  
which has an IC50 towards the phosphatase that is at least 3 times lower than for 
11 other PTPs that were tested 82. Even so, multiple other protein targets of the 
compound have been identified and the biological consequences of these 
interactions are currently unknown. Through virtual screening and experimental 
assays Zhang et al identified the natural compound cryptotanshinone as an 
inhibitor of SHP2; an active ingredient of the herbal plant Salvia miltiorrhiza, 
commonly used in Asian countries to treat coronary heart disease, acute 
ischemic stroke and cancer 83. However, again, lack of selectivity of 
cryptotanshinone for SHP2 was a concern and further studies utilising it as a 
treatment are yet to emerge.   
Structural studies showed all three inhibitors dock at the periphery of the protein’s 
catalytic domain via polar and non-polar interactions. Such interactions either 
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facilitate the closed autoinhibitory conformation of SHP2 or prevent electrostatic 
interactions otherwise essential to the catalytic activity of the phosphatase. 
Notably, they do not cause inhibition of SHP2 by adduction to the protein’s 
catalytic cysteine.  
1.6.1 Sulforaphane as an inhibitor of SHP2 
The catalytic cysteine of SHP2, Cys459, facilitates successful dephosphorylation 
of target substrates by nucleophilic attack towards the phosphorus ion. The 
phosphatase activity of SHP2 can be inhibited by oxidative modification of the 
negatively charged thiolate group of this cysteine. As SFN adducts nucleophilic 
moieties such as thiolates, it was anticipated this catalytic cysteine was where 
the electrophile was adducting SHP2. If so, adduction of SFN may inhibit the 
phosphatases activity. Indeed, preliminary in vitro studies carried out by Lewis et 
al demonstrated dietary ITCs such as SFN inhibit the phosphatase activity of 
recombinant SHP2.  
Due to the covalent nature of the interaction between SFN and target proteins, 
adduction of the electrophile is often perceived as permanent 84. The permanent 
adduction of chemical compounds has been shown to induce haptenization and 
drive an immune response towards proteins which are now rendered as foreign 
85. Drugs which form noncovalent electrostatic interactions such as H bonds, ionic 
bonds, van der Waals forces or hydrophobic bonds can overcome haptenization 
as they allow for transient association and disassociation with target proteins, 
which generates an equilibrium between a protein-bound and -unbound state. 
However, this also leads to reduced potency of the drug due to the discontinuous 
effect on protein function. Continual disassociation of the drug also increases the 
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time in which is it vulnerable to metabolism and excretion 86 87. Typically, higher 
drug amount and more frequent dosage are therefore needed. 
The high electrophilicity of SFN together with is relatively simple structure 
underlies a lack of selectively in the targets it interacts with and potentially 
covalently adducts to. Such electrophilic compounds are therefore typically 
unfavoured due to unknown and perhaps undesired biological effects that occur 
as a result of adduction to off-target proteins. However, off-target effects are not 
always a concern. For example, the thiol-reactive reagent ethacrynic acid inhibits 
protein phosphatase 2a and lymphoid tyrosine phosphatase achieved through 
chemical modification of their catalytic cysteines, with its adduction to additional 
off-target proteins having no undesired biological consequences 88 89 90. Indeed, 
published study results from human clinal trials using SFN have shown no severe 
side effects and minimal non-severe effects following chronic long-term use 91 92 
93 94 95. 
The increased biochemical efficiency of compounds which form covalent 
interactions is beneficial in terms of therapeutic margins, as low amounts of the 
drug are required along with fewer doses, and engineering drugs which 
encompass covalent properties, as well as reversibility, are now considered by 
some to be highly desirable. Such drugs are currently being achieved through 
incorporation of a nitrile group into electron-deficient alkenes 96 97. This allows for 
initial covalent interaction but also increases the acidity of the adduct, favouring 
the reverse reaction. Incorporation of this electrophile into a noncovalent protein-
recognition scaffold further aids the dissociation of the drug 96. The covalent 
interaction of SFN with protein thiols is historically perceived as permanent 98, 
however, recently published observations show thiol-SFN adducts are in fact 
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reversible, with transfer between thiol groups being possible 99. Although such 
trans-thiolation of SFN may lower protein selectivity, therapeutic desirability is 
increased by the covalent but reversible nature of the interaction. 
The development of SFN as a drug has been perturbed by its unstable nature, 
requiring the electrophile to be stored in a frozen buffer containing dimethyl 
sulfoxide (DMSO) 100 101 102. To overcome this, Evgen Pharmaceuticals 
developed Sulforadex (SFX-01), a chemically stabilised powder whereby SFN is 
encapsulated in an α-cyclodextrin complex 103. This encapsulation prevents 
thermal degradation of SFN above -20 ˚C, allowing storage of the drug at room 
temperature. Therapeutic potential of SFX-01 is currently being trialled in patients 
with prostate and breast cancer which to our knowledge also has little if any, 
toxicity concerns at the therapeutic concentrations used 104 105. The drug has 
been kindly donated for use throughout this research project.  
1.7 Research aims 
The data presented herein has overall furthered our understanding of SFN-
mediated inhibition of SHP2 and the benefits this may have in a scenario where 
hyperactivation of the phosphatase is pathological, such as NS. This thesis has 
four chapters of results from experiments carried out with the following research 
aims: 
• Chapter 3: determine if SFN inhibits SHP2 phosphatase activity in vitro as 
well as in WT mice and the Ptpn11D61G/+ NS mouse model.   
• Chapter 4: identify protein targets of SFN in cardiac tissue of mice following 
chronic treatment with SFX-01 and secondly explore if the electrophile can 
trans-thiolate between two thiol-containing proteins.  
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• Chapter 5: determine the effects of SFN on embryonic development and the 
progression of myeloproliferative disease in the Ptpn11D61G/+ NS mouse 
model.  
























2 General methods 
All chemicals were purchased from Merck, formerly Sigma-Aldrich, unless stated 
otherwise. 
2.1 Animals 
Male and female WT C57BL/6J and heterozygous Ptpn11D61G/+ mice (strain 
B6;129S4-Ptpn11tm1Bgn/Mmjax), referred to from here on as NS mice, were 
purchased from the Mutant Mouse Regional Research Centre and maintained in 
the animal facilities at King’s College London. Mice aged between 12 and 15 
weeks were used for experiments unless otherwise stated and treatment 
protocols are outlined in corresponding specific methods sections. Breeding and 
storerooms were maintained at 25 ˚C with a 12-hour light/dark cycle. Studies 
were performed in accordance with the Home Office guidance in the Operation 
of the Animals Scientific Procedures Act 1986, published by Her Majesty’s 
Stationary Office.  
2.2 Tissue isolation and preparation for western immunoblotting 
or protein immunoprecipitation 
At the end of in vivo experiments, mice were sacrificed using a single 
intraperitoneal injection comprised of 70 % sodium pentobarbitone and 30 % 
sodium heparin. Once the mouse had lost consciousness, tested by ensuring the 
mouse’s foot pain reflex was absent, tissue was rapidly isolated, flushed with 
saline (unless stated otherwise), placed immediately into liquid nitrogen and 
stored at -80 ˚C. When required, tissue was weighed and added to 10 % wt/vol 
ice-cold homogenisation buffer (100 mM Tris-HCl, 150 mM NaCl, 1 mM egtazic 
acid (EGTA), 1% triton, pH 7.4) supplemented with metal-chelator-free protease 
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inhibitor (Roche). On ice, tissue was homogenised using a mechanical tissue 
homogeniser. If sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was desired, equal volumes of homogenate and 2X SDS-PAGE 
sample buffer (100 mM Tris-HCl pH 6.8, 4 % SDS, 20 % glycerol, 0.01 % 
bromophenol blue) were mixed together and stored at -20 ˚C until required. If 
protein immunoprecipitation was desired, samples were maintained on ice and 
immunoprecipitation protocol was carried out immediately following 
homogenisation. 
2.3 Protein immunoprecipitation  
1 ml of control group tissue lysate or 500 µl of drug-treated group tissue lysate 
was transferred into separate microcentrifuge tubes and centrifuged at 15000 x 
g for 10 minutes at 4 ˚C. 50 µl of supernatant from each sample was added to 50 
µl 2X SDS-PAGE sample buffer in separate tubes to be used as ‘input’, whilst 
the remaining supernatant was transferred into fresh microcentrifuge tubes and 
placed on ice. Primary antibodies were bought either unconjugated or pre-
conjugated to agarose beads which were prepared using the following protocols: 
Primary antibody pre-conjugated to an agarose bead: 100 µl of the agarose bead-
conjugated primary antibody and 50 µl of unconjugated agarose bead alone (if 
phosphatase activity assay was required) were washed 3X via centrifugation at 
15000 x g at 4 ˚C for 3 minutes in 1 ml phosphate buffered saline (PBS). After 
the final wash, beads were re-suspended in either 100 µl or 50 µl PBS 
supplemented with metal chelator free protease inhibitor (1 tablet per 50 ml, 
Roche), depending on starting volume. 50 µl of agarose bead-conjugated primary 
antibody was added to 400 µl of tissue lysate supernatant from control or drug-
treated mice. The remaining 50 µl of agarose bead-conjugated primary antibody 
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was added to 400 µl PBS to be used as a negative control. 50 µl of unconjugated 
agarose bead was added to 400 µl of tissue lysate supernatant from the control 
group, which was also to be used as negative controls. Samples were rotated at 
20 rotations per minute (rpm) for 3 hours at 4 ˚C.  
Primary antibody not conjugated to an agarose bead: 10 µl of primary antibody 
was added to 400 µl tissue lysate supernatant and rotated at 20 rpm overnight at 
4 ˚C. The following morning, 20 µl protein A/G plus agarose beads (Santa Cruz 
#sc-2003) were added and rotated at 20 rpm for a further 3 hours at 4 ˚C.  
Following incubation of tissue homogenate supernatants with pre-conjugated or 
unconjugated primary antibodies, samples were centrifuged at 15000 x g at 4 ˚C 
for 5 minutes and the supernatant was collected as ‘output’. Samples were again 
washed 3X via centrifugation at 15000 x g at 4 ˚C for 3 minutes in PBS and re-
suspended in 125 µl PBS following the final wash.  For western immunoblotting, 
proteins were eluted from the beads by boiling for 5 minutes at 95 ˚C followed by 
centrifugation at 15000 x g at 4 ˚C for 3 minutes. The supernatant was added to 
an equal volume of 2X SDS-PAGE sample buffer, labelled as ‘capture’ and stored 
at -20 ˚C until required. For phosphatase activity assay, the protein was left 
conjugated to the bead and the activity assay protocol was performed 
immediately after immunoprecipitation.     
2.4 Phosphatase activity assay   
SHP2 phosphatase activity was measured using an EnzChek Phosphatase Kit 
(Thermo Fisher). This kit contained a fluorogenic substrate named 6,8-difluoro-
4-methylumbelliferyl phosphate (DiFMUP). Cleavage of its phosphate group 
generates the fluorescent reaction product 6,8-difluoro-4-methylumbelliferone. 
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Therefore, a higher fluorescent readout correlated to higher phosphatase activity. 
Continuous assessment of activity could be achieved using this assay, which 
allowed for endpoint experiments as well as the determination of the initial rate 
of reaction. Immunoprecipitation of protein from tissue lysate was carried out as 
described above and preparation of recombinant protein is outlined in the 
corresponding specific methods section of chapter 3. All reagents were brought 
to room temperature before use. In an area of reduced lighting, a 10 mM stock 
solution of DiFMUP was prepared by dissolving one vial of DiFMUP in 200 µl of 
N,N-dimethylformamide and a working 200 µM solution was subsequently 
prepared by diluting 1 µl of the stock in 49 µl PBS. 50 µl of protein-containing 
sample was loaded into a black 96-well flat-bottomed plate (Thermo Fisher). All 
samples were run in triplicate. The reaction was initiated by rapidly adding 50 µl 
of the DiFMUP working solution into each protein-containing well. DiFMUP alone 
and SFX-01 alone were used as negative controls for in vitro studies. Tissue 
lysate incubated with unconjugated agarose bead and antibody/bead or antibody 
alone, as described previously, were used as a negative control for in vivo 
studies. Fluorescence was measured with a microplate reader (Gemini XPS) at 
an excitation of 360 nm and an emission of 460 nm at room temperature. 
Readings were taken every 1-minute over a 10-minute time period and analysed 
using SoftMax Pro software. Unless otherwise stated, the 10-minute time point 
was taken for analysis. Values were calculated by using the average of the 
triplicate samples and subtracting the average negative control value from each 
sample. 0-100 µM DiFMU standards were also used in each experiment and a 
line of best fit was generated. The amount of product formed from experimental 
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samples was calculated by extrapolating the corresponding Y value from the line 
of best fit.  
2.5 SDS-PAGE 
Protein-containing samples were subjected to SDS-PAGE using a Bio-Rad mini-
protean tetra cell system. Precast polyacrylamide protein gels were purchased 
from Bio-Rad and consisted of a stacking gel and a 4-20 % gradient resolving 
gel.  Gels were held in place using gel chambers which were then inserted into a 
buffer tank and submerged in reservoir buffer. A 1X working solution of reservoir 
buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS, pH 8.3) was made by diluting 
100 ml of a 10X stock in 900 ml of deionised water. 50 µl of the protein sample 
was mixed via vortex with 50 µl 2X SDS-PAGE sample buffer before being loaded 
into the gel. When using a fifteen-well gel, 10 µl of the sample was loaded into 
each well and 15 µl was loaded if a ten-well gel was used. 3 µl of a molecular 
marker (Precision Plus protein dual colour standards, Bio-Rad) was loaded in a 
neighbouring lane, which contained proteins of various molecular weights, 
providing a visual aid to determine transfer efficiency as well as identifying the 
molecular weight of proteins. Electrophoresis was performed at 50 V for ~15 
minutes to allow proteins to migrate through the stacking gel followed by 180 V 
until the dye front had reached the bottom of the resolving gel.   
2.6 Western immunoblotting 
Immunoblot polyvinylidene fluoride (PVDF) transfer membranes (Bio-Rad), were 
soaked in 100 % methanol for 2 minutes followed by submersion in transfer buffer 
(25 mM Tris, 192 mM glycine, 20 % vol/vol ethanol, pH 8.3). Once electrophoresis 
was complete, the polyacrylamide gel was removed from the plastic cassette 
38 
 
using a metal opening lever and carefully placed on top of the PVDF membrane. 
The gel and membrane were then sandwiched between two stacks of electrode 
paper which had been wetted with transfer buffer. The sandwich was placed 
inside the bottom half of a Trans-Blot semi-dry rapid transfer system cassette 
(Bio-Rad). Air bubbles and excess transfer buffer were removed by rolling a long 
plastic tube over the top of the sandwich. The top of the transfer system cassette 
was then added and the whole cassette placed inside the semi-dry transfer 
machine. If one membrane was transferred at a time, 1.3 amps and a voltage of 
25 were applied for 7 minutes and if two membranes were transferred, 2.5 amps 
and a voltage of 25 was applied for the same amount of time. Once complete, 
the stacks of electrode paper and gel were discarded, and the membrane was 
then ready for immunostaining. 
2.7 Immunostaining western blots  
Membranes were blocked on a shaker for 1-hour at room temperature in a 
solution containing either of the following buffers: PBS containing 0.1 % Tween 
20 (PBS-T) plus 10 % wt/vol non-fat milk powder (Marvel) for non-phosphorylated 
proteins of interest or Tris buffer solution containing 0.1 % Tween (TBS-T) plus 
10 % wt/vol bovine serum albumin (BSA) for phosphorylated protein targets. The 
blocking solution was then discarded and desired primary antibody, diluted in 
either PBS-T plus 5 % wt/vol milk or TBS-T plus 5 % wt/vol BSA, was added to 
the membrane and incubated at room temperature for 2 hours on a shaker. 
Primary antibody dilution was determined either from the manufacturer’s 
recommendations or from previous studies. The membrane was then washed for 
1-hour at room temperature in either PBS-T or TBS-T, with the wash solution 
changed every 20 minutes. A solution containing horseradish peroxidase (HRP) 
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linked secondary antibodies (Cell Signalling) diluted 1:1000 in either PBS-T plus 
5 % wt/vol milk or TBT-T plus 5 % wt/vol BSA were then added to the membrane 
and incubated at room temperature for 1-hour on a shaker. The membrane was 
again washed for 1-hour at room temperature in either PBS-T or TBS-T, with the 
wash solution changed every 20 minutes and were then ready for enhanced 
chemiluminescence (ECL) and quantification to be performed.  
2.8 Enhanced chemiluminescence and quantification 
ECL was performed using Pierce ECL western immunoblotting substrate 
(Thermo Fischer). 500 µl of solution A was mixed with 500 µl solution B and then 
pipetted onto the membrane ensuring even and total coverage. After 1-minute 
membranes were placed inside a clear plastic wallet and air bubbles were 
removed. The plastic wallet was fixed in place inside a film cassette and 
chemiluminescence was detected using photographic film (GE Healthcare) which 
was subsequently developed using an automated machine (Fuji RG II). After 
development was complete, membranes were stained using Coomassie Blue 
(0.2 % Coomassie Blue R, 7.5 % acetic acid, 50 % ethanol) for 30 minutes 
followed by 3X 10-minute washes in destaining solution (5 % acetic acid, 50 % 
methanol). This was carried out to identify the efficiency of the transfer process 
and to aid in quantification of protein loading. For cellular experiments the 
analysis of GAPDH protein was used as quantification of protein loading.  
Developed film and Coomassie Blue stained membranes were digitally scanned 
and quantified by densitometry using Image Studio Lite (LI-COR Biosciences).     
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2.9 Colloidal Coomassie staining  
Following protein separation by SDS-PAGE, it was sometimes desirable to 
visualise total protein within samples. Once electrophoresis was complete, gels 
were stained overnight at 4 ˚C with Colloidal Coomassie Blue, which was made 
of two solutions: solution A (85 % orthophosphoric acid; 0.6 M ammonium 
sulphate) and solution B (5 % Coomassie G 250). 20 % methanol is added to the 
solution directly before use. The following morning, Colloidal Coomassie stain 
was removed and the gel was destained in deionised water at room temperature, 
on a shaker, until desired background staining was achieved.  
2.10 Statistical analysis  
All data sets with an n≥3 are displayed as mean values ± the standard error of 
the mean. Data sets containing only two groups were analysed for statistically 
significant differences using independent samples t-test. Data sets of three or 
more were first analysed using one-way analysis of variance (ANOVA) to identify 
the presence of statistically significant differences between any of the groups. If 
a statistical difference were identified, a follow-up Tukey’s honest significant 
difference (HSD) test was performed to identify which groups within the data set 
held the significant difference. Statistical analysis was carried out using Microsoft 
Excel. Differences were considered significant at the 95 % confidence level 
(p<0.05). 
2.11 Affinity purification of SFN antibody  
The anti-SFN primary antibody was purified from rabbit serum which had been 
stored at -80 ˚C since harvesting. To do this, an affinity column using N-
hydroxysuccinimide) NHS-activated Sepharose was used (GE Healthcare) which 
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was made via the batch method. 5 ml of activated Sepharose was added to a 10 
ml plastic column and washed in 10-15 column volumes of cold 1 mM HCl to 
remove the storage solvent. NHS-activated Sepharose was then incubated with 
50 mM L-cysteine in 8 ml coupling solution (0.2 M NaHCO3, 0.5 M NaCl, pH 8.3). 
The matrix mixture was left rotating overnight at 4 ˚C to allow coupling of cysteine 
to the NHS-activated Sepharose via its amino terminus. The following morning 
the column was centrifuged at 1000 x g for 1-minute to pellet the Sepharose 
beads and the supernatant was discarded. To minimise hyperoxidation and block 
any free NHS groups that had not been coupled to cysteine, beads were 
resuspended in 8 ml 0.1 M Tris-HCl pH 7.5 and incubated for 2 hours at room 
temperature. Rapid alternate washes were then carried out; firstly, using 0.1 M 
Tris-HCl pH 8.5 followed by 0.1 M acetate buffer pH 4.0 plus 0.5 M NaCl and this 
process was repeated three times. The column was then washed in 5 column 
volumes 10 mM dithiothreitol (DTT) in PBS pH 8.0, to reduce any disulfide bonds 
that may have formed, which was followed by 10 column volumes PBS. After the 
final wash, 5 ml 50 mM L-SFN was added to the beads and incubated overnight 
at 4 ˚C to enable coupling of SFN to the free-thiol group of cysteine to occur. The 
following morning, the column was washed with 20 column volumes PBS 
supplemented with 20 % DMSO followed by 5 column volumes PBS to remove 
any unbound SFN. 10 ml of rabbit antiserum was added to the column and 
rotated overnight at 4 ˚C. The following morning, beads were poured into a 
disposable PD10 column (GE Healthcare), the antiserum was allowed to drip 
through the column and the eluate was repassed through the beads to optimise 
binding. The column was then washed 3X with 10 ml PBS plus 500 mM NaCl 
followed by 10 ml PBS. 17 ml of acid-elution buffer (100 mM glycine, pH 2.5) was 
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added to the column to elute acid-labile antibodies which were collected in a 15 
ml falcon tube containing 3 ml 1 M Tris, pH 8.0. The column was then neutralised 
by washing with 9 ml PBS. 17 ml of basic-elution buffer (100 mM triethylamine, 
pH 11.5) was added to the column to elute alkali-labile antibodies which were 
collected in a 15 ml falcon tube containing 3 ml 1 M acetate pH 5.0. The column 
was subsequently washed with 9 ml PBS and stored in PBS plus 0.05 % azide 
at 4 ˚C. The two pools of antibody were then concentrated using spin columns 
with a 50 K cut-off (Milipore) via centrifugation at 3000 x g at 4 ˚C into storage 
buffer (PBS, 0.1 % Tween-20, 1 % trehalose, 0.01 % azide). Pools were 
concentrated until optical density at 280 nm exceeded 1 (where 1 OD at 280 nm 
= 0.7 mg/ml IgG). The purified antibody was finally aliquoted into 25 µl aliquots 
and stored at -20 ˚C until required for western immunoblotting or 
immunoprecipitation.  
2.12 High-performance liquid chromatography (HPLC) 
The HPLC system (LC-10 AD liquid chromatograph, Shimadzu) consisted of a 
gradient pump used at a flow rate of 1 ml/minute, an injection valve programmed 
to inject 20 µl of sample, a UV detector set to 205 nm and a Supelco reverse 
phase Titan C-18 column (Sigma-Aldrich) held in a column oven set to 37 ˚C. 
The mobile phase consisted of buffer A (100 % deionised water) and buffer B (90 
% acetonitrile:10 % deionised water) and the binary gradient programme is 
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Table 2.1. HPLC protocol for analysing the stability of SFX-01 in water 
 
2.13 Cell culture 
HEK293 cells (a cell line derived from human embryonic kidney) were maintained 
in Dulbecco’s modified Eagles media (DMEM) plus GlutaMAX-I (Thermo 
Fischer), supplemented with 10 % foetal bovine serum (FBS) and 
penicillin/streptomycin (1 unit/ml;1 µg/ml) in a 95 % O2/5 % CO2 incubator at 37 
˚C. Once cells reached 70-80 % confluency, media was removed and cells were 
washed in 10 ml of warmed Dulbecco’s PBS. Cells were detached from the flask 
by incubating with 1.5 ml warmed trypsin- EDTA (Invitrogen Life Technologies) 
for 5 minutes. The detachment of cells was confirmed using light microscopy. 
Warmed media was added to reach the desired dilution and cells were seeded 
into either a fresh T75 flask (10 ml total volume) for maintaining the cell line or 
into 6-well plates (2 ml/well) for experiments (Thermo Fisher). Transfection and 
treatment protocols are outlined in the corresponding specific methods sections.  
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3 Sulforaphane inhibits SHP2 activity in vitro and 
in vivo with effects on downstream signalling  
3.1 Introduction 
3.1.1 SHP2 regulation of the Ras/ERK signalling pathway 
SHP2 is a positive regulator of the Ras/ERK signalling pathway. The Ras/ERK 
cascade is the most extensively studied MAPK signalling pathway and couples 
signals from tyrosine kinase GFRs to a broad complement of effector proteins, 
including transcription factors. Binding of growth factors (GF) such as platelet-
derived GF, epidermal GF and fibroblast GF drives dimerization and trans-
phosphorylation of the receptors. Stimulation causes recruitment of SHP2 to 
phosphorylated receptors whereby it likely positively regulates GF signalling via 
both phosphatase-dependent and -independent mechanisms by acting as a 
scaffold protein (figure 3.1) 59. SHP2 then becomes phosphorylated at its C-
terminal domain, firstly on Tyr542 followed by Tyr580, with the former being the 
major docking site for GFR-bound protein 2 (GRB2) 106. This interaction forms 
the basis of a larger complex comprising GAB1, the PH domains of which likely 
bind the SH2 domains of SHP2 107 108. SOS, a guanine nucleotide exchange 
factor is then recruited to this complex, catalysing the exchange of GDP from the 
small GTPase Ras for GTP, a key step in Ras reactivation 109. The proto-
oncogene serine/threonine kinase RAF is next recruited, where it is activated 
by a complex multistage process likely involving the kinase suppressor of Ras 
(KSR), although this remains unconfirmed 110 111 112. RAF drives 
phosphorylation and activation of the dual-specificity mitogen-activated 
protein/extracellular signal-related kinase kinases (MEK) 1 and 2 which 
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subsequently phosphorylate a tyrosine and then a threonine residue in the 
threonine-glutamic acid-tyrosine motif within the activation loop of ERK 1 (p44) 
and 2 (p42), resulting in their activation 113 114. ERK then directly 
phosphorylates multiple proteins and transcription factors, including c-Myc, Ets 
1, the oncogene proteins c-Jun and c-Fos which form activator protein (AP) 1, 
as well as activating NF-кB and cAMP response element binding protein 
(CREB) via phosphorylation of their upstream kinases, IкB kinase and 
ribosomal s6 kinase 1 (S6K1) respectively 115 116 117. The expression of proteins 
involved in cell cycle progression and apoptosis prevention, including cyclins 
and cyclin-dependent kinases, GFs, cytokines and B-cell lymphoma 2 are 
subsequently upregulated. Non-transcriptional events are also triggered, 
including S6K1 regulation of autocrine signalling in pancreatic β cells as well 
as interleukin 2 driven T-cell proliferation 118 119.  
Phospho-tyrosines on both Ras and GFRs provide docking sites for the 
GTPase-activating protein RasGAP, which negatively regulates the ERK 
pathway by hydrolysing RasGTP to GDP 120. SHP2, on the other hand, 
stimulates signalling and is strongly suggested to act upstream of Ras, as 
dominant SHP2 negative fibroblasts show defective Ras activation 121. SHP2 
preferentially dephosphorylates tyrosine residues upon both GFRs and Ras, 
hindering RasGAP binding and promoting Ras activation 76 122. SHP2 also 
dephosphorylates Sprouty, a Ras/ERK pathway inhibitor. Sprouty becomes 
tyrosine phosphorylated in response to GFR activation and binds to SH2 domains 















ERK signalling, which can be stimulated independently of GFRs, is also initiated 
at the intracellular membrane of the endoplasmic reticulum in an SFK-dependent 
manner, which is negatively regulated by C-terminal Src kinase (Csk). Following 
Figure 3.1. Diagram of the Ras/ERK signalling pathway.  
GF binding drives receptor dimerization and trans-phosphorylation, providing docking 
sites for a protein complex involving SHP2 and SOS. Downstream ERK 1/2 activation 
occurs via RasGTP formation by SOS and subsequent RAF and MEK 1/2 
phosphorylation. ERK phosphorylates a range of transcription factors, some via 
upstream kinases, resulting in upregulation of proteins required for proliferation, 
migration and apoptosis. SHP2 is a positive regulator of Ras/ERK signalling by 
dephosphorylating phospho-tyrosines on the negative regulator Sprouty, as well as Ras 
which prevents RasGAP binding and GTP hydrolysis.   
47 
 
GF stimulation Csk is recruited to areas where SFKs localise via interaction of its 
SH2 domains with phospho-tyrosines on phosphoprotein associated with 
glycosphingolipid-enriched microdomains 1 (PAG1) 125 126 (figure 3.2). Csk 
phosphorylates tyrosine residues within the C terminal of SFKs which inhibits 
their activity. SHP2, on the other hand, can positively regulate SFK by docking 
GAB1 where it dephosphorylates PAG1 and blocks Csk recruitment 126. Once 
activated, SFK phosphorylates downstream targets including phospholipase C ƴ 
1 (Plcƴ1), which catalyses phospholipid hydrolysis and the generation of second 
messengers such as diacylglycerol (DAG) or inositol triphosphate (IP3) that can 


















3.1.2 SHP2 regulation of the JAK/STAT GH signalling pathway  
The JAK/STAT GH signalling pathway promotes cell cycle progression and 
proliferation as well as apoptosis following binding of GH to GH receptors (GHR), 
Figure 3.2. SHP2 positively regulates Ras/ERK signalling at the intracellular 
membrane of the endoplasmic reticulum.  
Following GFR activation, Csk docks phospho-tyrosines on PAG1, bringing it into 
proximity with SFK, which it inactivates by phosphorylation. SHP2 docking to phospho-
tyrosines on the receptor allows localisation to Csk/PAG1 where it dephosphorylates 
PAG1 and prevents Csk binding, allowing stimulation of the Ras/ERK pathway by 
phosphorylation of Plcƴ1 by SFK. 
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and SHP2 is a negative regulator of this pathway 127. GHs are secreted from the 
lateral wing of the anterior pituitary gland following synthesis by somatotropic 
cells. Binding of GH to GHRs initiates homodimerization of two monomeric 
receptor subunits 128. The cytoplasmic domain of each receptor monomer is 
associated with JAK2, bound via an amino-terminal FERM (Band-4.1, ezrin, 
radixin, moesin) domain 129. JAK2 belongs to a family of non-RTKs and is the 
only member involved in hormone-like cytokine signalling 130. Dimerization of the 
receptor allows trans-phosphorylation and subsequent activation of the kinase 
domain of each JAK2 131. Activated JAK2 then auto-phosphorylates itself on 
additional tyrosine residues as well as others in the cytoplasmic domain of the 
GHR 132. These phospho-tyrosine residues provide docking sites for a family of 
transcription factors named STAT, including STAT5 133. JAK2 subsequently 
phosphorylates conserved carboxy-terminal tyrosine residues within STAT5 
proteins, which facilitates their dimerization and translocation into the nucleus 
where they bind regulatory sequences to activate or repress the transcription of 
target genes 127 134. Phospho-tyrosine residues within the kinase domain of JAK2 
also provide docking sites for PTPs including SHP2 135. Through western blotting 
and knock-out models, the Carter-Su group demonstrate C-terminal SH2 
domains of SHP2 directly dock phospho-Tyr595 within GHRs, activating the 
phosphatase 135. SHP2 then acts as a negative regulator of GH signalling by 
dephosphorylating phospho-tyrosine residues on GHRs and/or JAK2 which 
removes binding sites for downstream signalling proteins including STAT5 (figure 













3.1.3 GH treatment of NS patients 
As mentioned previously, a distinctive feature of NS is short stature, occurring in 
almost 80 % of patients 137. Currently, treatment of attenuated growth in NS 
patients is limited to recombinant human (rh) GH therapy. Initial clinical trials in 
children showed promising results - increasing growth by roughly 5 cm. However, 
ongoing improvements in adult height are still inconclusive 138. Safety reports on 
the use of rhGH in children raise concerns about potential off-target effects on 
bone development due to intracranial pressure, scoliosis, and muscle and joint 
Figure 3.3. Diagram of the JAK/STAT signalling pathway.  
GH binding to GHRs causes dimerization of these RTKs. JAK2 proteins subsequently 
become trans-phosphorylated providing docking sites for STAT5 followed by their 
dimerization and translocation to the nucleus. STAT5 binding to DNA drives upregulation 
of proteins involved in proliferation, cell cycle progression and apoptosis. SHP2 is a 
negative regulator of this pathway by dephosphorylating JAK2 proteins. 
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discomfort in some patients 139. Further to this, information about the potential 
impact of GH therapy on ventricular development in patients with cardiac defects 
and/or abnormal cardiac function is also unavailable. As well as GHs regulating 
JAK/STAT signalling, there is also cross talk with the ERK pathway. 
Hyperactivation of ERK or upregulation of the kinase is seen in multiple cancers 
and its activation aids the growth and proliferation of these cells. Therefore, the 
prospect of a potentiated incidence of cancer following GH therapy warrants 
consideration. Although GH therapy may provide short term benefits to children 
with NS, the concerns highlighted above make it evident that further studies into 
utilising GH as novel therapies are needed. 
Short stature is most prevalent in NS patients with mutations in Ptpn11, the gene 
which encodes SHP2 140. In vivo studies identified reduced sensitivity to GHs in 
NS mice which are genetically engineered with a gain-of-function SHP2 mutation, 
although exactly how hyperactivation of the phosphatase induces growth 
retardation is still under investigation. The Yart group showed an association 
between early postnatal growth delay and low levels of insulin-like growth factor 
1 (IGF1) in a mouse model expressing a gain-of-function SHP2 mutation, 
Ptpn11D61G/+ 141. They subsequently found inhibition of SHP2 in GH responsive 
cell lines resulted in increased IGF1 levels following GH stimulation 141. Inhibitors 
of SHP2, or combined treatment with GH, may offer benefits over current 
therapies. 
Within the phosphatase domain of SHP2 lays a catalytic cysteine, Cys459, which 
must be in its negatively charged thiolate state to successfully carry out 
nucleophilic attack towards the phosphorus ion of phosphorylated substrates and 
dephosphorylate them, and the structure of the protein’s active domain and its 
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catalytic mechanism are outlined in chapter 6. Due to the electrophilic nature of 
SFN, it was logical to assume it would adduct at this nucleophilic catalytic 
cysteine and here I sought to determine if treatment of SHP2 with SFX-01 would 
inhibit the proteins phosphatase activity both in vitro and in vivo. Complementary 
experiments investigating alterations to downstream signalling pathways were 
















3.2 Materials and methods 
3.2.1 SDS-PAGE and western immunoblotting  
SDS-PAGE and western immunoblotting were performed as outlined in the 
general methods. For this chapter the following primary antibodies were used: 
 
 












SHP2 (for immunocapture) 
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Phosphorylated ERK 1/2  
 




SHP2 (for immunodetection) 
 










Phosphorylated STAT5  
 




Table 3.1. List of primary antibodies used for western blotting in chapter 3.  
 
3.2.2 Immunoprecipitation  
Immunoprecipitation of proteins from tissue was performed as outlined in the 
general methods. For this chapter, the capture antibody was agarose-conjugated 
anti-SHP2 (Rabbit, Santa Cruz, #sc-7384 AC). Subsequent immunoblotting was 
carried out using an anti-SHP2 primary antibody (Goat, R&D Systems #AF1894) 




3.2.3 Preparation of recombinant SHP2 for in vitro experiments   
Recombinant human SHP2 protein (Abcam) bought at 0.73 mg/ml in storage 
buffer (50 % glycerol, 0.05 % Tween 20, 75 mM NaCl, 25 mM Tris HCl, 2 mM 
EDTA, 10 mM GSH, 1 mM DTT, pH 8.0) was stored at -80 ˚C. When required, 
SHP2 was placed onto ice where it was held until experiments commenced. Prior 
to use in experiments, varying amounts of SHP2 were added to PBS, on ice, to 
make a total volume of 40 µl, which was routinely desalted to remove undesirable 
components of the storage solution, and in doing so swap for a suitable buffer. 
Desalting was carried out using a 7 kDa cut-off 0.5 ml Zeba Spin desalting column 
(Thermo Fisher) which was first centrifuged at 1500 x g at 4 ˚C for 1-minute to 
remove the storage buffer. The spin column was then washed three times to 
remove any remaining sodium azide from the resin by adding 100 µl of 
experimental buffer (25 mM Tris HCl, 75 mM NaCl, 0.05 % Tween 20, 2 mM 
EDTA, varying DTT concentration as described below, pH 7.2) to the top of the 
resin and centrifuging as before. Following the final wash step, the spin column 
was moved to a microcentrifuge tube containing 10 µl of the experimental buffer 
at reagent concentrations which generated a final concentration of 25 mM Tris 
HCl, 75 mM NaCl, 0.05 % Tween 20, 2 mM EDTA with varying DTT 
concentrations, pH 7.2. 40 µl of SHP2 in PBS was then added to the top of the 
resin and centrifuged at 1500 x g at 4 ˚C for 2 minutes. SHP2 was then placed 
back on ice until the experiment began. 
3.2.4 Optimisation of the SHP2 phosphatase activity assay    
A 50 µl sample of varying amounts of recombinant SHP2, prepared as described 
above, containing varying concentrations of DTT, was incubated at room 
temperature for 6 hours prior to loaded into a 96-well flat-bottomed plate and 
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phosphatase activity was measured using the fluorescence-based assay as 
described in detail in the general methods.  
3.2.5 Preparation of SFN stock for use in in vitro experiments 
A 50 mM SFN stock was prepared by dissolving 58 mg SFX-01 in 1 ml of 
deionised water. The sample was mixed by vortexing until all SFX-01 was 
dissolved. Working solutions were made by diluting the stock in deionised water. 
SFN stock was freeze-thawed no more than 4 times before being replaced with 
a new batch.  
3.2.6 Treatment of SHP2 with SFX-01 and determination of IC50 of inhibition 
by SFN 
Nine concentrations of SFX-01 from 0.007-1.75 µM were incubated with 0.011 
µg/ml recombinant SHP2 for varying lengths of time in PBS containing 0.016 mM 
DTT. Each experiment was performed in triplicate and the activity of the protein 
was assessed using the fluorescence-based phosphatase activity assay as 
outlined in the general methods. The IC50 for SFN-dependent inhibition of 
recombinant SHP2 phosphatase activity in vitro was determined using the curve-
fitting programme GraphPad Prism (GraphPad Software Inc.).  
3.2.7 Determining the stability of SFN in water over time 
12.5 mg SFX-01 was dissolved by vortexing it in 5 ml deionised water to make a 
final solution of 2.5 mg/ml SFX-01 (0.385 mg/ml SFN). Dissolved SFX-01 was 
stored in the dark at room temperature. Each morning the solutions were 
analysed by HPLC using the protocol outlined in the general methods. A 
deionised water only sample was used as a negative control followed by a 0.385 
mg/ml SFN standard to determine its retention time.  
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3.2.8 Acute or chronic treatment with SFN in vivo 
For acute SFN treatment, SFX-01 (0-10 mg/kg, which is equivalent to 0-1.54 
mg/kg SFN) was dissolved in 175 µl deionised water and vortexed thoroughly. 
WT or NS mice then received a single intraperitoneal injection of a specified 
concentration and were sacrificed after 30 minutes. For chronic SFN treatment, 
the requisite amount of SFX-01 was dissolved in deionised water to make a final 
amount of 2.5 mg/ml SFX-01. WT or NS mice then received this as a substitute 
for their drinking water over a 10-day period and were sacrificed at varying time 
points. The water containing the SFX-01 was replaced every 4 days. Following 
acute and chronic treatment, cardiac and liver tissue was harvested for further 
analyses.    
3.2.9 Growth hormone treatment in vivo 
WT mice were treated with either SFX-01 alone, recombinant mouse GH (rmGH) 
alone or a combination of both. 40 or 70 µg rmGH, purchased from the Harbour-
UCLA Research and Education Institute, was prepared by diluting 40 or 70 µg in 
175 µl saline supplemented with 10 mM NaOH and injected subcutaneously. 2.5 
mg SFX-01 was prepared by diluting 2.5 mg in 175 µl deionised water and 
injected intraperitoneally. Vehicle-treated control mice received an equivalent 
volume of saline by intraperitoneal injection. When combined treatment was 
required, rmGH was first injected subcutaneously followed immediately by an 
intraperitoneal injection of SFX-01. Mice were sacrificed at time points 0, 30, 60 




3.3.1 Optimisation of the fluorescence-based SHP2 phosphatase activity 
assay  
A commercial fluorescence-based phosphatase activity assay kit, which required 
optimisation prior to use in the in vitro experiments, was used to assess the 
catalytic activity of recombinant SHP2 as well as that found in tissues in vivo. As 
expected, increasing amounts of recombinant SHP2 (0.011 - 0.73 µg/ml) 
prepared as described previously, showed proportionately greater phosphatase 
activity (figure 3.4 A). For this first experiment, an experimental buffer containing 
1 mM DTT was used. Fluorescence of sufficient intensity above baseline was 
generated with 0.011 µg/ml SHP2 and was the concentration used in subsequent 
experiments. Desalting 0.011 µg/ml recombinant SHP2 into an experimental 
buffer containing increasing concentrations of DTT, from 0 – 1 mM, was found to 
increase phosphatase activity in a concentration-dependent manner (figure 3.4 
B). As minimal DTT was desired, as it would likely also react with SFN, the lowest 



































Figure 3.4. Optimisation of protein and DTT concentrations for a fluorescence-
based phosphatase activity assay.  
A) A fluorescence-based phosphatase activity assay showing an increase in SHP2 
activity when increasing amounts of recombinant protein were used in the assay. The 
experimental buffer used in this experiment contained 1 mM DTT. B) A fluorescence-
based phosphatase activity assay showing an increase in SHP2 phosphatase activity 
when the protein was incubated in an experimental buffer which contained increasing 
concentrations of DTT.    
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3.3.2 SFN inhibits SHP2 phosphatase activity in vitro  
Concentration- and time-dependent inhibition of SHP2 phosphatase activity was 
seen using the fluorescence-based activity assay following incubation of 0.011 
µg/ml SHP2 in the presence of 0.016 mM DTT with 0-1.75 µM SFX-01 for 0-6 
hours (figure 3.5 A). Using the initial rate of reaction, calculated between the first 
and third minute of the assay, the IC50 for SFN-dependent inhibition of SHP2 was 
calculated for each time point. These values were time-dependent, varying from 
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Figure 3.5. SFX-01 inhibits SHP2 phosphatase activity in vitro.  
A) A fluorescence-based phosphatase activity assay carried out using 0.011 mg/ml 
recombinant SHP2 in a buffer containing 0.016 mM DTT incubated with varying 
concentrations of SFX-01 for varying lengths of time. SFX-01 inhibits SHP2 
phosphatase activity in a concentration- and time-dependent manner. B) IC50 values of 
SFN inhibition of SHP2 in different conditions. (n = 5, *p<0.05 versus 0 µM SFN control). 
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3.3.3 SFN adducts recombinant SHP2 
Western immunoblotting showed SFN adduction to recombinant SHP2 following 
incubation with 1.75 µM SFX-01 for 30 minutes which was stable for a further 6 
hours (figure 3.6 A). SHP2-SFN was also detected following incubation of the 
protein with 0.109 µM SFX-01 for 0.5-6 hours although a loss of the adduct was 
detected at the 2-6-hour time points compared to 0.5-1 hours (figure 3.6 B). 
Adduction of the protein by the electrophile was only detected following 2 hours 
of incubation with 0.007 µM SFX-01 which again decreased at later time points 


























Figure 3.6. SFN adducts SHP2 in vitro.  
A) A representative immunoblot showing SFN adduction upon SHP2 following 30-minute 
incubation with 1.75 µM SFX-01 which was stable for 6 hours. B) A representative 
immunoblot showing SHP2-SFN following 30-minute incubation with 1.09 µM SFX-01. 
Reduction of the adduct was seen following 2 hours of incubation. C) A representative  
immunoblot showing SFN adduction upon SHP2 following 2 hours incubation with 0.007 
µM SFX-01. Almost complete loss of the adduct was seen 4 hours post-incubation. 
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3.3.4 Characterisation of the NS mouse model 
Daily weighing from 3-22 weeks of age showed both male and female NS mice 
weigh less than their WT counterparts (figure 3.7 A). Visual inspection showed 
that NS mice were shorter in height and length, had a flatter skull and a webbed 
neck compared to their WT littermates (figure 3.7 B). Immunoblotting of SHP2 
protein immunoprecipitated from cardiac tissue of WT or NS mice revealed 
comparable protein expression. However, a subsequent activity assay identified 
~3.5-fold hyperactivity of SHP2 in the mutants compared to WT (figure 3.7 C). 
Immunoblotting also revealed elevated ERK phosphorylation in the cardiac tissue 
of NS mice, with total ERK protein remaining comparable to WT littermates 


































Figure 3.7. Characterisation of the NS mouse model.  
A, B) NS mice present with a webbed neck, shorter skull and weigh less than their WT 
littermates. C, D) An immunoblot and fluorescence-based phosphatase activity assay 
showing comparable protein levels but increased phosphatase activity in NS mice using 
SHP2 immunoprecipitated from WT or NS cardiac tissue. E) An immunoblot showing 




3.3.5 SFN adducts protein targets in a concentration-dependent manner in 
vivo  
To establish if SFN could adduct protein targets following in vivo treatment with 
SFX-01 instead of L-SFN, which was used in preliminary experiments to identify 
protein targets of the electrophile in cardiac tissue, WT or NS littermate mice were 
intraperitoneally injected with varying concentrations of SFX-01 acutely for 30 
minutes. An increase in SFX-01 concentration (0-10 mg/kg) correlated with the 
increased abundance of protein-SFN adducts in cardiac and liver tissue of WT 
mice (figure 3.8 A, B). SFX-01 treatment of NS mice also resulted in protein-SFN 
adducts in both cardiac and liver tissue, however, only one concentration (10 































   
 
Figure 3.8. SFN adducts proteins in vivo in a concentration-dependent manner.  
A-D) Immunoblots showing concentration-dependent increase in protein-SFN adducts 
in the cardiac and liver tissue of WT or NS mice 30 minutes after intraperitoneal injection 
of varying concentrations of SFX-01. Note: only one concentration of SFX-01 was 
assessed in NS mice as the number of these mice was limited. (n = 6, *p<0.05 versus 
water only control). 
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3.3.6 Acute treatment with SFX-01 does not inhibit SHP2 phosphatase 
activity in vivo  
To assess inhibition of SHP2 phosphatase activity following acute treatment with 
SFX-01, SHP2 was immunoprecipitated from the cardiac tissue of WT or NS mice 
following intraperitoneal injection with 10 mg/kg SFX-01. Immunoblotting of the 
input and immunocaptured SHP2 identified comparable protein expression 
between WT and NS mice (figure 3.9 A). SHP2 phosphatase activity was basally 
higher in the NS mice compared to WT, consistent with their activating mutation 
(figure 3.9 B). However, no inhibition in activity was observed following the 30-












































Figure 3.9. Acute exposure to SFX-01 does not inhibit cardiac SHP2 phosphatase 
activity.  
A) An immunoblot of input and capture samples following immunoprecipitation of SHP2 
from cardiac tissue of WT or NS mice 30 minutes after intraperitoneal injection of 10 
mg/kg SFX-01. B) A fluorescence-based phosphatase activity assay using 
immunoprecipitated SHP2 shows no inhibition of SHP2 phosphatase activity following 
30-minute treatment with 10 mg/kg SFX-01. (n = 6). 
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3.3.7 SFX-01 is stable in water for 6 days  
SFX-01 was dissolved in drinking water as a method of administration in some in 
vivo experiments. To establish the stability of SFX-01 in water over time, the drug 
was dissolved in water and analysed by HPLC at varying time points. A 
chromatogram of L-SFN, which was used as a positive control, revealed its 
retention time as ~9.56 minutes under the analytical conditions used (figure 3.10 
B). The peak intensity of SFN following the addition of SFX-01 to water did not 
change over 0-6 days and it was therefore assumed the drug was stable for this 
duration (figure 3.10 C-E). A small peak with a retention time of ~8.70 minutes 
appears after 4 days, which may correspond to a degraded form of SFN, 








































Figure 3.10. HPLC chromatograms showing SFX-01 is stable in water for 6 days.  
A) A water only negative control. B) 0.385 mg/ml L-SFN in water positive control. C-E) 
2.5 mg/ml SFX-01 dissolved in water, stored at room temperature and analysed at time 
points of 0, 4 and 6 days respectively. A small peak with a retention time of ~8.70 
minutes, which likely represents a minimal amount of degradation, became apparent 
after 4 days. mAU represents absorbance using a UV detector set at a wavelength of 
205 nm.  
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3.3.8 SFN adducts protein targets in a time-dependent manner in vivo  
As 30-minute treatment with 10 mg/kg SFX-01 was not successful in inhibiting 
SHP2 phosphatase activity, WT or NS mice were subsequently treated with 2.5 
mg/ml SFX-01 in their drinking water for up to 10 days. Protein-SFN adducts were 
observed following 4 days of treatment in the cardiac tissue of WT or NS mice, 






































Figure 3.11. Protein-SFN adducts accumulate in vivo in a time-dependent manner. 
 A, B) Immunoblots showing time-dependent increase in protein-SFN adducts in the 
cardiac tissue of WT or NS mice after receiving 2.5 mg/ml SFX-01 chronically for up to 10 
days in their drinking water. (n = 10, *p<0.05 versus water only control). 
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3.3.9 Chronic SFX-01 treatment inhibits SHP2 phosphatase activity in vivo  
SHP2 was immunoprecipitated from the cardiac tissue of WT or NS mice 
following 4 days treatment with 2.5 mg/ml SFX-01 in their drinking water. As with 
the previous study in which the drug was administered for 30 minutes, 
immunoblotting of the input and immunocaptured SHP2 identified comparable 
protein expression between WT and NS mice (figure 3.12 A) with SHP2 
phosphatase activity basally greater in NS mice compared to WT (figure 3.12 B). 
However, unlike the 30-minute treatment, inhibition of SHP2 phosphatase activity 
was observed following treatment with 2.5 mg/ml SFX-01 for 4 days in WT or NS 
mice (figure 3.12 B). Indeed, 4 days of SFX-01 treatment nearly normalised the 








































Figure 3.12. 4-day treatment with SFX-01 inhibits cardiac SHP2 phosphatase 
activity.  
A) An immunoblot of input and capture samples following immunoprecipitation of SHP2 
from cardiac tissue of WT or NS mice after receiving 2.5 mg/ml SFX-01 for 4 days in 
their drinking water. B) A fluorescence-based phosphatase activity assay using 
immunoprecipitated SHP2 from cardiac tissue shows inhibition of SHP2 phosphatase 
activity following treatment with 2.5 mg/ml SFX-01 for 4 days in WT or NS mice. (n = 10, 
* and # p<0.05 versus water only control of the same genotype). 
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3.3.10 Treatment with clinically-relevant amounts of SFX-01 inhibits SHP2 
phosphatase activity  
The amount of SFX-01 used in previously described in vivo experiments where 
mice received the drug for 4-10 days was higher than those currently used by 
Evgen Pharmaceuticals in their clinical trials in humans. Thus, WT mice were 
orally gavaged with varying concentrations (0-500 mg/kg) of SFX-01 and 3 hours 
later cardiac tissue was harvested for analysis. SFX-01 caused inhibition of SHP2 
activity only at 500 mg/kg (figure 3.13 A). Subsequent studies in which varying 
amounts of the drug, which was approximately 0-500 mg/kg, was provided for 7 
days in the drinking water resulted in inhibition of the phosphatase as low as 
approximately 5 mg/kg (figure 3.13 B). SHP2 immunoprecipitated from mice 
administered 2.5 mg/ml SFX-01 for 7 days in their drinking water served as a 








































Figure 3.13. Treatment with SFX-01 at clinically-relevant concentrations inhibits 
SHP2 activity.  
A, B) Fluorescence-based phosphatase activity assays using SHP2 immunoprecipitated 
from cardiac tissue of WT mice showing inhibition in activity either 3 hours post-oral 
gavage with 500 mg/kg SFX-01 (A) or approximately 5-500 mg/kg SFX-01 when 
received in their drinking water for 7 days (B). Positive control was derived from mice 
administered 2.5 mg/ml SFX-01 for 7 days. (n = 5, *p<0.05 versus water only control). 
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3.3.11 Chronic SFX-01 treatment increases global tyrosine phosphorylation  
Immunoblotting with a pan-specific anti-phospho-tyrosine antibody revealed an 
increase in tyrosine phosphorylation of multiple proteins in cardiac tissue of WT 
mice following 4, 7 or 10 days SFX-01 treatment at 2.5 mg/ml in their drinking 










3.3.12 Chronic SFX-01 treatment increases ERK phosphorylation  
Immunoblotting showed ERK phosphorylation was increased in the cardiac 
tissue of WT mice that received 2.5 mg/ml SFX-01 in their drinking water, but 
only at the 10-day time point. A trend towards an increase was also notable after 
7 days of treatment, however, this did not reach statistical significance. Over the 
Figure 3.14. SFX-01 treatment increases global tyrosine phosphorylation.  
An immunoblot showing an increase in global tyrosine phosphorylation in cardiac tissue 
of WT mice administered 2.5 mg/ml SFX-01 in their drinking water for up to 10 days. (n 
= 6, *p<0.05 versus water only control). 
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3.3.13 SFX-01 or rmGH treatment increases STAT5 phosphorylation  
As expected, phosphorylation of STAT5 was increased in the cardiac tissue of 
WT mice 30 minutes after subcutaneous injection of 70 µg rmGH. STAT5 
phosphorylation was also increased 30 minutes after an intraperitoneal injection 
Figure 3.15. SFX-01 treatment increases ERK phosphorylation over time.  
An Immunoblot showing increased ERK phosphorylation in cardiac tissue of WT mice 
following treatment with 2.5 mg/ml SFX-01 for 10 days in their drinking water. (n = 5, 
*p<0.05 versus water only control). 
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of 2.5 mg/ml SFX-01, although to a lesser extent than rhGH. Combination 
treatment with 70 µg rmGH and 2.5 mg/ml SFX-01 did not potentiate STAT5 
phosphorylation compared to rmGH alone at any time point examined. 
Phosphorylation decreased over time in all treatment groups, although it 
remained elevated compared to control 120 minutes after treatment with rmGH 













Figure 3.16. SFX-01 and rmGH increase STAT5 phosphorylation.  
An immunoblot showing increased cardiac STAT5 phosphorylation 30 minutes following 
a single intraperitoneal injection of 2.5 mg SFX-01 or a single subcutaneous injection of 
70 µg rmGH to WT mice. STAT5 phosphorylation was not potentiated when SFX-01 was 
co-administered with 70 µg rmGH. In all treatment groups, STAT5 phosphorylation 
decreased over time. (n = 3, *p<0.05 versus water control). 
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3.3.14 STAT5 phosphorylation by 40 µg rmGH is potentiated by SFX-01 
Previous in vivo studies showed SFX-01 did not potentiate STAT5 
phosphorylation induced by 70 µg rmGH. This experiment was repeated, but a 
lower 40 µg dose of subcutaneously injected rmGH was used, as the 70 µg may 
have been maximally stimulating STAT5 phosphorylation. As with the previous 
study, immunoblotting revealed an increase in STAT5 phosphorylation in cardiac 
tissue of WT mice 30 minutes following intraperitoneal injection of 2.5 mg SFX-
01. 40 µg rmGH alone increased STAT5 phosphorylation, and this was 















Figure 3.17. SFX-01 potentiates phosphorylation of STAT5 by 40 µg rmGH.  
An immunoblot showing increased cardiac STAT5 phosphorylation 30 minutes after a 
single intraperitoneal injection of 2.5 mg SFX-01 or a single subcutaneous injection of 
40 µg rmGH to WT mice. STAT5 phosphorylation was potentiated when a combined 




3.4 Discussion  
Studies are underway by multiple research groups to identify efficacious 
inhibitors of SHP2. Here, I investigated whether SHP2 was inhibited by SFN, 
which was rationally anticipated for the reasons outlined in the introduction of this 
chapter. Such inhibition could offer the prospect of a therapy for NS by 
normalising hyperactive SHP2 to WT levels. 
Assessing the effect of SFN on SHP2 phosphatase activity required utilisation of 
a commercial, fluorescence-based phosphatase activity assay. Although the 
assay was established by the company, optimisation was required to determine 
the minimum amount of recombinant SHP2 protein to generate a consistently 
detectable signal from the fluorometer without the assay substrate becoming 
saturated. The experimental buffer for these experiments contained DTT, a 
reducing agent which resolves disulfide bonds via a disulfide-exchange 
mechanism (figure 3.18). DTT is essential within the storage and experimental 
buffer of recombinant SHP2 to maintain the catalytic and surrounding cysteines 
in a reduced state 142, and as expected, desalting SHP2 into a solution with no 
DTT caused the protein to become air oxidised and inactive. As discussed in 
greater detail in chapter 4, SFN can ‘trans-thiolate’ and so move between thiol-
containing compounds and/or proteins 99. As DTT is a dithiol-containing 
compound, I next optimised a minimal concentration in order to keep the protein 
reduced and active prior to the experiment, but also minimise the amount of 























In line with the rationale presented in the introduction of this chapter, I observed 
the inhibition of SHP2 phosphatase activity by SFX-01 in vitro. At shorter time 
points inhibition was achieved in a concentration-dependent manner, likely due 
to more SFN being readily available to adduct the catalytic cysteine of SHP2 as 
the abundance of the electrophile increased. Indeed, I observed no adduction of 
SHP2 by SFN after a 30-minute incubation with the lowest concentration of the 
electrophile, whereas a high abundance of SHP2-SFN was detected at the two 
higher concentrations investigated. This correlates with previous observations 
from Lewis et al, who demonstrated that dietary ITCs, including allyl ITC and 
SFN, are concentration-dependent inhibitors of SHP2 phosphatase activity 143. 







 SH SH 
Figure 3.18. Protein-disulfide reduction by DTT.  
DTT reduces disulfides via two sequential thiol-disulfide exchange reactions. 
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phosphate containing compounds. This is likely due to these phosphate groups 
being cleaved at the active site, occupying the catalytic cysteine and preventing 
inhibitory adduction by SFN. They therefore also hypothesised that ITC inhibition 
of SHP2 is active site-directed.  
SFN also inhibited SHP2 in a time-dependent manner in vitro. I anticipate this 
was due to the covalent nature of the SHP2-SFN interaction. Covalent versus 
non-covalent drug-protein interactions are considered in detail in the general 
introduction. Non-covalent drug-protein interactions are reversible, and this 
generates an equilibrium between a protein-bound and -unbound state. 
Therefore, this class of drug typically results in an eventual plateau in protein 
inhibition. Compounds with high electrophilicity such as SFN, on the other hand, 
form covalent interactions with proteins which are typically stable and permanent, 
or only slowly reversed. Extended periods of time increase the opportunity for 
SFN to adduct the catalytic cysteine of SHP2, and if this interaction is indeed 
permanent this may explain the time-dependent accumulation in inhibition of the 
phosphatase. Indeed, incubation with low amounts of SFX-01 for longer 
durations resulted in the same level of inhibition of SHP2 phosphatase activity as 
when incubated with higher amounts for a shorter time period. This was also 
visualised by immunoblotting as adduction of SHP2 by SFN required 2-hour 
incubation with the lowest concentrations of the electrophile. This cumulative 
effect also results in differences in IC50 values, which range from 47.28 to 0.49 
µM depending on the duration that the phosphatase was exposed to SFN. Similar 
observations are also documented by the Darley-Usmar group, whereby 
prolonged treatment (days) with the electrophile 15-deoxy-Δ12,14-prostaglandin J2 
resulted in accumulative adduction of the signalling protein KEAP1 144. However, 
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if accumulative adduction of a stable SFN adduct upon SHP2 were the sole 
mechanism for the time-dependent increase in inhibition of the phosphatase then 
I would have expected to see cumulative protein-adduct formation as measured 
using immunoblotting. In fact, the formation of SHP2-SFN was followed by a time-
dependent loss of the adduct even though the proteins phosphatase activity 
remained inhibited. A detailed hypothesis and proposed mechanism for SFN-
induced inhibition of SHP2 are outlined in chapter 6.  
I next wanted to establish if inhibition of the phosphatase by SFN could be 
achieved in vivo using a mouse model for NS with hyperactive SHP2 activity. 
Since clinical drugs are typically administered in a single, daily bolus dose I used 
this delivery approach of SFX-01 for initial experiments. However, even though 
multiple protein-SFN adducts were identified, adduction or inhibition of SHP2 by 
SFN was not observed. Due to the findings of the preceding in vitro experiments 
I speculated that a lower amount of SFX-01 administrated continually over a 
longer duration may provide the time needed for SFN to adduct and inhibit low 
abundance proteins such as SHP2; consequently, my experimental design was 
altered accordingly. The method of continual drug administration was by addition 
to the drinking water, which unlike repeated oral gavage offered a stress-free and 
non-invasive delivery approach. SFX-01 is orally bioavailable, and it was not 
rational to administer using osmotic minipumps, as this was considered a 
backward step in terms of developing the compound for clinical use. Also, the 
amount of SFX-01 that we delivered over a sustained period cannot be 
accommodated in a single minipump. Cardiac SHP2 phosphatase activity was 
inhibited in WT or NS mice following administration of lower amounts of SFX-01 
in this chronic manner. Again, this provides evidence that prolonged treatment 
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with low doses of SFN allows time for the electrophile to adduct and inhibit SHP2. 
This inhibition was maintained up to 10 days of treatment, which was perhaps 
due to the covalent nature of the interaction. Although, this mechanism of 
inhibition is challenged and reviewed in detail in chapter 6. As drug metabolism 
is notably higher in mice than in humans 145 146 the amount of SFX-01 given 
throughout the chronic in vivo study was ~5-fold that used in clinical trials; ~250 
mg/kg compared to 50 mg/kg. However, importantly, I also established that SHP2 
phosphatase activity was significantly inhibited in cardiac tissue of WT mice 
following 7 days treatment of SFX-01 in drinking water at a concentration as low 
as ~5 mg/kg. Again, these data provide evidence for electrophiles achieving 
biological effects when administered at low amounts over prolonged treatment 
times. Importantly, due to its requirement in essential signalling pathways, levels 
of SHP2 phosphatase activity were not completely reduced under any of these 
experimental conditions and in fact, the activity of the phosphatase in NS mice 
was reduced to levels comparable to their untreated WT littermates.  
After establishing SFN induced inhibition of SHP2 activity I next assessed 
changes in signalling events downstream of the phosphatase. As SHP2 is a 
tyrosine phosphatase, it is logical to assume that increased global tyrosine 
phosphorylation following SFX-01 treatment was due, at least in part, to its 
inhibition. The adduction of SFN to proteins other than SHP2 also likely 
contributes to this biological effect and perhaps the electrophile could adduct and 
inhibit other PTPs with essential catalytic cysteines.   
Oxidative modification of the catalytic cysteines of PTPs by ROS can also inhibit 
their activity, as outlined in chapter 6. Several studies have identified SFN can 
increase cellular ROS 147 148 149, which I speculate may involve the antioxidant 
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GSH. Due to its high cytoplasmic abundance, GSH is readily available to adduct 
free-SFN before the electrophile can interact with other target proteins. GSH 
plays a major role in the removal of ROS. Therefore, although SFN induces 
production of this antioxidant via activation of the KEAP1/Nrf2 signalling pathway, 
the pool of reactive GSH is overall reduced due to adduction by the electrophile. 
This resulting SFN-induced increase in cellular ROS may be contributing to 
increased global tyrosine phosphorylation by inhibiting an array of PTPs.  
SFN-induced upregulation in gene expression of many kinases via the 
KEAP1/Nrf2 signalling pathway, such as phosphatidylinositol 3 and 4, protein 
kinase C and MAP kinase kinase kinase 4 and 5 has also been documented and 
may be another explanation for the increase in protein phosphorylation 150.  
SHP2 is a positive regulator of the Ras/ERK signalling pathway through 
mechanisms outlined in the introduction of this chapter and I rationally anticipated 
that SFN-induced inhibition of the phosphatase’s activity would result in 
decreased phosphorylation and activation of ERK. The reverse effect was 
observed, with SFX-01 treatment inducing an increase in ERK phosphorylation 
in cardiac tissue. These data correlate to an accumulating body of evidence 
showing SFN-induced increase in ERK phosphorylation in multiple cell lines, 
including liver carcinoma, cortical neuronal, intestinal epithelial and glioblastoma 
151 152 153 154. Perhaps SFN-induced inhibition of SHP2 does result in a decrease 
in SHP2-stimulated ERK phosphorylation due to a resulting increase in RasGAP, 
Sprouty and Csk activity, but these effects may be outweighed by regulation of 
other SHP2-dependent and -independent mechanisms which induce 
phosphorylation of the kinase, as described below. 
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SHP2 positively regulates IGF1-induced activation of Akt 155 72 156. It has been 
shown that following its activation, Akt can phosphorylate RAF at Ser259 in its 
amino-terminal regulatory domain, which inhibits the protein 157 and prevents 
RAF from subsequently phosphorylating ERK. Perhaps SFN-induced inhibition 
of SHP2 reduces Akt activation and prevents its negative regulation of ERK 
phosphorylation.  
SFN may also increase ERK phosphorylation independent of SHP2 by increasing 
levels of cellular ROS. I have outlined a proposed mechanism for SFN-induced 
increase in ROS in detail above. ROS produced in an IGF1 dependent manner 
activate GFRs resulting in downstream stimulation of ERK signalling as well as 
other MAPKs 158 159. A common feature of GFRs is cysteine-rich motifs that are 
susceptible to modification by ROS, which may be responsible for driving 
receptor activation. Perhaps another mechanism by which oxidative stress 
increases ERK phosphorylation is altering the activity of MAPK phosphatases. 
MAPK phosphatase 1 is inhibited by H2O2-induced sulfenic acid intermediates 
upon its catalytic cysteine which results in increased phosphorylation of ERK, its 
primary substrate 160. As well as this, activation of protein kinase Cδ by 
glutamate-induced ROS stimulates degradation of MAPK phosphatase 1 via a 
ubiquitin-proteasome pathway 161. Finally, although the mechanism remains 
unclear, ROS can also induce phosphorylation of MEK 1/2 and increase 
downstream ERK phosphorylation 162. SFN itself also carries oxidant-like 
properties as it can directly adduct thiolates and inhibit protein function, much like 
H2O2. Therefore, perhaps the ROS-induced mechanism of ERK phospho-
activation considered above can also be achieved through direct adduction of 
mentioned protein cysteines by SFN.  
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SHP2 is a negative regulator of the JAK2/STAT5 signalling pathway and finally, 
I assessed the impact of SFX-01 treatment on this cascade. As GHs directly bind 
GHRs and stimulate signalling, it was as expected that rmGH treatment alone 
increased STAT5 phosphorylation in cardiac tissue. One observation is a peak 
in STAT5 phosphorylation 30 minutes post-rmGH treatment followed by a 
relatively rapid decline. Studies in both rats and primary hepatocytes have also 
shown that high levels of circulating GH result in a peak in signalling followed by 
fast induction of down-regulation 163 164. Including dephosphorylation of JAK2 by 
SHP2, GH signalling has multiple negative feedback mechanisms, such as 
ligand-induced endocytosis of the GHR 165, and upregulation of a family of 
cytokine-inducible suppressors of cytokine signalling (SOCS) 166. SOCS proteins 
dock phospho-tyrosine residues on both JAK2 and GHRs which interferes with 
STAT5 binding and induces degradation of the receptor complex. Either of these 
negative feedback mechanism may explain the rapid decline in STAT5 
phosphorylation 167.  
An increase in STAT5 phosphorylation followed by a time-dependent decline was 
also observed following treatment with SFX-01. I speculate that SFN-induced 
inhibition of SHP2 activity may be responsible for this increase in STAT5 
phosphorylation, as the phosphatase could no longer dephosphorylate JAK2.  
As explained in the results section of this chapter, two in vivo experiments were 
conducted using different amounts of rmGH. At higher amounts, no potentiation 
in STAT5 phosphorylation induced by rmGH was observed following combined 
treatment with SFX-01. I speculated that when mice were given high amounts of 
hormone, even though SFX-01 may be inhibiting SHP2 activity, JAK2 
phosphorylation cannot be increased as it is already saturated by high levels of 
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GH stimulation. Indeed, combined treatment with SFX-01 using less rmGH 
resulted in potentiated STAT5 phosphorylation compared to rmGH alone.  
Interestingly, studies in rats showed that low levels of circulating GH result in 
maximal activation of the JAK/STAT signalling pathway 168. This low level of 
stimulation may avoid a rapid increase in negative regulation by the mechanisms 
explained above. Perhaps the lower levels of GH utilised in my latter experiment 
prevented induction of such negative feedback loops and heightened potentiation 
of the combined treatment. With this in mind, it may have been beneficial to 
examine longer time points to determine whether sustained activation of the 
pathway can be detected.  
These findings are, however, contradictory to previous studies which found 
decreased STAT3 or STAT5 phosphorylation in human nasopharyngeal, 
prostate and lymphocyte cancer cell lines following treatment with SFN 169 170 171. 
Although notably, these studies were all conducted using human cancer cell 
lines, which may have basally altered signalling mechanisms and activity and are 
not comparable to the murine cardiac tissue analysed in my experiments which 
predominantly consists of non-proliferative cardiomyocytes. For example, mRNA 
expression of GHR is elevated in human prostate cancer cell lines where rapid 
induction of JAK2/STAT5 phosphorylation by GH is detected 172. Secondly, in 
proliferating cells, including a range of cancer cell lines, GHs induce a high level 
of nuclear localisation of GHRs where they can bind to transcriptional regulators 
themselves and upregulate target genes without driving STAT5 phosphorylation 




4 Sulforaphane can trans-thiolate between 
proteins 
4.1 Introduction 
4.1.1 SFN adducts are reversible 
Adduction of ITCs to intracellular GSH is the first step in their metabolism 175. In 
most cases, this adduction is permanent and results in urinary excretion of 
subsequent metabolites. However, the resultant dithiocarbamate can also 
sporadically reverse i.e. the resolution of the adduct to regenerate reactive forms 
of the thiol and SFN, with no catalysis by another protein or chemical 176 177. 
Bruggeman et al found that treatment of rat liver cells with certain ITCs was 
cytotoxic and these same detrimental effects were seen when treated with GSH-
ITC, where there was the apparent release of the ITC at the plasma membrane 
178. They also showed that 2 hours post addition of L-cysteine to GSH-ITC, 80 % 
of total conjugates were L-cysteine-ITC and vice versa. This process is widely 
regarded as non-enzymatic, although increased catalysis has been observed 
with the presence of GSH transferases 179 180. It is therefore recognised that 
adduction to GSH does not always result in detoxification of the ITC. This is not 
to say that reversal of the adduct occurs only intracellularly. GSH-ITC can be 
rapidly excreted from the cell via MRP1 and/or Pgp1, as shown in the general 
introduction and reversal may, therefore, occur within the bloodstream or 
following transportation across cellular membranes into other tissues. 
Irrespective of location, regenerated electrophile is again available to react with 
free thiols 181. The Uchida group have also shown using MS analysis that as well 
as the spontaneous reversal of a GSH-SFN interaction, the electrophile can 
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actively transfer directly from a thiol-containing protein to GSH without the 
generation of free-SFN 182. This mechanism, termed ‘trans-thiolation’ in this 
document, involves direct nucleophilic attack of the reactive thiolate of GSH to 
the protein-SFN interaction. These data, therefore, suggest the transient 
movement of an SFN adduct between protein thiols, which may or may not 
require the flow of the electrophile to and from GSH to aid transport.  
In chapter 3 I reported a time-dependent increase in protein-SFN adducts in the 
cardiac tissue of WT or NS mice following treatment with SFX-01 for 4-10 days. 
Here liquid chromatography (LC) with tandem (MS/MS) analysis was utilised to 
identify SFN-adducted proteins of interest following treatment with SFX-01 or 
broccoli sprouts, a rich source of naturally occurring SFN. Subsequent 
biochemical analysis was used to investigate if the transient movement of the 
SFN adduct was responsible for such accumulation upon these proteins, which 












4.2 Materials and methods 
4.2.1 SDS-PAGE and western immunoblotting  
SDS-PAGE and western immunoblotting were performed as outlined in the 
general methods. For this chapter the following primary antibodies were used: 
 
 






























Haemoglobin subunit β 
 




Table 4.1. List of primary antibodies used for western immunoblotting in chapter 
4.  
 
4.2.2 Immunoprecipitation  
Immunoprecipitation of proteins from tissue was performed as outlined in the 
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Santa Cruz #sc-2003 
 
Table 4.2. List of antibodies used for immunoprecipitation in chapter 4.  
 
4.2.3 Preparation and administration of broccoli sprouts  
Individually housed male or female WT or NS mice were used in this study. 
Control group mice continued their regular diet of pelleted food. 15 mg of 
pesticide-free broccoli sprouts (Planet Organic) were weighed and placed in a 
glass jar. 1 g of their regular pelleted food was crushed and distributed over the 
sprouts to encourage eating. A plastic screw lid was placed on top which had a 
3 cm diameter access hole cut out from the middle. Each morning broccoli 
sprouts were replenished. Remaining broccoli sprouts were weighed to monitor 




4.2.4 Proteomic analysis following SFX-01 treatment 
LC-MS/MS was carried out by Dr Xiaoke Yin and Professor Manuel Mayr (The 
James Black Centre, King’s College London). Proteins from heart homogenates 
of WT mice which had received 2.5 mg/ml SFX-01 in their drinking water for 7 
days were separated by SDS-PAGE. Following electrophoresis, a yellow band 
appeared on the polyacrylamide gel which corresponded to a ~15 kDa protein in 
lanes containing SFX-01-treated samples. This gel band and equivalent controls 
were carefully excised under sterile conditions and subjected to in-gel tryptic 
digestion using a ProGest (DigiLab Inc.) robotic digestion system. Peptides were 
subsequently separated by nanoflow LC using a reverse-phase column (PepMap 
C18, 3 µM, 100 Å, 25 cm x 75 µm inner diameter, Thermo Fisher). Separated 
peptides were then applied to an interfacing linear ion trap mass spectrometer 
(LTQ Orbitrap XL, Thermo Fisher) and collected from the analyser using full ion 
scan mode over an m/z range of 300-2000. MS/MS was performed to analyse 
the top six ions using dynamic exclusion. Generated spectra were analysed 
against the mouse protein database using the Mascot search engine (Matrix 
Science). Two missed cleavages per peptide were allowed. Protein 
identifications were verified using the proteomics computer program Scaffold 
(Version 4, Proteome Software Inc.). Peptides with above 95 % probability of 
identification were accepted as specified by the Scaffold software. A modification 
of 177.03 Da was searched for using the proteomic software PEAKS 
(Bioinformatics Solutions Inc.).  
4.2.5 Protein separation by size-exclusion chromatography 
In order to explore the transfer of the electrophile between proteins, a thiol-
containing protein with SFN adducted was required and for these experiments 
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BSA was used. A 200 mM BSA stock was made by dissolving 13.30 mg BSA in 
1 ml of either 10 mM Tris pH 7.4 or PBS pH 7.4. A 50 mM SFN solution was then 
made by dissolving 115.23 mg SFX-01 in 2 ml of either 10 mM Tris buffer or PBS. 
5 µl of the 200 mM BSA stock and 100 µl of the 50 mM SFN stock were added 
to 895 µl Tris or PBS, making a working solution containing 1 mM BSA and 5 mM 
SFN. The solution was then incubated at 37 ˚C for 30 minutes. 
BSA-SFN was separated from free-SFN by size-exclusion LC (Bio-Rad BioLogic 
Duoflow liquid chromatograph), which comprised a pump operated at a flow rate 
of 1 ml/minute, an injection valve fitted with a 500 µl sample loop, a UV detector 
set to 280 nm and a Hi-Load 16/600 Superdex 200 prep grade column (Bio-Rad). 
The mobile phase consisted of either 10 mM Tris pH 7.4 or PBS pH 7.4. The 
programme is outlined in table 4.3. A 10 mM Tris or PBS buffer sample was used 









Table 4.3. Chromatography protocol for purifying BSA-SFN from unbound 
electrophile. 
 
When absorption at 280 nm was detected by visual inspection of the real-time 
chromatogram, the eluate was continuously collected in serial 5 ml fractions. 
Volume, 
ml 














































Following analysis of all samples, the pumps and column were flushed with 70 % 
methanol for 10 minutes and left stored in 70 % methanol until next required. 
Following the chromatography procedure, 50 µl of each eluted fraction was 
added to 50 µl of 2X SDS-PAGE sample buffer and the remaining eluate divided 
into 100 µl aliquots and stored frozen at - 20 ˚ C until required. Samples were then 
subjected to SDS-PAGE followed by either Colloidal Coomassie staining or 
western immunoblotting as described in the general methods.  
As the methods name suggests, separation is achieved by differences in protein 
or compound size, more specifically their Stokes radius, which considers not only 
size of the solute but also its mobility within a solution 183. Separation of the 
analytes greatly depends on the size of the pores within gel beads that form the 





























4.2.6 Treatment of purified BSA-SFN with cysteine containing compounds 
To investigate the ability of SFN to trans-thiolate, BSA-SFN purified using the gel 
filtration outlined above was incubated with other cysteine-containing 
compounds, including; haemoglobin subunit β (Hgb β), haemoglobin (Hgb), 
GSH, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), L-cysteine or 
tissue homogenate from WT mice. 100 µl of 25 µM Hgb β, Hgb, GSH, GAPDH 
Figure 4.1. A diagram illustrating the size-exclusion chromatography system. 
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or L-cysteine in PBS pH 7.4 or 9.0 were incubated with 50 mM Bond-Breaker Tris 
(2-carboxyethyl) phosphine (TCEP) solution (Thermo Fisher) for 30 minutes to 
reduce any oxidative modifications. Following reduction with TCEP, solutions 
were desalted using 0.5 ml Zeba Spin desalting columns with a 7 kDa molecular 
weight cut-off (Thermo Fisher). 100 µl of cardiac, liver, kidney or blood 
homogenates from untreated WT mice were also prepared, using the protocol 
described in the general methods. 100 µl of 25 µM BSA-SFN, purified by size-
exclusion chromatography, was added to each solution, generating a final BSA-
SFN concentration of 12.5 µM. Samples were then incubated at 37 ˚C for 0-60 
minutes followed by addition of an equal volume of 2X SDS-PAGE sample buffer. 
Negative controls were used containing either BSA, Hgb, GSH, GAPDH, L-
cysteine or tissue homogenate alone. A time-matched control was also made by 
incubating 12.5 µM BSA-SFN alone for 1-hour at 37 ˚C. Western immunoblotting 
was carried out following the protocol described previously in the general 
methods.  
4.2.7 Using HPLC to assess transfer of an SFN adduct from SHP2 to GSH  
Incubation of 65 µM SFX-01 with 10 µM SHP2 for 30 minutes at room 
temperature was followed by desalting to remove any unbound electrophile using 
a 7 kDa cut-off 0.5 ml Zeba Spin desalting column (Thermo Fisher). The solution 
was then analysed by HPLC using the protocol outlined in the general methods 
and the UV detector set at a wavelength of 205 nm. The solution was 
subsequently incubated with 10 mM GSH for 30 minutes at room temperature 
and again analysed using the HPLC method. Finally, the sample was incubated 
with 10 mM TCEP and incubated at room temperature for 30 minutes and again 
analysed using the HPLC method.  
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A deionised water-only sample was used as a negative control followed by a 
GSH-SFN standard to determine its retention time.  
4.2.8 Isolation of adult mouse ventricular myocytes 
Adult mouse ventricular myocytes were isolated from WT C57BL/6 mice using a 
collagenase-based enzymatic digestion procedure. Isolation was carried out by 
Dr Shiney Reji (The Rayne Institute, King’s College London) using the following 
protocol. Hearts were excised, cannulated and sequentially perfused in 
Langendorff mode at 37 ˚C with solutions outlined in table 4.4. Perfusion was 
conducted using modified Tyrode’s solution 1 for 2 minutes followed by calcium-
free modified Tyrode’s solution for 5 minutes. This was followed by subsequent 
perfusion with modified Tyrode’s solution containing collagenase (250 mg/L) for 
~12 minutes. The ventricles were then removed from the apparatus and excised 
into smaller pieces to allow extra surface area for the collagenase digestion to 
occur. The homogenate was then bubbled with O2 for 4 minutes at 37 ˚C. 
Following incubation, the tissue was gently triturated until a uniform suspension 
was obtained and the cell suspension was subsequently filtrated through a nylon 
mesh. The cells were allowed to settle for 5 minutes which was followed by 
washing in modified Tyrode’s solution 2. The cells were again allowed to settle 
for 5 minutes which was followed by resuspension in modified Tyrode’s solution 
2. After a 2-hour recovery period, the supernatant was removed, and the cells 
washed in PBS prior to lysis and addition to an equal volume of 2X SDS-PAGE 



















NaCl 130 130 130 130 
KCl 5.4 5.4 5.4 5.4 
MgCl2 1.4 1.4 1.4 1.4 
NaH2PO4 0.4 0.4 0.4 0.4 
HEPES 4.2 4.2 4.2 4.2 
Glucose 10 10 10 10 
Taurine 20 20 20 20 
Creatine 10 10 10 10 
EGTA - 0.1 - - 
CaCl2 0.75 - 0.5 - 
Type-1 - - 342 U/mg - 
Collagenase 
pH at 37 ˚C 
7.3 7.3 7.3 7.3 
 
Table 4.4. Solutions used for the isolation of adult mouse ventricular myocytes. 
 
4.2.9 Treatment of HEK293 cells  
Just prior to treatment, growth media was removed from HEK293 cells and 
replaced with fresh media containing no FBS. Cells were then treated for 0-60 
minutes with 10 µM of either GSH-SFN (Santa Cruz #sc-207496) or GSH.  
Following treatment, 200 µl of 2X SDS-PAGE sample buffer was added to each 
well. Cells were then detached from the well using a cell scraper, moved into a 
microcentrifuge tube and lysed via sonication for 7 seconds at 30 kHz and 40 % 
amplitude. Western immunoblotting was then carried out using the protocol 




4.3.1 SFN adducts a ~15 kDa protein in cardiac tissue 
As detailed in chapter 3, treatment of WT mice with 2.5 mg/ml SFX-01 for 4-10 
days in their drinking water identified a time-dependent increase in protein-SFN 
adducts in cardiac tissue. These samples were reanalysed by immunoblotting 
which included collecting shorter detection film exposure times, which illustrated 
that SFN predominantly adducts a protein with a mass of ~15 kDa. This SFN 












Figure 4.2. SFN adducts a ~15 kDa protein in cardiac tissue of WT mice.  
An immunoblot showing a time-dependent increase in SFN adduction to a ~15 kDa 
protein in cardiac tissue of WT mice following treatment with 2.5 mg/ml SFX-01 in their 
drinking water for 4-10 days. (n = 10, *p<0.05 versus water-only control). 
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4.3.2 Protein-SFN adducts are detected after consumption of broccoli 
sprouts 
I next wanted to assess if protein-SFN adducts could be detected in vivo following 
ingestion of a naturally occurring source of the electrophile. WT or NS mice were 
therefore given broccoli sprouts for 7 days. SFN adduction of a ~15 kDa protein 
was seen in cardiac tissue of WT or NS mice after consumption of the sprouts 











Figure 4.3. Ingestion of a naturally-derived source of SFN results in protein adduct 
formation.  
An immunoblot showing SFN adduction of a ~15 kDa protein in cardiac tissue of WT or 




4.3.3 SFX-01 treatment increases Trx and GRX1 protein expression 
I next began to investigate if the ~15 kDa protein adducted by SFN following 
treatment with SFX-01 for 4-10 days in their drinking water was Trx or GRX1, 
which were considered rational because they are thiol-dependent enzymes of 
approximately this molecular weight. Immunoblotting under reducing conditions 
identified an increase in protein expression of Trx or GRX1 in cardiac tissue of 
WT mice following 10-day treatment with 2.5 mg/ml SFX-01 (figure 4.4 A, B). 
 










Figure 4.4. SFN treatment increases protein expression of Trx and GRX1.  
A, B) Representative immunoblots showing an increase in protein expression of Trx and 
GRX1 in cardiac tissue of WT mice following treatment with 2.5 mg/ml SFX-01 in their 
drinking water for 10 days.  
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4.3.4 Trx or GRX1 do not comigrate with the ~15 kDa protein adducted by 
SFN 
Proteins from cardiac tissue of WT mice who received 2.5 mg/ml SFX-01 in their 
drinking water were resolved in triplicate by SDS-PAGE. Immunoblotting 
revealed Trx nor GRX1 resolved at the same molecular weight as the ~15 kDa 








4.3.5 Immunoprecipitation of the ~15 kDa protein adducted by SFN was 
unsuccessful  
I next attempted to immunoprecipitate the ~15 kDa protein adducted by SFN from 
cardiac tissue of WT or NS mice following 10-day treatment with 2.5 mg/ml SFX-
01 in their drinking water. Immunoprecipitation was conducted using our in-house 
anti-SFN primary antibody, however, the protein of interest was not present in 
the immunocaptured sample (figure 4.6). 
 
Figure 4.5. Neither Trx nor GRX1 comigrate with a ~15 kDa protein target of SFN.  
A representative immunoblot showing the ~15 kDa protein adducted by SFN from the 
cardiac tissue of WT mice following 10-day treatment with 2.5 mg/ml SFX-01 in their 

















4.3.6 The ~15 kDa protein adducted by SFN was identified by mass 
spectrometry 
Unexpectedly, the ~15 kDa protein adducted by SFN following 10-day treatment 
with SFX-01 could be visualised on a polyacrylamide gel following 
electrophoresis by a yellow colouring (figure 4.7). Table 4.5 documents the 
proteins identified by LC-MS/MS within gel pieces excised from both SFX-01 
treated and untreated samples, which was conducted using biological repreats. 
Hgb subunits α and β1 (Hgb α and Hgb β1 respectively) were the most abundant. 
Subsequent analysis using the computer program Mascot identified an addition 
Figure 4.6. A ~15 kDa protein adducted by SFN was not successfully 
immunoprecipitated from cardiac tissue.  
A representative immunoblot of input and immunocaptured cardiac tissue of WT or NS 
mice treated with 2.5 mg/ml SFX-01 for 10 days in their drinking water. Precipitation was 
conducted using the anti-SFN primary antobody although no enrichment of the ~15 kDa 
protein adducted by SFN was achieved.  
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of +177.03 Da, the mass of SFN, upon cysteine within the peptide sequence 























Figure 4.7. The ~15 kDa protein adducted by SFN can be visualised following 
electrophoresis.  
A representative polyacrylamide gel showing the yellow appearance of the ~15 kDa 
protein adducted by SFN in cardiac tissue of WT mice who received 2.5 mg/ml SFX-01 
in their drinking water for 10 days.  
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Protein name Abbreviation Mol. Wt 
Hgb subunit α Hgb α 15 kDa 
Hgb subunit β1 Hgb β1 16 kDa 
Histone H4 H4 11 kDa 
Cytochrome c oxidase subunit 6c COX6C 8 kDa 
ATP synthase subunit e, mitochondrial ATP51 8 kDa 
Fatty acid-binding protein, heart FABPH 15 kDa 
Cytochrome c, somatic CYC 12 kDa 
Cytochrome c oxidase subunit 5A COX5A 16 kDa 
Fatty acid-binding protein, adipocyte FABP4 15 kDa 
Cytochrome c oxidase subunit NDUFA4 NDUA4 9 kDa 
Cytochrome b-c 1 complex subunit 8 QCR8 10 kDa 
ATP synthase subunit g, mitochondrial ATP5L 11 kDa 
Cytochrome c oxidase subunit 4 isoform 1 COX41 20 kDa 
Cardiac phospholamban PPLA 6 kDa 
NADH dehydrogenase subunit 1 beta 
subunit 3 
NDUB3 12 kDa 
NADH dehydrogenase subunit 1 alpha 
subunit 6 
NDUA6 15 kDa 
Cytochrome b-c1 subunit 7 QCR7 14 kDa 
Cytochrome c oxidase subunit 5b C0X5B 14 kDa 
ATP synthase subunit f, mitochondrial ATPK 10 kDa 
Mitochondrial pyruvate carrier 2 MPC2 14 kDa 
ADP/ATP translocase 1 ADT1 33 kDa 
NADH dehydrogenase 1 subunit C2 NDUC2 14 kDa 
NADH dehydrogenase 1 β subunit 4 NDUβ4 15 kDa 
Cytochrome c oxidase subunit 6B1 CX6B1 10 kDa 
ATP synthase protein 8 ATP8 8 kDa 
Ubiquitin-60S ribosomal protein L40 RL40 15 kDa 
Histone H2A type 2 H2A2C 14 kDa 
Myoglobin MYG 17 kDa 
CDGSH iron-sulphur domain-containing 
protein 1 
CISD1 12 kDa 
NADH dehydrogenase 1 alpha subunit 7 NDUA7 13 kDa 
 





4.3.7 SFN can adduct Hgb β 
Immunoblotting revealed SFN can adduct recombinant Hgb β following 30-
minute treatment with SFX-01 (figure 4.9). Hgb β has a monomeric weight of 16 
kDa. SFN adducts are identified at a molecular weight of both 16 and 32 kDa, 





Figure 4.8. Mass spectra of the Hgb β1 peptide sequence GTFASLSELHCDK 
which contained a +177.03 mass adduct upon Cys93. 
Figure 4.9. SFN can adduct Hgb β.  
An immunoblot showing SFN adducted to monomeric and dimeric Hgb β following 




4.3.8 The ~15 kDa protein adducted by SFN comigrates with Hgb β 
Immunoblotting revealed the ~15 kDa protein adducted by SFN in cardiac tissue 
of WT mice following treatment with 2.5 mg/ml SFX-01 in their drinking water for 
4-10 days resolved at the same molecular weight as recombinant Hgb β following 








4.3.9 Immunoprecipitation of Hgb β-SFN was unsuccessful 
I attempted to immunoprecipitate Hgb β-SFN from cardiac tissue of WT mice 
following 10-day treatment with 2.5 mg/ml SFX-01 in their drinking water. 
Immunoprecipitation was conducted using an anti-Hgb β primary antibody 
however no presence of Hgb β-SFN was detected in the immunocaptured sample 






Figure 4.10. Hgb β comigrates with the SFN adducted ~15 kDa protein.  
A representative immunoblot showing comigration of Hgb β with the ~15 kDa protein 
adducted by SFN in cardiac tissue of WT mice following 4-10-day treatment with SFX-


















4.3.10 SFX-01 treatment did not increase Hgb β expression 
As the ~15 kDa protein accumulatively adducted by SFN following continuous 
SFX-01 treatment was identified as Hgb β by LC-MS/MS, I assessed if the 
expression of the protein was increased. Spectral counts for Hgb β revealed there 
was no change in the abundance of the protein in cardiac tissue from WT mice 
after receiving 2.5 mg/ml SFX-01 for 10 days in their drinking water compared to 
control (figure 4.12). 
 
 
Figure 4.11. Hgb β-SFN was not successfully immunoprecipitated from cardiac 
tissue.  
A representative immunoblot of input and immunocaptured cardiac tissue of WT mice 
treated with 2.5 mg/ml SFX-01 for 10 days in their drinking water. No enrichment of Hgb 













4.3.11 Hgb β was not detected in isolated cardiomyocytes  
I next investigated if Hgb β-SFN present in cardiac tissue was a result of this 
protein being present in cardiomyocytes, as it is found in tissues other than red 
blood cells which is discussed in detail in the discussion of this chapter. 
Immunoblotting analysis, with a blood sample as a positive control, did not find 







Figure 4.12. Spectral counts of Hgb β in cardiac tissue of WT mice following 











4.3.12 Detection of cardiac Hgb-SFN is attenuated by coronary perfusion  
Hearts were isolated from WT mice treated with SFX-01 for 10 days and 
subjected to different stringencies of coronary vascular perfusion to ascertain 
whether the adduct observed was due to residual blood. Immunoblotting showed 
that flushing blood from the heart reduced the Hgb-SFN signal, consistent with 





Figure 4.13. A representative immunoblot showing Hgb was not detected in 






















4.3.13 BSA-SFN was purified using size-exclusion chromatography 
Following incubation of 1 mM BSA with 5 mM SFN for 30 minutes in either 10 
mM Tris pH 7.4 or PBS pH 7.4, free-SFN was removed from either solution using 
Figure 4.14. Hgb β-SFN present in cardiac tissue was perhaps from residual blood. 
Representative immunoblots showing a decrease in cardiac Hgb-SFN and Hgb following 




gel filtration chromatography. Regardless of the buffer used, the chromatogram 
showed similar profiles with two broad peaks appeared during the 120-minute 
run time (figure 4.15 A, B). To determine if these peaks contained BSA-SFN and 
assess the purity of the samples, fractions were collected and subjected to SDS-
PAGE followed by Colloidal Coomassie staining or western immunoblotting. 
Immunoblotting identified which samples contained SFN adducted to monomeric 
BSA and the fractions to be used in subsequent experiments are indicated by an 
arrow in figure 4.16 A, B. Colloidal Coomassie staining of the fractions after 
separation on a polyacrylamide gel together with BSA standards (1.25-5 nmol) 
allowed the concentration of BSA present in the samples following 
chromatography to be measured. This was ~50 µM for the Tris-containing sample 

























Figure 4.15. Chromatograms showing retention times for BSA treated with SFN.  
A) 1 mM BSA incubated with 5 mM SFN in 10 mM Tris pH 7.4 B) 1 mM BSA incubated 
with 5 mM SFN in PBS pH 7.4. AU represents absorbance using a UV detector set at a 























Figure 4.16. BSA-SFN is present in eluates following size-exclusion 
chromatography.  
A, B) Immunoblots and Colloidal Coomassie stained polyacrylamide gels of fractions 
collected following gel filtration of BSA treated with SFN in either a 10 mM Tris or PBS 
buffer respectively. Immunoblotting revealed SFN had adducted BSA and indicated 
which fractions contained predominantly monomeric BSA which was desirable for 
subsequent experiments. C) A Colloidal Coomassie stained polyacrylamide gel following 
electrophoresis using varying amounts of BSA to use as standards. Colloidal Coomassie 
stained polyacrylamide gels of gel filtrated BSA-SFN samples were compared to these 
standards to estimate the amount of protein present. 
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4.3.14 The interaction between BSA and SFN is stable in a PBS buffer  
To assess the stability of the SFN adduct over time, chromatographically-purified 
BSA-SFN was incubated at room temperature for 0-60 minutes and resolved 
using SDS-PAGE. Immunoblotting identified a time-dependent loss of the SFN 
adduct from BSA when in a Tris-containing buffer. When using a PBS buffer, the 
SFN adduct was stable upon BSA over time (figure 4.17 A, B). 
 













Figure 4.17. The SFN adduct is stable upon BSA within a PBS buffer.  
A) An immunoblot showing removal of the SFN adduct from BSA when BSA-SFN in a 
10 mM Tris buffer purified by size-exclusion chromatography was incubated at room 
temperature for 0-60 minutes. B) An immunoblot showing stable adduction of SFN to 
BSA following incubation of chromatographically-purified BSA-SFN in a PBS buffer at 
room temperature for 0-60 minutes. (n = 3, *p<0.05 versus 0-minute control). 
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4.3.15 SFN can transfer from GSH to cellular proteins 
To investigate if SFN could transfer from GSH to cellular proteins, HEK293 cells 
were incubated for 30 or 60 minutes with commercially available GSH-SFN. 
Immunoblotting identified multiple proteins adducted by SFN following incubation 
for 30 or 60 minutes. Immunoblotting also revealed there was no increase in 
protein glutathionylation at either time point, suggesting SFN had directly 















Figure 4.18. SFN can transfer from GSH to cellular proteins.  
A representative immunoblot showing an increase in protein-SFN adducts following 
incubation of HEK293 cells with GSH-SFN for 30 or 60 minutes. No increase in 
glutathionylation of proteins was detected.  
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4.3.16 L-cysteine can remove the SFN adduct from BSA  
Immunoblot analysis showed there was a loss of the SFN adduct over time when 
BSA-SFN was incubated with L-cysteine for 5-40 minutes (figure 4.19). A time-
matched untreated BSA-SFN control showed no loss of the adduct over time in 













4.3.17 SFN can transfer from BSA to Hgb β  
To investigate if the SFN adduct could move between thiol-containing 
biomolecules, BSA-SFN purified by size-exclusion chromatography was 
incubated with either Hgb β or GSH for 1-60 minutes at either pH 7.4 or pH 9.0. 
Following 1-minute incubation at pH 7.4 Hgb β-SFN was identified by 
immunoblotting, consistent with rapid trans-thiolation of the electrophile from 
BSA. Although the amount of Hgb β-SFN did not increase, adduction of the 
electrophile to BSA significantly decreased over time and to a greater extent 
Figure 4.19. L-cysteine can remove the SFN adduct from BSA.  
A representative immunoblot showing loss of the SFN adduct from BSA following 
incubation of BSA-SFN with L-cysteine for 5-40 minutes.  
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when incubated with GSH (figure 4.20 A). These observations were replicated at 
pH 9.0, although a greater amount of Hgb β-SFN was observed at all incubation 
times examined (figure 4.20 B). SFN adduction upon GSH was not detectable by 































Figure 4.20. SFN can transfer from BSA to Hgb β.  
A, B) Immunoblots showing time-dependent loss of SFN from BSA following incubation 
of BSA-SFN with either Hgb β or GSH for 1-60 minutes at pH 7.4 (A) or pH 9.0 (B). Hgb 
β-SFN is detected following 1-minute incubation and to a greater extent at pH 9.0 (B) than 
pH 7.4 (A). GSH-SFN was not detected due to the small size of this tripeptide. (n = 3, 
*p<0.05 versus 0-minute control. #p<0.05 versus treatment with Hgb β). 
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4.3.18 SFN can transfer from SHP2 to GSH  
HPLC analysis following incubation of SFX-01 with SHP2 identified a doublet 
peak upon the chromatogram at 14.89 and 15.19 minutes (figure 4.21 B). I 
hypothesised that the latter peak corresponded to SHP2 alone, whilst the peak 
with a shorter retention time was perhaps the protein adducted with SFN. 
Following incubation of the solution with GSH, HPLC analysis identified a peak 
at 15.19 minutes not associated with a doublet, likely unbound SHP2 and a broad 
peak at 9.12 minutes which correspond to a GSH-SFN standard (figure 4.21 C). 
The GSH-containing solution was then incubated with TCEP, to resolve any 
disulphide bonds. HPLC analysis identified two new peaks upon the 
chromatogram at 1.27 and 9.35 minutes. These two products were likely GSH 
and SFN respectively (figure 4.21 D), as the retention time is similar to that 
produced from an SFN standard shown in chapter 3 figure 3.10, and GSH is not 
retained on this HPLC column and will therefore pass through the column and be 


































Figure 4.21. HPLC chromatograms showing SFN moving from SHP2 to GSH.  
A) A GSH-SFN standard. B) 65 µM SFN incubated with 10 µM SHP2 for 30 minutes. C) 
SHP2-SFN incubated with 10 mM GSH for 30 minutes. D) SHP2-SFN incubated with 10 
mM GSH for 30 minutes and subsequent incubation with 10 mM TCEP for 30 minutes. 
mAU represents absorbance using a UV detector set at a wavelength of 205 nm. 
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4.3.19 SFN can transfer from BSA to a protein present in the blood 
To determine whether an SFN adduct could transfer from BSA to proteins within 
a biological sample, BSA-SFN was incubated with blood from WT mice for 1-60 
minutes. Immunoblotting revealed SFN adducted with a ~15 kDa protein 
following 40 or 60 minutes of incubation (figure 4.22). A loss in SFN adduction of 
BSA was also noted over time. A time-matched untreated BSA-SFN control 


















Figure 4.22. SFN can transfer from BSA to blood proteins.  
A representative immunoblot showing a loss of an SFN adduct from BSA in conjunction 
with adduction of the electrophile to a ~15 kDa protein present in blood from WT mice 




The studies outlined here along with those in chapter 3 showed there is a 
prominent protein target of SFN, with adduction increasing in a time-dependent 
manner, following chronic treatment with SFX-01 or ingestion of broccoli sprouts. 
As well as identifying this protein I analysed the mechanism by which the SFN 
adduct accumulated on the prominent target protein.  
Naturally derived sources of SFN in the form of cruciferous vegetables are 
frequently consumed by the general public. In this chapter, I first sought to 
determine if ingestion of the electrophile in this manner would result in its 
adduction to proteins, as occurred when synthetic SFN or SFX-01 was orally 
consumed. Increasing levels of chemophobia among the general population also 
support the need for such studies to identify if biological effects can also be 
achieved using these natural sources 184. This aversion to chemical compounds 
including therapeutics gained momentum with the introduction of 
dichlorodiphenyltrichloroethane as a routinely-used pesticide as well as the 
production of genetically-modified organisms. This has led to a sustained 
increase in sales of both organic foods and natural health supplements. The use 
of natural therapies either alone or in combination with prescribed drugs is also 
surprisingly prevalent among patients not only with minor illnesses but also 
chronic and life-threatening diseases, driven largely by chemophobia 185 186 187.  
There has consequently been extensive research into the efficiency of naturally 
derived compounds as therapeutics, including ITC 188 189. For example, 1-Methyl-
1,2,3,4-tetrahydroisoquinoline, which is present in several plant sources as well 
as the human brain, exhibits neuroprotective and antidepressant effects by 
inducing the production of brain-derived neurotropic factor and nerve GF as well 
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as scavenging free radicals 190 191. Resveratrol, present in the seeds of many 
plants has shown multiple biological activities, including cardioprotection, in part 
due to its induction of antioxidant enzymes including glutathione peroxidase, 
superoxide dismutase and HO1 via an Nrf2-mediated pathway 32 33.  The efficient 
antioxidant properties of vitamin C, a prominent component in many fruit and 
vegetables, is also well characterised 34 35. Biological effects following ingestion 
of plant/fruit/vegetable sources of the vitamin have been studied with promising 
outcomes 196 197 198. For example, drinking beetroot juice protected against post-
ischemic reperfusion injury, myocardial infarction and ventricular dysfunction in 
mice by a mechanism in which cyclic guanosine monophosphate and 
subsequently hydrogen sulfide were increased 199. I detected SFN adducting to 
proteins following voluntary ingestion of broccoli sprouts, providing evidence that 
the ITC is bioactive and that any therapeutic effects of this electrophile may 
potentially be achievable following administration in this manner. This is 
consistent with previous studies identifying an increase in antioxidant protein 
expression in cardiovascular and kidney tissue of stroke-prone hypertensive rats 
following ingestion of broccoli sprouts 200 201. These studies also observed a 
correlation to attenuated oxidative stress, increased endothelial-dependent 
relaxation of the aorta, lowered blood pressure and increased response to NO in 
vascular smooth muscle cells 200 201. Cardioprotective effects were also seen 
following ingestion of broccoli sprouts for 30 days in rats whereby increased 
ventricular function, reduced myocardial infarct size and reduced cardiomyocyte 
cell death were observed following ischemia and reperfusion 202. A reduced 
incidence of prostate cancer in mice via SFN-mediated reduction of histone 
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deacetylase enzyme expression and subsequent loss in interaction with their 
corepressors has also been documented 203.  
Consistent with previous in vivo studies where SFX-01 was administered to mice 
in the drinking water, SFN adduction of a ~15 kDa protein was detected following 
ingestion of broccoli sprouts. The amount of SFN adducted to this protein 
following treatment with 2.5 mg/ml SFX-01 for 10 days was much greater than 
after the ingestion of broccoli sprouts. This is somewhat unsurprising as these in 
vivo studies vary largely in the amount of SFN received. Broccoli sprouts contain 
~255 mg glucoraphanin per 100 g 204. Throughout this study, the mice ate 
between 5–10 mg sprouts a day and therefore had a maximum intake of 0.025 
mg glucoraphanin. It has previously been calculated that ~75 % of glucoraphanin 
is cleaved to form active SFN 204. If I, therefore, assume that the mice received 
0.00625 mg SFN/day this is a considerably lower amount than those who 
received SFX-01 treatment (0.115 mg SFN/day) for an equivalent time period.  
Upregulation of antioxidant proteins by SFN via the Nrf2 pathway is well 
characterised and outlined in detail in the general introduction. This includes the 
low molecular weight ubiquitous disulfide reductases Trx and GRX1, which have 
molecular weights of 11.7 and 12 kDa respectively 205. Figures 4.23 and 4.24 
below show the enzymatic reactions of the Trx or GRX1 disulfide reduction 
systems respectively. These dithiol proteins each contain reactive cysteines 
within their active site motifs, Cys-Gly-Pro-Cys and Cys-Pro-Tyr-Cys 
respectively, and I therefore rationally investigated if the ~15 kDa protein on 





















Figure 4.23. A diagram showing the enzymatic reactions involved in a two-step 
dithiol mechanism for catalytic reduction of protein disulfides by Trx. 
Figure 4.24. A diagram showing enzymatic reactions of GRX1.  
A) A two-step dithiol mechanism for catalytic reduction of protein disulfides by GRX1 B) 




As anticipated and consistent with stimulation of an Nrf2-mediated cellular 
antioxidant gene response upon exposure to electrophiles 208 209, treatment with 
SFX-01 for several days increased Trx and GRX1 protein expression. These 
observations are in alignment with previous studies whereby Trx protein 
expression was increased in the neural retina of mice following 3 days of oral 
treatment with SFN 210. Treatment of a human breast epithelial cell line with SFN 
for 48 hours was also shown to upregulate GRX1 expression levels 211. As 
depicted in figure 4.24 B a GSH adduct can trans-thiolate to GRX1. Therefore, 
as well as accumulation of Trx- or GRX1-SFN as a result of increased protein 
expression i.e. there is more reactive protein available for the electrophile to 
adduct to, perhaps trans-thiolation of the adduct from proteins onto the 
antioxidant is also occurring (figures 4.25 and 4.26). This concept of trans-
thiolation of an SFN adduct between proteins is discussed in greater detail on 
page 133. If GSH and the TrxR/glutaredoxin reductase (GRXR) systems were 
unable to remove the SFN adduct from Trx or GRX1, then it may be anticipated 
this continual exposure to SFX-01 may cause accumulation of the adduct on 

























Western immunoblotting concluded the ~15 kDa protein was not Trx or GRX1 as 
neither resolved at the same molecular weight as the protein containing the SFN 
adduct following gel electrophoresis. Consequently, LC-MS/MS analysis was 
Figure 4.25. Proposed mechanism for transfer of the SFN adduct to Trx. 
Figure 4.26. Proposed mechanism for transfer of the SFN adduct to GRX1. 
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undertaken as a method of identifying proteins present in a gel piece taken from 
where the modified protein migrated on an SDS-PAGE gel. No silver or Colloidal 
Coomassie staining was required to locate the ~15 kDa modified protein on the 
gel as it could be visualised by a yellow colouring, likely due to the high presence 
of sulphur within the adducted SFN. In addition to identifying proteins present in 
the gel sample, a mass equivalent to that of SFN was detected covalently 
adducted to Cys93 of the β1 subunit of Hgb.  
Mammalian Hgb is a tetrameric structure consisting of two sets of dimeric 
polypeptide chains; α-globin subunits 1 and 2 and β-globin subunits 1 and 2 212. 
Bound by non-covalent forces within each globin subunit is an iron-
protoporphyrin IX molecule, which is primarily in the physiological ferrous (FeII) 
chemical valance state 213. Two highly conserved amino acids, a proximal 
histidine and a distal phenylalanine, coordinate the iron moiety and without them, 
Hgb cannot perform its primary function as a two-way respiratory carrier 214. 
Reversible binding of O2 at the four ferrous iron atoms allows transport of the gas 
from pulmonary vessels to tissues throughout the body 215. The return of CO2 is 
then subsequently facilitated not by the ferrous iron but instead via weak 
interactions at the amino-terminal of the globins 213.   
Although the mechanism is still under investigation, circulating NO plays a role in 
the regulation of hypoxic vasodilation with both proposed hypotheses being 
dependent on red blood cells and deoxy-Hgb. The first involves the highly 
reactive Cys93 within the β subunit of Hgb which is conserved between all 
vertebrate species possessing advanced cardiovascular systems 216. Extensive 
research from many laboratories, predominantly led by the Stamler group, have 
demonstrated NO can bind at this highly reactive residue, either directly or via 
132 
 
trans-nitrosylation (the transfer of NO) from the heme group to the thiol, 
generating Hgb-SNO 217 218 219. They report significant levels of Hgb-SNO within 
red blood cells isolated from arterial blood of anesthetised rats and almost 
undetectable amounts in venous blood 220. It is proposed the increased rate of S-
nitrosylation in areas of high O2 concentration is due to an allosteric change 
induced by O2 binding, which exposes Cys93 which would otherwise be blocked 
by the C-terminal His146 220. It is well characterised that physiological O2 gradients 
regulate vascular tone and blood flow, whereby lower concentrations of the gas 
result in hypoxic vasodilation 221 222. It is now suggested that this endocrine-like 
transportation of NO upon Hgb may have a role in this coupling of metabolic 
demand with increased delivery of O2. Not only via the induction of allosteric 
changes which enhance the release of O2 but also the disassociation of NO itself 
from the macromolecule in areas of low O2 where it regulates vascular tone. 
Whereby, this offloading of bioactive NO from Cys93, via trans-nitrosylation to 
GSH or the cytoplasmic domain of the anion exchanger AE1 facilitates its 
excretion from red blood cells, where it subsequently enters the vascular 
endothelium and elicits its role as a potent vasodilator 223 224 225 226 227.  If Cys93 
does indeed play a key role in transportation and bioactivity of NO, it’s adduction 
by SFN may have detrimental effects on the NO-mediated regulation of vascular 
tone. Perhaps if Cys93 is occupied by SFN, it can no longer scavenge NO at high 
O2 concentrations and subsequently cannot deliver it to areas of low saturation. 
Consequently, this may cause vasoconstriction and reduced blood flow in areas 
where metabolic demand for O2 is high. 
This being said, the relevance of Hgb-SNO formation in erythrocytes to the 
overall regulation of hypoxic vasodilation is still debated, with some researchers 
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in favour of a second ideology named the nitrite-reductase hypothesis 228 229 230. 
Studies have observed a clear arterial to venous plasma nitrate gradient with 
arterial levels reduced during exercise 231 232. A significant increase in red blood 
cell NO metabolite accumulation is also detected in veins compared to arteries, 
with the most dominant species being iron-nitrosylated Hgb 231 232. This theory, 
therefore, proposes the endocrine reservoir is in fact nitrite which is converted to 
NO by deoxy-Hgb which can then either diffuse through the vessel wall and elicit 
local effects on vasodilation or adduct vicinal deoxy-heme groups. NO adducted 
to deoxy-heme produces the six-coordinate species nitrosyl-Hgb, involving iron 
bound to four nitrogens, a proximal histidine and NO 233 234 which may act as a 
transport mechanism for NO. In areas of low O2 tension, the proximal histidine 
bond can break producing a five-coordinate species resulting in lowered affinity 
for and release of O2 from the neighbouring heme groups 233 234. These studies 
do detect non-significant formation of Hgb-SNO in arterial plasma although to a 
much lower extent than NO-heme and suggest it’s likely not a primary transport 
mechanism for NO although may facilitate its release from heme. As well as this, 
a mouse model with a Cys93 to Ala93 mutation generated by the Townes group 
identified no deficit in systemic or pulmonary haemodynamics and concluded it 
is not essential for the physiological coupling of erythrocyte deoxygenation to NO 
bioactivity 235. Nevertheless, the effects of prolonged SFN treatment on blood 
pressure warrant further investigation.   
Regulation of NO bioavailability by Hgb, in particular, Hgb α, has also been 
demonstrated in endothelial cells at myoendothelium junctions within the blood 
vessel wall 236. The expression of Hgb α increases as the diameter of the vascular 
wall decreases, correlating with an increase in microvascular junctions in these 
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smaller resistance arteries 237. Again, Hgb appears to play a role in regulating 
NO-dependent vasodilation of these arterioles 238 239. When O2 concentrations 
are high, NO produced by endothelial NO synthase is scavenged by oxy-Hgb to 
produce nitrate ions and methaemoglobin with a ferric iron, which prevents 
diffusion into and vasodilation of vascular smooth muscle cells 236 240. As 
endothelial cells predominantly express Hgb α and only minimal Hgb β, it is 
unlikely that adduction of SFN at Cys93 of the β subunit is occurring within this 
cell type. Hgb α and/or β expression have been reported in multiple somatic cell 
types such as alveolar epithelial cells 241, renal mesangial cells 242, hepatocytes 
243, macrophages 244 and neurons 245. However, I did not detect Hgb in isolated 
mouse ventricular cardiomyocytes. Further to this, flushing coronary arteries from 
isolated hearts of mice who had received SFX-01 with increasing amounts of 
buffer correlated with a loss of Hgb as well as Hgb-SFN. This is consistent with 
Hgb-SFN originating from the blood and likely red blood cells. Immunostaining of 
blood cells from mice who had received SFX-01 treatment with an anti-SFN 
antibody and subsequent analysis by flow cytometry or fluorescent microscopy 
should be conducted to confirm this.  
As outlined in the introduction to this chapter, it has been shown a protein-SFN 
adduct can either spontaneously resolve, or trans-thiolate to another thiol 
containing protein. Following treatment of HEK293 cells with GSH-SFN, the 
accumulation of SFN adducts was seen upon multiple proteins with no detectable 
increase in glutathionylation. This corroborates findings that the interaction 
between the electrophile and GSH is reversible and perhaps the accumulation of 




I next sought to assess if SFN adducts could also be reversed from proteins other 
than GSH and if so, whether trans-thiolation of the electrophile may account for 
its time-dependent accumulation on Hgb β Cys93 following chronic in vivo 
treatment with SFX-01. 
It is established that amine groups have nucleophilic properties and so can 
adduct ITCs including SFN 246 247 248 249, albeit with reduced affinity compared to 
thiols as they are a weak base with high pKa 250 251. Transfer of allyl-ITC from Nα-
acetyl-L-cysteine to either Nα-benzoyl-glycyl-L-lysine or lysine residues on BSA 
has been reported 252. Similar transfer reactions of fluorescein-ITC were also 
shown between thiol and amine groups upon sarcoplasmic vesicles in vitro 253. 
Indeed, in the studies reported here in which I purified BSA-SFN in an amine-
containing Tris buffer, this resulted in the loss of the SFN adduct over time which 
was not observed using a PBS buffer. A loss of the electrophile was also seen 
following incubation of BSA-SFN with L-cysteine or GSH. In addition, HPLC 
analysis suggested that SFN can transfer from SHP2 to GSH. Together these 
data provide evidence that SFN-modification of protein thiols can be reversed, 
which may be mediated by nucleophilic attack towards the protein-SFN 
interaction by another thiol or amine group, which results in the transfer of the 
electrophile to this second nucleophilic moiety. Importantly, I also observed SFN 
can indeed trans-thiolate from BSA to Hgb β, supporting the ideology Cys93 may 
serve as a sink for the electrophile as a result of trans-thiolation from other thiol-
containing proteins.  
Whilst published MS data from the Uchida group suggests that trans-thiolation of 
an SFN adduct occurs by direct transfer to a second thiol without the generation 
of a free-electrophile 182, other published studies suggest the transfer of ITCs 
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occurs via a two-step process whereby the dithiocarbamate resolves to 
regenerate the free-electrophile, which can subsequently adduct other thiol or 
amine groups 176 179 252 253. Should sporadic reversal be solely responsible for the 
transfer of the electrophile, we would expect an equal loss of the adduct when 
BSA-SFN was incubated with either GSH or Hgb β. However, a greater loss of 
the adduct was detected following incubation with GSH. This increased loss of 
the adduct following incubation with GSH was unexpected, as Hgb β was 
predicted as the stronger nucleophile due to Cys93 being recognised as highly 
reactive with a much lower pKa than the tripeptide. Nevertheless, this data 
suggests a second and perhaps dominant mechanism for trans-thiolation 
involving direct nucleophilic attack of the unbound thiol towards the 
dithiocarbamate, which is outlined in figure 4.27. This paradigm is further 
supported by a detectable increase in both removal of the SFN adduct from BSA 
and trans-thiolation to Hgb β at pH 9.0 compared with 7.4. A salt bridge between 
Asp94 and His146 which is responsible for structural auto-inhibition of Cys93 of Hgb 
β is loosened in alkaline conditions. The higher pH of 9.0, therefore, induces a 
conformational change in Hgb β which would increase access of the thiolate of 
Cys93 to conduct nucleophilic attack towards the SFN adduct upon BSA 220. A 
lowered H+ content will also create an equilibrium in favour of the thiol being 










Notably, SFN adduction to Hgb β following incubation of the protein with BSA-
SFN occurs rapidly but does not accumulate over time. Perhaps Cys93 of Hgb β 
becomes saturated with SFN within 1-minute of exposure, with the availability of 
the cysteine increasing at pH 9.0 than 7.4 for reasons explained above. 
Repeating these studies with a higher concentration of Hgb β may result in time-
dependent accumulation of the adduct. Indeed, time-dependent accumulation of 
SFN upon an ~15 kDa protein, presumably Cys93 of Hgb β, was observed when 
BSA-SFN was incubated with blood. Also, time-dependent loss of the SFN 
adduct from BSA did not correlate with the level of accumulation upon Hgb β. 
Transfer of the adduct to amines may also be occurring, either via direct 
nucleophilic attack or subsequently to sporadic reversal, which could not be 
detected using the SFN antibody.  
Figure 4.27. Proposed mechanism for trans-thiolation of SFN from BSA to Hgb β 
involving directed nucleophilic attack of the unbound thiol towards to adduct. 
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Of course, SFN accumulation upon Hgb β following chronic in vivo treatment with 
SFX-01 could be due to direct adduction of the protein by a free-form of the 
electrophile. However, together, these studies suggest Cys93 of Hgb β may serve 
as a sink for SFN as a result of the transfer of the electrophile from other protein 
thiol or even amine groups. The efficiency of trans-thiolation of SFN from BSA to 
GSH compared with Hgb β highlights this tripeptide may facilitate this transient 
movement of the electrophile. Perhaps the adduct first trans-thiolates from a 
protein thiol to GSH, with a subsequent nucleophilic attack by Cys93 of Hgb β. As 
the pKa of the thiol of GSH is notably higher than that of the reactive thiol of BSA, 
this highlights that transfer of the adduct may not depend on the thiol pKa of the 
receiving protein, although what does control the direction of trans-thiolation is 
still undetermined. Perhaps thiol accessibility plays a role. The simple structure 
of GSH may allow the tripeptide to easily access protein-SFN adducts to perform 
a nucleophilic attack, and also, GSH-SFN would subsequently be easily 
accessible by other free protein thiols. Why Cys93 upon Hgb β is more efficient in 
this process than other abundant reactive-thiol containing blood proteins such as 
Cys34 upon BSA is unclear 254. Perhaps it is simply due to Hgb being 3X more 
abundant 255 256. The progressive build-up of Hgb β-SFN could elude the adduct 
is relatively stable. However, these studies suggest it is likely GSH will 
subsequently remove SFN and perhaps due to the large amount of SFX-01 
administered to mice the rate of adduct formation is simply greater than the rate 
by which GSH or other proteins can remove the adduct. Further investigation into 
trans-thiolation of SFN from Hgb β to other proteins warrants investigation as this 




5 Therapeutic potential of sulforaphane in a NS 
mouse model 
5.1 Introduction 
5.1.1 The role of SHP2 in cardiac development 
SHP2 protein expression is distributed throughout the embryo suggesting it holds 
various functions in embryonic development 126. Indeed, homozygous N-terminal 
deletion of SHP2 results in embryonic lethality mid-gestation due to several 
defects in cell differentiation, mesodermal patterning and body organisation 
including node, notochord and posterior elongation 257. These developmental 
processes are all dependent upon SHP2 for full and sustained activation of the 
SFK/Ras/ERK signalling pathway following stimulation by fibroblast GF, which 
stabilises the pro-apoptotic protein Bcl-2-like-protein-22 (BIM) 257 258. Studies 
using amphibian and avian embryos showed cardiac cell specification and 
differentiation occur at the onset of gastrulation 259 260. The fibroblast GF 
signalling pathway induces expression of key progenitors which regulate cardiac 
cell differentiation, including homeobox protein NK-2 homolog B, T-box 5 and 
GATA-binding protein 4 261. A lack of cardiac cell differentiation was seen in 
Xenopus embryos with knockdown of SHP2 following cardiac explant assays, 
revealing an essential role of the phosphatase in the specification and 
maintenance of such cardiac progenitors 262. Following gastrulation, cardiac 
development and morphogenesis occur 263. As homozygous deletion of the 
phosphatase in mice results in embryonic lethality mid-gestation, elucidation of 
the role of SHP2 in cardiac development has been challenging 257. Progress has 
since been made using Xenopus and zebrafish whereby embryonic lethality pre- 
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or mid-gastrulation were overcome. Morpholino-mediated knockdown in 
zebrafish showed SHP2 regulates convergence and extension of myocardial and 
endocardial precursor cells during gastrulation via RhoA and SFK signalling 264 
61. The same conclusion was made by expressing mRNA encoding gain-of-
function or loss-of-function SHP2 mutations associated with NS or NS with 
multiple lentigines respectively in zebrafish embryos 61. Interestingly, they 
suggest both an activating and an inhibitory role of SHP2 in SFK signalling during 
gastrulation, as the injection of either a hyperactivating or deactivating mutation 
had the same physiological outcome 61. Parallel studies injecting mRNA 
encoding a loss-of-function mutation found in patients with NS with multiple 
lentigines into SHP2-deficient Zebrafish embryos further identified a role of the 
phosphatase in neural crest development and migration post-gastrulation in an 
ERK-dependent manner 265.  
Rightward looping of the linear heart tube initiated by fusion of bilateral heart 
primordia is the first morphological manifestation of embryonic laterality 264. This 
mainly occurs due to left/right asymmetric localisation of transcription factors and 
signalling molecules such as the transcription GF β cytokine, nodal 266. The 
leftward movement of nodal occurs by transport within Kupffer’s vesicles which 
are mechanistically transported by motile cilia 267 268 269. SHP2 plays multiple 
roles in this process with randomisation of such left/right markers and impaired 
leftward heart displacement in zebrafish embryos was seen when expressing 
SHP2 mutations which altered the phosphatases activity 270. Expression of 
Kupffer’s vesicles is stimulated by fibroblast GF 8, and this signalling event is 
regulated by SHP2 261 271. Vesicle development is dependent upon the 
distribution of receptor-mediated calcium release from the endoplasmic reticulum 
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272. Calcium signalling via the calcium-permeable cation channel polycystin 2 is 
also important in both the formation and sensing of cilia 273. It is suggested SHP2 
functions in calcium signalling either indirectly via ERK-mediated phosphorylation 
of the cav(1.2) subunit or direct association with inositol triphosphate 3 receptors 
274 275. As well as asymmetrical localisation of nodal, actin polymerisation and 
non-muscle myosin 2 activity are also required for left/right patterning 276. Gain-
of-function SHP2 mutations cause reduced formation and polarity of cardiac actin 
fibres likely via hyperactivation of Rho-associated protein kinase, resulting in 
smaller hearts with impaired cardiac looping 277.  
Segmentation into the atrium, ventricles, atrioventricular canal and outflow tract, 
as well as the aorta and pulmonary tract, is the next stage of cardiac development 
278. Endocardial cushions subsequently form between the atrioventricular canal 
and outflow tract which later evolve into semilunar and atrioventricular valves. 
The localisation of multiple signalling molecules and pathways regulate this 
process, including vascular endothelial GF, ERK, nuclear factor of activating T-
cells cytoplasmic 1, notch, β-catenin and bone morphogenetic protein 279 280 281, 
all of which involve SHP2 and indeed, heterozygous deletion of the phosphatase 
results in valve enlargement 282.  
Finally, aortic and pulmonary circulation are separated by the development of 
ventricles, atria and the outflow tract whilst the septum forms due to the 
expansion of the left and right ventricle 278 283 284. Hyperactivation of SHP2 in the 
myocardium of mouse embryos results in thinner ventricular walls and septal 
defects 285. Although, the same is also seen following reduced activation of the 
phosphatase 286. Perhaps SHP2 regulates cardiac chamber maturation via a 
phosphatase-independent mechanism, a hypothesis proposed by Paardekooper 
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Overman et al. They propose increased association of kinase c-Src with SHP2 
due to the phosphatase being in an open conformation, acting as a scaffold to 
bring the proteins into proximity 287 288.  
5.1.2 White blood cell production  
Blood cells, including leukocytes, are short-lived and require continual production 
via differentiation from haematopoietic stem cells (HSCs), a process termed 
haematopoiesis 289 290 291 292. A detailed overview of this process is shown in 
figure 5.1. The main site of haematopoiesis in adult mammals under normal 
circumstances is the bone marrow, however, can also occur extramedullary in 
the liver and spleen in response to severe haematopoietic stresses 293. This 
process is hierarchical, with a progressive commitment to a certain cell-type 
coupled with a loss of self-renewal 45 47 295. Initially, HSCs are defined as long-
term, which self-renew indefinitely and are distinguished by cell surface markers 
296 297 298 299. Molecular regulation of self-renewal and inhibition of differentiation 
of long-term HSCs is coupled with notch and wingless signalling 300. The progress 
of long-term HSCs to multipotent progenitor (MPP) cells is marked by RTK foetal 
liver kinase-2 (Flk-2)+ and cluster of differentiation 90 (Thy-1.1)- with an 
intermediate HSC formed named short-term HSC (Flk-2+ Thy-1.1+), which has 
limited self-renewal capacity 296. MPP cells can no longer self-renew but are 
heterogeneous in their cellular content and retain the potential to differentiate into 
any white blood cell lineage 301. Long- and short-term HSCs and MPP cells differ 
in expression of transcription factors as shown in figure 5.1 302 303 304 305, which 
is regulated by discrete changes in the niche microenvironment in which HSCs 
reside. Long- and short-term HSCs and MPP cells reside in perivascular niches 
associated with sinusoidal blood vessels in adult bone marrow 306 307 308. 
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Certain GFs maintain HSCs in these niches, including stem cell factor (SCF), 
CXC-chemokine ligand 12 and thrombopoietin (TPO), synthesised by 
endothelial and reticular perivascular stromal cells 309 310 311 312 313 314. The 
niche microenvironment is also manipulated by other cell types including 
megakaryocytes, monocytes and macrophages, which directly or indirectly 
alter the fate of residing HSCs 315 316 317 318. Akashi et al identified MPP cells 
differentiate to common lymphoid or common myeloid MPP cells, distinguished 
by different cell surface markers, IL-7Rα+Thy-1.1−Lin−Sca-1loc-Kitlo and 
CD34+FcγRIII−/loThy-1.1−IL-7Rα−Lin−Sca-1−c-Kit+ respectively 71 72. This cellular 
differentiation occurs in part due to stimulation by circulating cytokines, which is 
also true for subsequent differentiation and commitment steps, as depicted in 
figure 5.1 321 322 323. As well as differentiation commitment, these cytokines 
promote cell survival, induction of maturation and functional activation 321. 
Common lymphoid cells differentiate into mature B-, T-, or natural killer (NK)-cells 
where the lymphoid lineage ends 324. Common myeloid cells on the other hand 
further differentiate into megakaryocyte-erythroid or granulocyte-myeloid 
progenitor cells 325. The megakaryocyte-erythroid lineage ends with 
differentiation to either platelets or erythrocytes 291 325. Granulocyte-myeloid cells, 
however, require an additional differentiation step forming either myeloblasts or 
monoblasts, with final maturation into basophils, eosinophils and neutrophils or 
monocytes respectively 319 326.  
Although most lymphocytes then enter the circulation, a large pool of neutrophils 
reside in the bone marrow until mobilised in response to chemoattractant cues  
81 82 327. Whilst a proportion of monocytes circulate freely in the blood awaiting 
recruitment and differentiation into macrophages, these are outnumbered by 
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monocytes residing in the subcapsular red pulp of the spleen 330 331 332 333. 
Genetic and cell-fate mapping identified spleen-resident macrophage 
populations represent a separate and distinct phagocyte lineage established 
prior to birth, either from elements present in the yolk-sac or foetal liver 
precursors 334 335 336 337. How and why monocyte clusters are recruited and 
maintained within the spleen remains unclear. Although inflammatory signals 
mobilize these cells en masse to distant tissues, so it likely serves as a reservoir 
until required to differentiate to macrophages and fight infection 338. Perhaps they 
also contribute to the replenishment of spleen-residing macrophages, although 
this remains undetermined. It is also suggested the spleen can act as a reservoir 
for neutrophils within the perifollicular zone, which aid antibody production by 
marginal zone residing B-cells 339 340 341. An immature population of spleen 
residing neutrophils have also been discovered, although whether they arise via 
bone marrow-dependent or -independent haematopoiesis could not be 















Figure 5.1. White blood cell production in the bone marrow by haematopoiesis.  
Blue = cell surface receptors. Lin (Linear), Kit (Mast/stem cell GF receptor), Sca (Stem 
cell antigen), CD (Cluster of differentiation), Slam (Signalling lymphocyte activation 
molecule), FcgR (Fragment crystallizable gamma receptor, IL7-R (Interleukin 7 
receptor). Green = cellular transcription factors. SCL (Stem cell leukaemia), GATA 
(Formerly termed Erythroid transcription factor), C/EBP (CCAAT-enhancer binding 
protein), PU (PU-box binding). Red = cytokines and chemokines which aid each 
differentiation step. IL (Interleukin), GM-CSF (Granulocyte-macrophage colony 
stimulating factor), M-CSF (Macrophage colony stimulating factor), G-CSF (Granulocyte 
colony stimulating factor), TPO, SCF.  
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A detailed overview of haematopoiesis was provided above to highlight the 
important roles of SHP2 in the proliferation and survival of HSCs and progenitors. 
As indicated in figure 5.1, the cell-surface receptor Kit is highly expressed in 
HSCs 344. Following binding of SCF to Kit, SHP2 creates a positive feedback 
loop, an important process in maintaining adult HSC quiescence and survival 345 
346 347. The Eder group showed SHP2 acts downstream of the RTK breakpoint 
cluster region-abelson murine leukaemia (Bcr/Abl), promoting HSC proliferation 
and survival through activating STAT5 signalling 348. SHP2 also acts upstream of 
the cell-proliferation pathways Ras, ERK and Akt, with inducible SHP2-deficient 
HSC and progenitors undergoing apoptosis in response to SCF and TPO 349. 
Through overexpressing gain-of-function SHP2 mutants in progenitor cells the 
Chan group demonstrate a higher number of these cells residing in the synthesis 
and gap 2 phase of the cell cycle along with increased markers of progression, 
including cyclin D1, B-cell lymphoma-2 and B-cell lymphoma extra-large 350, as 
well as reduced expression of apoptotic markers p27, p21 and B-cell lymphoma-
like-protein 11 350. Using shRNA-mediated inhibition of SHP2 expression, Li et al 
identified reduced myeloid differentiation following GF stimulation 351. This was 
driven by an initial increase in STAT5 phosphorylation, correlating with my own 
observations in cardiac tissue as outlined in chapter 3, with a subsequent 
decrease that reduced expression of anti-apoptotic genes including myeloid 
leukaemia cell differentiation protein and B-cell lymphoma extra-large 351. 
Through the use of a lymphocyte cell line, Ba/F3, the Friedman group further 
suggest stimulation with G-CSF leads to SHP2 phosphorylation with subsequent 
activation of STAT3 signalling and granulocyte lineage determination 352. Finally, 
Xu et al show hyperproliferation of lineage-committed myeloid, T-cell and B-cell 
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progenitors following transfection with SHP2 which has a gain-of-function 
mutation, E76K/+ 353. They speculate activated SHP2 distributes into 
centrosomes driving the amplification and genomic instability of these transfected 
cells 353.  
As highlighted above, SHP2 plays key roles in cardiac development and white 
blood cell production. It is perhaps unsurprising that NS patients with gain-of-
function SHP2 mutations often present with cardiac structural defects and a 
myeloproliferative phenotype as detailed in the general introduction  78 354. 100 
% of homozygous Ptpn11D61G+/+ NS mice and approximately 50 % of 
heterozygous Ptpn11D61G/+ NS mice, which I will refer to as HOM and HET 
respectively in this chapter when referencing foetal experiments, die in utero due 
to several cardiovascular structural defects 78. Here, I first sought to establish if 
foetal treatment with SFX-01, by administering the drug to pregnant dams, 
inhibits SHP2 phosphatase activity to perhaps enhance the birth rate of HET 
offspring and allow HOM offspring to survive through to birth. Of course, if SFX-
01 did enhance viability, a rational next question was whether their cardiac 
function and bone and skeletal muscle defects were also improved. The second 
aim of this chapter was to establish if prolonged treatment with SFX-01 could 
reduce white blood cell production in these mice, in particular, the myeloid 
lineage. As the increase white blood cell production in this mouse model likely 
contributes to the splenomegaly they present with, the effect of prolonged SFX-





5.2 Materials and methods 
5.2.1 SDS-PAGE and western blotting  
SDS-PAGE and western immunoblotting were performed as outlined in the 
general methods. For this chapter the following primary antibodies were used: 
 
 
Table 5.1. List of primary antibodies used for western immunoblotting in chapter 
5. 
 
5.2.2 Immunoprecipitation  
Immunoprecipitation of proteins from tissue was performed as outlined in the 
general methods. For this chapter the following antibodies were used: 
 
Table 5.2. List of antibodies used for immunoprecipitation in chapter 5. 
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5.2.3 Foetal treatment with SFN 
Three genotype breeding pairings were used for foetal studies: WT/WT, 
WT/HET, with the male mouse being HET, and HET/HET. In preliminary studies, 
male and females were housed separately and received 2.5 mg/ml or 0.8 mg/ml 
SFX-01, which is equivalent to 0.385 mg/ml or 0.123 mg/ml SFN respectively, for 
3 days in their drinking water prior to breeding. Males were then added to the 
females’ cages, where they remained until pregnancy was confirmed by visual 
inspection of the female. Dams continued receiving SFX-01 throughout their 
pregnancy. Neonates were sacrificed and snap frozen by liquid nitrogen within 
24 hours of birth.  
In additional studies, males and females were mated, and the date of conception 
was calculated by identification of a vaginal plug and at this point, the males were 
removed. Treatment with 2.5 mg/ml SFX-01 in the dams drinking water began 11 
days post-conception, the time point determined as the completion of 
gastrulation. Neonates were sacrificed and snap frozen by liquid nitrogen within 
24 hours of birth.  
5.2.4 Blood sampling via the tail vein 
10 minutes prior to sampling, mice were placed in a warming chamber set to 37 
˚C to induce dilation of the blood vessels. Mice were then placed into an induction 
chamber and anaesthesia was induced for 1-minute using 3 % isoflurane mixed 
with 97 % O2 at a flow rate or 1 l/min. Mice were put into a face-down position 
and held in place using surgical tape. Anaesthesia was maintained using a nose 
mask with 1.5-2 % isoflurane and 98-98.5 % O2 at a flow rate of 1 l/min. Body 
temperature was measured using a rectal probe and maintained at 37 ˚C ± 1.5 
˚C via a heat lamp when required. Tails were washed with an antimicrobial 
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solution prior to sample collection, and a heparinised 0.3 ml U-100 insulin syringe 
(BD Benelux) inserted into the lateral vein. 50 µl of blood was immediately 
collected into the syringe and pressure was carefully applied to terminate 
bleeding at the sampling site. After sampling, animals recovered in a 
temperature-controlled incubator. 
5.2.5 Wright-Giemsa stain  
1 µl of blood was spread thinly onto a glass slide and allowed to air dry. Once 
fully dried, blood films were submerged in Wright-Giemsa stain for 30 seconds, 
after which they were placed directly into deionised water for 10 minutes. Slides 
were then washed in running deionised water and left to fully air dry before being 
analysed by light microscopy. The nucleus and cytoplasm of white blood cells 
were stained dark purple, whilst red blood cells were stained light pink. White 
blood cells were counted from five fields of view at a 10X magnification for all 
samples and white blood cell count was represented as an average of these five 
values.   
5.2.6 Tissue preparation for flow cytometry  
Following the sacrifice of mice, the spleen, femur and tibia were harvested and 
placed into separate falcon tubes containing 30 ml of PBS supplemented with 5 
µl heparin. Blood was also collected via the abdominal aorta into a 1 ml syringe 
lined with heparin. All samples were placed on ice until needed and prepared as 
subsequently described. All centrifugation steps were carried out for 10 minutes 
at 1800 x g at 4 ˚C and all incubation steps were carried out at room temperature. 
Blood: 50 µl of blood was transferred to a 15 ml falcon tube with the remaining 
blood used to analyse MIP1α and MIP2 levels as described below. For lysis of 
red blood cells, 1 ml 10X PBS and 9 ml deionised water was added to the 15 ml 
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falcon tube followed by inverting 5 times. 5 ml of 1X PBS was then added, and 
samples were centrifuged. Spleen: Spleen tissue was transferred into a petri dish 
containing 20 ml PBS, any attached fat tissue was removed, and the spleen was 
dissected into two halves along the long axis. Half of the tissue was snap frozen 
at -80 ˚ C to be used in future experiments, whilst the remaining tissue was placed 
into a 40 µm nylon mesh cell strainer (Thermo Fischer), which was placed into a 
fresh petri dish containing 5 ml PBS. Using the flat end of a syringe plunger the 
tissue was forced through the cell strainer. PBS containing the strained spleen 
cells was transferred into a 50 ml falcon tube containing 25 ml PBS and 
centrifuged. Cells were resuspended in 10 ml red blood cell lysis buffer 
(BioLegend), incubated for 10 minutes on a rolling shaker and then centrifuged. 
Bone marrow: Femur and tibia bones were transferred into a petri dish containing 
20 ml PBS. The knee joint and either side of each bone were cut using scissors. 
A needle attached to a 1 ml syringe filled with PBS was inserted into the cavity 
of each bone and the marrow was flushed out into a 50 ml falcon tube containing 
25 ml PBS and samples were centrifuged. Cells were resuspended in 10 ml red 
blood cell lysis buffer, incubated for 10 minutes on a rolling shaker and then 
centrifuged. After centrifugation of all tissue samples, supernatants were 
removed, and pellets were resuspended in 1 ml PBS. Myeloid cell staining was 
then carried out.  
5.2.7 Cell staining for flow cytometry  
Tissue samples prepared as described above were passed through a 35 µm 
nylon mesh cell strainer upon a 5 ml round-bottomed glass test tube (Thermo 
Fisher). 50 µl from each tissue type were combined in a separate 5 ml round-
bottomed glass test tube to be used for staining with a dead cell marker. 200 µl 
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of each sample was also transferred into a fresh 5 ml round-bottomed glass test 
tube to be used as unstained sample controls, with the remaining sample to be 
used for myeloid cell staining. 5 ml PBS was added to all tubes and centrifuged, 
after which 4.8 ml of the supernatant was discarded, and the pellet was 
resuspended thoroughly by vortexing in the remaining 200 µl. The remaining 
protocol was carried out in reduced lighting. 1 µl of cell viability dye, Zombie Aqua 
(BioLegend), was added to each ‘staining’ sample as well as the dead cell marker 
only control. Zombie Aqua is an amine-reactive dye which is non-permeant to live 
cells but permeant to cells with compromised membranes. Samples were 
incubated in the dark for 20 minutes. During this time, flow cytometry buffer was 
prepared (2 % FBS, 2 mM EDTA in PBS) and passed through a filter unit (Thermo 
Fisher). 5 ml of buffer was then added to each sample tube and centrifuged. 4.8 
ml of supernatant was discarded, and the pellet was resuspended thoroughly by 
vortexing in the remaining 200 µl. 1 µl of each antibody; cluster of differentiation 
molecule 11b (CD11b)- allophycocyanin Cy7 (ApcCy7), lymphocyte antigen 6C 
(Ly6C)-peridinin-Chlorophyll-Protein (PerCP) lymphocyte antigen 6C (Ly6G)-
fluorescein Isothiocyanate (FITC), all purchased from BD Biosciences, were 
added to each ‘staining’ tube and were incubated for 1-hour. During this time, 
single staining control samples were prepared as follows: 100 µl of compensation 
beads (BioLegend) were added to 400 µl buffer and split equally between three 
5 ml round-bottomed glass test tubes which were to be used as single staining 
control. 30 minutes later, 1 µl of either antibody was added to one of the single 
staining control tubes and incubated for 30 minutes. Following incubation, 5 ml 
of buffer was added to all tubes and centrifuged. 4.8 ml of supernatant was 
removed, and the pellets were resuspended thoroughly by vortexing in the 
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remaining 200 µl. Caps were then placed on all tubes and stored in the dark at 4 
˚C until flow cytometry analysis was carried out.  
5.2.8 Flow cytometry analysis 
Flow cytometry was conducted using a FACSCanto II cell analyser system (BD 
Biosciences) using a 633 nm excitation red laser to detect CD11b-ApcCy7, a 488 
nm excitation red laser to detect Ly6C-PerCP and a 488 nm excitation green 
laser to detect Ly6G-FITC. 50,000 cells per sample were analysed. Firstly, using 
an ‘unstained’ sample, the cell population of interest was gated and the 
photomultiplier tubes (PMT) voltages for forward scatter (FCS) and side scatter 
(SSC) as well as fluorescent channels were optimised. Compensation % values 
were calculated using each single staining antibody control and values were 
applied to all experiments conducted on the same day. ‘Staining’ tubes for each 
tissue sample were then analysed by the cytometer and the following analysis 
was conducted for each sample using FlowJo software (BD Biosciences): 
Elimination of cell debris: SSC-area (SSC-A) (y-axis) was plotted against FSC-
height (FSC-H) (x-axis) and a fluorescence intensity threshold of 5,000 was 
generated to eliminate any cell debris from the analysis. Elimination of cell 
doublets: FSC-H (y-axis) was plotted against FSC-A (x-axis) and the main cell 
population was gated for. Elimination of dead cells: Cell count (y-axis) was plotted 
against 405 nm excitation using a violet laser. Two peaks were generated; 
correlating to live cells (lower fluorescence intensity) and dead cells (higher 
fluorescence intensity). Dead cells were eliminated by gating only for the lower 
intensity peak. Identification of inflammatory monocyte population: Ly6C (y-axis) 
was plotted against CD11b (x-axis) and inflammatory monocytes were analysed 
by gating only the CD11b+Ly6CHi cell population. Identification of neutrophil 
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population: Ly6G (y-axis) was plotted against CD11b (x-axis) and neutrophils 
were analysed by gating only the CD11b+Ly6GHi cell population. 
5.2.9 Ultrasound 
Ultrasound was performed using the VisualSonics Vevo 770 imagine system 
fitted with an RMV707B scan head at 15-45 MHz. Mice were placed into an 
induction chamber and anaesthesia was induced for 1-minute using 3 % 
isoflurane mixed with 97 % O2 at a flow rate or 1 l/min. Mice were then placed in 
a supine position on top of a heated pad embedded with electrocardiogram 
electrodes and fixed in place using surgical tape. Anaesthesia was maintained 
using a nose mask with 1.5-2 % isoflurane and 98-98.5 % O2 at a flow rate of 1 
l/min. The electrocardiogram was monitored throughout the procedure, as was 
the body temperature, which was measured using a rectal probe and maintained 
at 37 ˚C ± 1.5 ˚C via the heated pad as well as a heat lamp when required. Hair 
was removed from the abdominal area using a razor followed by hair removal 
cream. A generous layer of preheated ultrasound gel was then added to the 
abdominal area. The probe was lowered onto the gel and moved into position 
until the largest area of the long axis of the spleen was identified, which was 
measured in mm2. After the ultrasound was completed, treatment animals 
recovered in a temperature-controlled incubator.  
5.2.10 Macrophage inflammatory protein 1 alpha (MIP1α) measurement  
Levels of MIP1α were measured in blood samples using an enzyme-linked 
immunosorbent assay (ELISA) kit (Abcam #ab200017). Wash buffers and an 
antibody cocktail were prepared as advised by the manufacturer’s protocol. All 
incubation steps were carried out at room temperature, with shaking at 400 rpm. 
Plasma samples were then prepared. Firstly, ~1 ml of blood was collected in a 
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heparin-coated syringe and transferred to a microcentrifuge tube. Blood was 
centrifuged at 2000 x g for 10 minutes with separated plasma placed into a fresh 
microcentrifuge tube. 50 µl of plasma sample or standard were added to wells of 
the provided 96-well plate, which were pre-lined with an immobilized anti-tag 
MIP1α antibody. All samples were run in triplicates. 50 µl of an antibody cocktail 
containing an affinity-tag labelled capture antibody and a reporter conjugated 
detector antibody was added and incubated for 2 hours followed by 3X washing 
with 350 µl wash buffer. After the final wash, 100 µl of 1:1 H2O2 and the 
chromogenic substrate 3,3',5,5'-tetramethylbenzidine were added, which is 
catalysed by the addition of HRP which generates a blue colour during incubation 
in the dark for 10 minutes. The reaction was terminated by adding 100 µl of 
sulfuric acid-containing stop solution, generating a yellow colour during 
incubation for 1-minute. An endpoint reading of optical density was then 
measured at 450 nm using a microplate reader. Values were calculated by using 
the average of triplicate samples and subtracting the average zero standard from 
each sample.  
5.2.11 Macrophage inflammatory protein 2 (MIP2) measurement  
Levels of MIP2 were measured in blood samples using an ELISA kit (R&D 
Systems #DY435). Plasma was prepared as described previously. All incubation 
steps were carried out at room temperature and all washes conducted 3X with 
400 µl wash buffer (0.05 % Tween 20 in PBS, pH 7.4). The assay plate was 
prepared by first coating required wells of a 96-well plate with 100 µl of MIP2 
capture antibody, incubated overnight and the following morning the plate was 
washed. Wells were blocked using 300 µl of 1 % BSA in PBS, pH 7.2-7.4 for 1-
hour followed by washing. 100 µl of sample or standard was added to the wells 
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and the plate was incubated for 2 hours and then the wells were washed. 100 µl 
of detection antibody was then added to each well and again incubated for 2 
hours and washed. 100 µl of Streptavidin-HRP was then added in the dark and 
incubated for 20 minutes followed by washing. 100 µl of 1:1 H2O2 and 3,3',5,5'-
tetramethylbenzidine were then added in the dark and incubated for 20 minutes 
followed by washing. Finally, 50 µl of 2 M H2SO4 was added. An endpoint reading 
of optical density was then immediately measured at 450 nm using a microplate 
reader. Values were calculated by using the average of triplicate samples and 
subtracting the average zero standard from each sample. Average values from 
positive control standards were plotted against their concentration and a standard 
curve was generated. Unknown MIP2 concentrations were then interpolated from 
















5.3.1 High amounts of SFX-01 is embryonic lethal in pregnancies carrying 
NS foeti  
I first sought to investigate if foetal treatment with SFX-01 would result in HOM 
offspring being born from HET/HET NS breeding pairs or increase the number of 
HET offspring born from WT/HET breeding pairs. Treatment with 2.5 mg/ml SFX-
01 had no detrimental effects on conception, pregnancy or litter size for WT/WT 
breeding pairs (figure 5.2 A). All females from WT/HET breeding pairs who 
received SFX-01 conceived and gave birth to litters. However, all females from 
HET/HET breeding pairs that received SFX-01 before pregnancy, and in which 
pregnancy had been confirmed, did not deliver litters, with termination estimated 
by visual inspection within 10 days of conception (figure 5.2 A). Treatment of 
WT/HET breeding pairs with SFX-01 significantly reduced litter size (figure 5.2 
B) with genotyping identifying a trend towards fewer HET offspring born 
compared to untreated controls (figure 5.2 C). All females from HET/HET 
breeding pairs that received SFX-01 post-gastrulation, and in which pregnancy 







































Figure 5.2. Foetal treatment with high amounts of SFX-01 pre-gastrulation is 
embryonic lethal in pregnancies carrying NS foeti.  
A) Treatment of HET/HET breeding pairs with 2.5 mg/ml SFX-01 in their drinking water 
before and during pregnancy resulted in no litters being born. B, C) Treatment of 
WT/HET breeding pairs with 2.5 mg/ml SFX-01 in their drinking water before and during 
pregnancy significantly reduced litter size with a trend for a lower percentage of HET 












5.3.2 Only WT neonates are born following foetal treatment with low 
amounts of SFX-01 
As treatment of HET/HET breeding pairs with 2.5 mg/ml SFX-01 resulted in the 
termination of pregnancies, foetal studies were repeated using 0.8 mg/ml SFX-
01. As above, SFX-01 treatment had no detrimental effects on conception, 
pregnancy or litter size for WT/WT breeding pairs (figure 5.4 A). All females from 
HET/HET breeding pairs who received SFX-01 conceived and gave birth to litters 
(figure 5.4 A). However, SFX-01 treatment significantly reduced the litter size of 
HET/HET breeding pairs and genotyping confirmed all offspring were WT (figure 
5.4 B, C). 
Figure 5.3. Foetal treatment with high amounts of SFX-01 post-gastrulation under 
these conditions is embryonic lethal in pregnancies carrying NS foeti.  
A) Treatment of HET/HET breeding pairs with 2.5 mg/ml SFX-01 in their drinking water 






























Figure 5.4. Foetal treatment with low amounts of SFX-01 results in the birth of only 
WT neonates in pregnancies carrying NS foeti.  
A) Percentage of pregnancies resulting in the birth of litters was not altered following 
treatment of WT/WT or HET/HET breeding pairs with 0.8 mg/ml SFX-01 before and 
during pregnancy. B, C) Treatment of HET/HET breeding pairs with 0.8 mg/ml SFX-01 




5.3.3 Foetal treatment with SFX-01 only partially reduces neonatal SHP2 
phosphatase activity  
A fluorescence-based activity assay identified no inhibition in global SHP2 
phosphatase activity in WT neonates from WT/HET or HET/HET breeding pairs 
following foetal treatment with 2.5 or 0.8 mg/ml SFX-01 respectively (figure 5.5 
A, B). Partial inhibition of SHP2 phosphatase activity by ~17 % was detected in 
HET offspring from WT/HET breeding pairs following foetal treatment with 2.5 
































Figure 5.5. Foetal treatment with SFX-01 partially reduces SHP2 phosphatase 
activity in HET neonates. 
 A) A fluorescence-based phosphatase activity assay which shows no inhibition of global 
SHP2 activity in WT neonates and partial inhibition in HET neonates from WT/HET 
breeding pairs who received 2.5 mg/ml SFX-01 in their drinking water before and 
throughout pregnancy. B) A fluorescence-based phosphatase activity assay identified 
no inhibition of global SHP2 activity in WT neonates from HET/HET breeding pairs who 




5.3.4 Protein-SFN adducts are detected in neonates following foetal 
treatment with SFX-01 
Western immunoblotting was conducted to determine whether SFN crosses the 
placenta and labels foetal tissue. Protein-SFN adducts were detected in both WT 
and HET neonates from WT/HET breeding pairs who had received 2.5 mg/ml 

















Figure 5.6. SFN adducts proteins in WT or HET neonates following foetal treatment 
with SFX-01.  
An immunoblot showing SFN adduction of a ~15 kDa protein in WT and HET neonates 
from WT/HET breeding pairs who had received 2.5 mg/ml SFX-01 in their drinking water 
before and during pregnancy. (n = 5). 
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5.3.5 Foetal treatment with SFX-01 increases neonatal ERK 
phosphorylation  
Western immunoblotting identified increased ERK phosphorylation in WT 
neonates from WT/WT breeding pairs who had received 0.8 mg/ml SFX-01 in 



















Figure 5.7. Foetal treatment with SFX-01 increases ERK phosphorylation in WT 
neonates.  
An immunoblot showing increased ERK phosphorylation in WT neonates from WT/WT 
breeding pairs who had received 0.8 mg/ml SFX-01 in their drinking water before and 
during pregnancy. (n = 3, *p<0.05 versus untreated control). 
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5.3.6 SFX-01 treatment lowers total white blood cell count in WT and NS 
mice  
Blood sampling followed by Wright-Giemsa staining, as represented in figure 5.8 
A, showed total white blood cell count was elevated in 17- and 22-week-old NS 
mice compared to their WT littermates (figure 5.8 B) which was in line with 
previous studies. 5- and 10-week treatment with SFX-01 reduced total white 
blood cell count in NS mice compared to untreated controls, which was also 



































Figure 5.8. SFX-01 treatment reduces white blood cell count in WT and NS mice.  
A) A representative light microscopy image of Wright-Giemsa stained blood samples 
from a 22-week-old WT mouse. B) Total white blood cell count was lowered in NS mice 
following 5- and 10-weeks treatment with SFX-01. Cell count was also lowered in WT 
mice at the later time point. (n = 13-16, *p<0.05 versus untreated control). 
167 
 
5.3.7 SFX-01 treatment lowers myeloid cell count in the blood and spleen 
of NS mice  
Inflammatory monocyte and neutrophil cell counts were calculated using flow 
cytometry as outlined in figure 5.9. Analysis from 17- or 22-week-old NS mice 
revealed an increase in inflammatory monocytes and neutrophils in the blood 
compared to their WT littermates (figure 5.10). No difference in myeloid cell count 
was detected in bone marrow of 22-week-old NS mice compared to their WT 
littermates (figure 5.11), however, the number of neutrophils was significantly 
greater in the spleen (figure 5.12). 10-week treatment with 2.5 mg/ml SFX-01 in 
drinking water had no effect on total myeloid cell count in the blood of WT mice 
(figure 5.10), however, caused a significant decrease in the number of 
neutrophils and therefore total myeloid count in the blood of NS mice (figure 
5.10). No elevation of total myeloid cell count was detected in bone marrow of 
22-week-old NS mice compared to WT littermates, although 10-week treatment 
with SFX-01 caused a small reduction in neutrophil count in this tissue in either 
genotype (figure 5.11). A significant increase in total myeloid cell count 
comprising of an increase in neutrophils was detected in the spleen of 22-week-
old NS mice compared to their WT littermates (figure 5.12). Treatment with SFX-
01 for 10 weeks significantly reduced neutrophil and inflammatory monocyte 






























Figure 5.9. Representative flow cytometry analyses of blood from 22-week-old NS 
mice. 
Representative FLOW-JO plots and histograms showing gates used to calculate 
percentages of each cell population within the blood. Leukocytes (SSC-A vs FSC-H), 
single cells (FSC-H vs FSC-A), live cells (Cell count vs Pacific Blue), inflammatory 
monocytes (CD11b+Ly6CHi) and neutrophils (CD11b+Ly6CHi). Values represent 

































Figure 5.10. SFX-01 treatment reduces neutrophil count in the blood of NS mice.  
A-C) Flow cytometry analysis showing reduced myeloid cell count in the blood from 22-
week-old NS mice following 10-week treatment of 2.5 mg/ml SFX-01 in their drinking 
water, which was attributed to a reduction in neutrophils. No effect on total myeloid cell 
count from the blood of WT mice was detected. (n = 13-16, *p<0.05 versus WT or 


























Figure 5.11. SFX-01 treatment causes a small reduction in neutrophil cell count in 
the bone marrow of NS mice.  
A-C) Flow cytometry analysis showing a small reduction in myeloid cell count in the 
bone marrow of 22-week-old WT or NS mice following 10-week treatment of 2.5 mg/ml 




























Figure 5.12. SFX-01 treatment reduces total myeloid cell count in the spleen of NS 
mice.  
A-C) Flow cytometry analysis showing reduced myeloid cell count in the spleen of 22-
week-old NS mice following 10-week treatment of 2.5 mg/ml SFX-01 in their drinking 
water, which was attributed to a reduction in both inflammatory monocytes and 
neutrophils. A reduction in inflammatory monocyte cell count was detected in the spleen 
of 22-week-old WT mice following treatment with the drug. (n = 14-16, *p<0.05 versus 
WT or untreated control as stated). 
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5.3.8 SFX-01 treatment reduces the plasma concentration of MIP2 but not 
MIP1α in NS mice 
MIP1α was not elevated in the plasma of untreated 22-week-old NS mice 
compared to their WT littermates and no reduction of the chemokine was seen 
following 10-week treatment with 2.5 mg/ml SFX-01 in their drinking water (figure 
5.13 A). However, a trend towards an increase in levels of MIP2 was seen in the 
plasma of 22-week-old NS mice compared to WT, with a trend for a decrease in 
levels of MIP2 following 10-week treatment with 2.5 mg/ml SFX-01 treatment in 





































5.3.9 SFX-01 treatment reduces the spleen growth of NS mice  
Ultrasound analysis of the size of the spleen and weighing of this tissue showed 
22-week-old NS mice had larger and heavier spleens compared to their WT 
littermates (figures 5.14 and 5.15). The ultrasound analysis also identified a trend 
Figure 5.13. The concentration of MIP2 but not MIP1α is reduced in the plasma of 
NS mice following SFX-01 treatment.  
A, B) Analyses of MIP1α and MIP2 levels in plasma from 22-week-old WT or NS mice 
following 10-week treatment with 2.5 mg/ml SFX-01 in their drinking water. SFX-01 
treatment reduced MIP2 levels in NS mice. Neither chemokine was reduced in WT mice. 
(n = 13-15). 
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for a decrease in the spleen size of NS mice following 10-week treatment with 
2.5 mg/ml SFX-01 in their drinking water compared to untreated controls (figure 
5.15 B). A significant reduction in spleen growth was apparent in NS mice when 
data was analysed as a delta change in the spleen size for each mouse over the 
duration of the10-week treatment period with 2.5 mg/ml SFX-01 (figure 5.15 C). 
Weighing of the spleens at the end of the experiment corroborated the trend for 
a reduction in the spleen weight of NS mice following 10-week treatment with 
SFX-01 (figure 5.15 A). Spleen weight and size were unaffected in WT mice 
























Figure 5.14. Adult NS mice have splenomegaly.  
A, B) Representative ultrasound and photographic images of spleens from 22-week-old 




























Figure 5.15. The growth of the spleen of NS mice is reduced when they receive a 
10-week treatment of SFX-01.  
A, B) Weighing of the spleen tissue and analysis by ultrasound identified a trend for a 
reduction in spleen weight and size from 22-week-old NS mice following treatment with 
2.5 mg/ml SFX-01 in their drinking water for 10 weeks compared to untreated controls. 
C) Representation of ultrasound data as Δ change in the spleen size for each mouse 
over the duration of the treatment period identified a significant reduction in NS mice 
who received the drug. (n = 14-16, *p<0.05 versus WT or untreated control as stated). 
177 
 
5.3.10 SFN adducts proteins in the spleen  
Western immunoblotting revealed SFN-adducted proteins in spleen tissue from 
22-week-old WT or NS mice following 10-week treatment with 2.5 mg/ml SFX-















5.3.11 SFX-01 treatment reduces SHP2 phosphatase activity in the spleen 
of NS mice  
SHP2 was immunoprecipitated from spleen tissue of 22-week-old WT or NS mice 
following 10-week treatment with 2.5 mg/ml SFX-01 in their drinking water (figure 
5.17 A). The activity of the phosphatase was subsequently analysed using the 
Figure 5.16. Protein-SFN adducts are detected in the spleen following SFX-01 
treatment.  
A representative immunoblot showing SFN-adducted proteins in spleen tissue from 22-
week-old WT or NS mice following 10-week SFX-01 treatment with 2.5 mg/ml SFX-01 in 
their drinking water. 
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fluorescence-based assay, which was reduced in NS mice following 10-week 
SFX-01 treatment compared to untreated controls. The activity of the 





















Figure 5.17. SFX-01 treatment reduces the phosphatase activity of SHP2 in the 
spleen of NS mice.  
A) An immunoblot of input and capture samples following immunoprecipitation of SHP2 
from spleen tissue of22-week-old WT or NS mice following 10-week treatment with 2.5 
mg/ml SFX-01 in their drinking water. B) A fluorescence-based phosphatase activity 
assay using immunoprecipitated SHP2 shows inhibition of SHP2 activity in NS mice 
following 10-week treatment with 2.5 mg/ml SFX-01. (n = 6 *p<0.05 versus WT or 




In chapter 3 I demonstrated and characterised the inhibition of SHP2 by SFN 
both in vitro and in vivo. In this chapter, I sought to determine if this inhibition 
would prove therapeutic in the NS mouse model, which was considered a rational 
prospect as it expresses hyperactive SHP2. Thus, perhaps by supplying SFN to 
pregnant dams carrying NS foeti, their aberrant cardiac and skeletal development 
during embryogenesis would be corrected. Alternatively, perhaps administering 
SFN to NS mice after they are born might reduce the incidence of 
myeloproliferative disease that develops during adulthood. 
NS patients with gain-of-function SHP2 mutations often have several congenital 
defects in cardiac structure 354 355. The NS mouse model also develop congenital 
cardiac defects in a gene-dosage dependent manner 78 137 356 357 358 and the 
variable penetrance and severity of phenotypes of this mouse model are 
discussed in greater detail in the general introduction. HOM NS embryos have 
severe atrial, atrioventricular or ventricular septal defects, double-outlet right 
ventricle, enlarged outflow tract and defective atrioventricular valve primordia 
which all contribute to heart failure and lethality by E13.5 78. Approximately 50 % 
of HET embryos also die mid-gestation, although with less severe cardiac defects 
78. The remaining HET embryos are born with less-severe non-cardiac 
abnormalities 78. As outlined in the introduction of this chapter, several studies 
identified roles for SHP2 in multiple stages of cardiac development. Through 
inducible knock-in approaches using NS mouse models with either a D61G/+ or 
D61Y/+ mutation, which cause hyperactivation of SHP2, the Neel group conclude 
all NS cardiac defects develop in utero and arise from the increased activity of 
the phosphatase in the endocardium.  Detection by ultrasound of excessive 
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amniotic fluid is suggestive of NS in the unborn child which can further be 
diagnosed through genetic testing 359. If the diagnosis was achieved prior to or in 
the early stages of cardiac development, perhaps inhibition of hyperactive foetal 
SHP2 may prove therapeutic in reducing cardiac structural defects along with 
other congenital phenotypes. Using concentrations previously shown as 
inhibitory to SHP2 of adult mice (2.5 mg/ml), foetal treatment with SFX-01 
resulted in all mothers from WT/WT conceiving and giving birth to healthy litter 
sizes. Detection of SFN adducted to a ~15 kDa protein in these neonates, which 
is likely Hgb β for reasons outlined in chapter 4, is indicative that the electrophile 
can cross the placenta. Although not statistically significant, this amount of drug 
did induce partial inhibition of SHP2 phosphatase activity in HET neonates from 
WT/HET breeding pairs. To achieve greater inhibition of SHP2, it is likely a higher 
amount of SFX-01 is required. However, unfortunately, treatment with the drug 
at these amounts resulted in no HOM NS offspring born from HET/HET breeding 
pairs. Litter size from WT/HET pairs was also reduced, with a lower number of 
HET neonates born and therefore this amount of SFX-01 exerted harmful effects 
upon foeti with this genotype. Foetal treatment with a lower amount of SFX-01 
(0.8 mg/ml) again had no effect on rates of conception, the number of births or 
litter size of WT mice. With this reduced amount of drug, offspring were also born 
from HET/HET breeding pairs, although again, unfortunately, this treatment was 
detrimental to NS foeti.  
Further analysis showed foetal treatment with this lower amount of SFX-01 
increased ERK phosphorylation in WT neonates born from HET/HET breeding 
pairs. As SHP2 activity was not significantly altered in neonates following foetal 
treatment with this lower amount of the drug, it is logical to assume the SFN-
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induced increase in ERK phosphorylation occurs independently of SHP2. An 
SFN-induced increase in the phosphorylation of ERK via SHP2-independent 
mechanisms was discussed in chapter 3. Basally, NS foeti have increased ERK 
phosphorylation in endocardial cushion cells as well as their face and limb buds 
compared to WT mice, which is causative of their developmental abnormalities 
for reasons outlined below 78. If SFX-01, therefore, increased ERK 
phosphorylation even further in NS foeti, perhaps severe cardiac and skeletal 
developmental defects were causative of their embryonic lethality. As mentioned 
previously, endocardial cushions evolve into semilunar and atrioventricular 
valves. During normal early and late stage valve development ERK activation is 
increased in the endocardial cushion cells overlaying distal tips of the 
atrioventricular canal and outflow tract valves and its hyperactivation has been 
shown to increase cushion explant outgrowth 74 360. Constitutive activation of ERK 
in mouse valve primordia replicates the valve phenotypes observed in embryos 
which have either the D61G/+ or D61Y/+ gain-of-function SHP2 mutation, whilst 
deletion of ERK completely rescued the endocardial cushion phenotype 361. It is 
therefore accepted that hyperactivation of ERK in SHP2 gain-of-function NS 
mouse models as well as patients is causative of their valvular septal defects, 
although the exact mechanism of action is still under investigation. Krenz et al 
have shown that increased ERK activation in the endocardial cushion cells of 
embryos who have the gain-of-function SHP2 mutation Q79R/+ causes 
excessive mesenchymal cell proliferation, with no effect on endocardial-
mesenchymal transformation 361. The Neel group, on the other hand, suggest 
ERK hyperactivation does extend the interval during which cardiac endocardial 
cells undergo an endocardial-mesenchymal transformation, likely by enhancing 
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ErbB RTK signalling, in particular, Erb3, which is a positive regulator of valve 
development 73 78 281. Nakamura et al also report increased ERK activation and 
enhanced cardiomyocyte proliferation in the trabecular myocardium which 
inhibits ventricular compaction and closure of the ventricular septum in their 
cardiomyocyte-specific Q79R/+ NS mouse model 362.  
These studies suggest SFX-01 could not prevent congenital skeletal and cardiac 
developmental defects in NS foeti. However, optimising the amount of the drug 
received by the parents, as well as the stage of embryogenesis which it is 
administered are worth pursuing. For example, foetal treatment with SFX-01 
post-gastrulation may avoid embryonic lethality by allowing initial skeletal and 
cardiac development to occur, with the electrophile then correcting SHP2 
dependent abnormalities associated with later stages of cardiac development 263. 
Whilst this would not allow for full correction of the cardiac phenotype, it may 
improve cardiac function. A pilot study administering SFX-01 post-gastrulation 
was unsuccessful, although only a higher, perhaps sub-optimal, dose of the drug 
was tested. The date of conception was also only an estimate, based on the 
presence of a vaginal plug, and so perhaps the SFX-01 was in fact administered 
pre- or mid-gastrulation in some mice. In future studies, conception and 
gastrulation should be confirmed using ultrasound. As ERK phosphorylation is 
increased in WT offspring from parents who received the drug and increased 
activity of the kinase is implicated in congenital phenotypes associated with NS, 
subsequent studies monitoring these offspring for skeletal and cardiac defects 
should be carried out.  
Finally, the phosphorylation and activation of ERK stimulate downstream 
upregulation of cell growth and proliferation. Therefore, although ERK 
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hyperactivation is detrimental in the context of embryonic development, perhaps 
the increase in the phosphorylation of this kinase which was observed in adult 
mice following SFX-01 treatment, as seen in chapter 3, may be beneficial 
regarding the impaired growth that NS patients face.  
Some NS patients also present with myeloproliferative disease, which can 
develop into JMML; a rare myeloproliferative neoplasm associated with 
excessive monocytic and macrophagic proliferation 363 364 365 366 367. Unlike 
cardiac complications, haematopoietic defects are completely penetrant in NS 
mice. As outlined in the introduction of this chapter, multiple studies have 
implicated SHP2 in HSC survival, proliferation and differentiation and both the 
Neel group and I have demonstrated elevated total white blood cell counts in 
adult NS mice 96-105. Further to this, SHP2 promotes progenitor cell differentiation 
of the myeloid cell lineage. Indeed, bone marrow haematopoietic progenitors 
from NS mice have cell-autonomous signalling defects, developing into myeloid 
colonies independently of factor-stimulation. They are also more sensitive to IL-
3 and GM-CSF, factors which promote differentiation and proliferation of the 
myeloid lineage 78. Flow cytometry analysis conducted by the Neel group showed 
myeloid count in the bone marrow and spleen of NS mice, which was conducted 
using a granulocyte receptor 1 antibody with affinity for both Ly6C and Ly6G cell 
surface markers, was elevated 78. Separate Ly6C or Ly6G antibodies were used 
in my analysis reported here, allowing for differentiation between inflammatory 
monocyte and neutrophil cell populations respectively 368. Using this method, I 
too identified adult NS mice had increased myeloid cell count in the spleen and 
blood but also made the novel observation this was predominantly due to an 
increased number of neutrophils. Although, there was only a slight increase in 
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neutrophil count in the bone marrow of NS mice compared to WT littermates. 
Using a mouse model with a gain-of-function SHP2 mutation which was pan-
haematopoietic cell-inducible, E76K/+, Xu et al similarly observed accumulation 
of neutrophils in the blood. Observations made following my own flow cytometry 
analysis support studies outlined in the introduction of this chapter which 
implicates a more specific role for SHP2 in differentiation and proliferation of the 
granulocyte lineage, which encompasses neutrophils 352.  
I also observed a trend towards an increase in levels of the chemokine MIP2 in 
the plasma of NS mice compared to WT. MIP2 is a potent chemoattractant for 
neutrophils, with intravenous injection of the chemokine causing selective and 
rapid mobilisation of neutrophils from the bone marrow 369 370. Perhaps in NS 
mice, this higher abundance of circulating MIP2 causes greater attraction of 
neutrophils from the bone marrow, thus, as soon as they are produced, they are 
rapidly released into the circulation. This may also explain why the number of 
neutrophils appears not to be elevated in the bone marrow. There was, however, 
a trend towards increased inflammatory monocytes in the bone marrow of NS 
mice compared to WT. This was coupled with no increase in plasma levels of the 
chemokine MIP1α, a chemoattractant known to drive recruitment and maturation 
of monocytes 371 372. These mice may, therefore, have increased production of 
monocytes and neutrophils within the bone marrow, with the former accumulating 
because of deficient chemoattractant signals that would otherwise trigger their 
release into the circulation. It would perhaps be illuminating to conduct an 
analysis of a broader range of monocyte chemoattractants, such as chemokine 
ligand 2 or protein expression levels of its receptor chemokine ligand receptor 2 
373, as this may further support this speculation. As differentiation between 
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inflammatory monocyte and neutrophil populations in the bone marrow or spleen 
of NS mice was not achievable by the Neel group, perhaps the elevated myeloid 
cell counts they identified in these mice also represented monocytes in the bone 
marrow and neutrophils within the spleen.  
Together with an increase in the number of neutrophils in the spleen, I have 
shown adult NS mice develop splenomegaly, a phenotype that characterises 
some NS patients 374 375. As total white blood cell count, including neutrophils, 
was increased in the circulation, perhaps this enlargement of the spleen occurs 
due to their accumulation within this organ. Such an idea is consistent with 
evidence outlined in the introduction of this chapter whereby the spleen can act 
as a reservoir for certain white blood cells 81, 82, 327, 330-333. A higher number of 
long- and short-term HSCs, as well as MPP cells, have been observed in spleens 
of mice carrying the gain-of-function SHP2 mutation E76K/+ 353. With this in mind, 
perhaps splenomegaly in the D61G/+ mouse model is a result of extramedullary 
haematopoiesis occurring in this tissue. As my flow cytometry analysis only 
assessed mature neutrophils, a more in-depth analysis of cell-surface markers 
of lymphocytes from the spleen may help elucidate if excessive extramedullary 
haematopoiesis is also occurring simultaneously to white blood cell production in 
the bone marrow.  
Consistent with the in vivo data described in chapter 3 where mice were treated 
chronically for 10 days with SFX-01, prolonged 10-week treatment with the drug 
significantly reduced SHP2 phosphatase activity in NS mice. Notably, inhibition 
of SHP2 occurs to a much greater extent in these mice compared to WT, which 
may be due to the gain-of-function SHP2 mutation alleviating N-terminal 
structural inhibition of the phosphatase domain allowing easier access to the 
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catalytic cysteine, an idea outlined in the general introduction. Also discussed 
previously was the logical assumption that SFN adducts multiple proteins in vivo 
and with this modification potentially altering their biological function. Even so, 
SHP2 plays essential roles in multiple stages of myeloid cell differentiation and 
progression, in particular, granulocytes. I therefore strongly suggest the reduction 
in neutrophil count in the blood, spleen and bone marrow of NS mice following 
treatment with SFX-01 was substantially mediated by inhibition of the 
phosphatase. To further confirm this, fluorescence-activated cell sorting could be 
utilised to isolate HSCs and progenitor cells from bone marrow and spleen 
following drug treatment. Subsequent culture and analyses of SHP2 inhibition, 
as well as cell proliferation, differentiation or apoptosis markers may uncover 
which haemopoietic cell type is most affected by SFN.  
Balasubramanian et al discovered SHP2 is a positive regulator of p38 MAPK-
dependent MIP2 production through the formation of a stable complex with the 
kinase and GRB2 376. Plasma levels of MIP2 are reduced in NS mice following 
treatment with SFX-01. MIP2 is produced in a range of tissue and blood cells. 
Perhaps SFN-dependent inhibition of SHP2 is also preventing its recruitment to 
GRB2 and p38 MAPK, resulting in reduced MIP2 expression levels. In turn, this 
may reduce the stimulation for neutrophils to exit the bone marrow, potentially 
explaining the reduced neutrophil counts in the blood and spleen. If this was the 
case, an accumulation of neutrophils within the bone marrow following SFX-01 
treatment may have been anticipated, which I did not observe. Perhaps 
neutrophils initially accumulate within the bone marrow, which may act as a 
feedback mechanism to reduce white blood cell production. Although, I anticipate 
a more rational explanation is SFN-dependent inhibition of SHP2 reduced both 
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MIP2-mediated release of neutrophils from the bone marrow as well as myeloid 
cell proliferation and differentiation.  
Studies have also shown that SHP2 can translocate to the mitochondria where it 
interacts with and dephosphorylates p135. This stimulates the production of ROS 
in myeloid progenitor cells and causes hypersensitivity to cytokines 377. 
Treatment of these cells with the antioxidant N-acetyl-cysteine prevents the 
biological effects caused by the modification of proteins by these ROS and in 
turn, reduces myeloid colony formation. Perhaps SFN is also lowering cytokine 
sensitivity and differentiation of myeloid progenitor cells in NS mice by reducing 
the intracellular levels of ROS, either through inhibition of SHP2 or activation of 
the KEAP1/Nrf2 signalling pathway.  
As SHP2 phosphatase activity was not significantly inhibited in WT tissue 
following 10-week treatment with SFX-01, the observed reduction in total white 
blood cells, as well as inflammatory monocytes in the spleen of these mice, may 
be caused by the modification of other proteins by SFN. Of course, biological 
events which may be stimulated by adduction of the electrophile to proteins other 
than SHP2 may also contribute towards the reduction in total white blood cell 
count and inflammatory monocytes in the spleen of NS mice. Multiple studies 
have demonstrated anti-inflammatory effects of the electrophile regarding the 
monoblast lineage. Particularly through suppression of tumour necrosis factor-α-
induced NF-кB transcriptional activity in monocytes, macrophages and 
endothelial cells by either adducting and inhibiting the catalytic cysteine within 
NF-кB β subunit or inhibiting the RhoA/ROCK signalling pathway 378 379. This 
leads to a subsequent reduction in gene expression of intracellular adhesion 
molecule 1 and vascular adhesion molecule 1 and reduces the adhesion of 
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monocytes to sites of inflammation 380 381 382. SFN also reduces the expression 
and release of macrophage migration inhibitory factor, IL-1β, IL-6, tumour 
necrosis factor-α and matrix metallopeptidase 9, which are pro-inflammatory 
cytokines that stimulate the release of monocytes from the bone marrow as well 
as their maturation to macrophages 248 379 383 384.  
As well as decreasing total white blood cell and myeloid cell populations, the 
prolonged treatment of SFX-01 also prevented excessive growth of the spleen 
and the incidence of splenomegaly in the NS mouse model. Analysis of the 
spleen size of mice was achieved using ultrasound. When only end-point 
ultrasound data was analysed, the spleen size of NS mice did not appear to be 
significantly reduced by SFX-01 treatment compared to water only controls. 
However, the ultrasound method enabled calculation of spleen size before, 
during and after drug treatment, allowing analysis of the amount of spleen growth 
of each mouse through the duration of the study. When analysed in this way, 
spleen growth was significantly reduced in NS mice when treated with SFX-01. I 
outlined in the introduction of this chapter that myeloid cells can reside within the 
spleen until they are stimulated by an inflammatory response. Perhaps the 
reduction in the growth of the spleen of NS mice who received the drug was due 
to a lower number of circulating, and as a result, spleen residing neutrophils, 
which prevented the expansion of this tissue. The necessity to analyse each 
mouse as an individual and not as a grouped cohort can be explained by the 
variability in the severity of the splenomegaly that is present in different NS mice, 
and the variable penetrance of different phenotypes in this mouse model is 




6 The mechanism of sulforaphane-induced 
inhibition of SHP2 
6.1 Introduction 
6.1.1 Catalytic mechanism of SHP2  
Amino acid sequence alignment of PTPs showed an evolutionarily conserved 
catalytic domain with a signature motif (I/V)VHCXAGXGR(S/T)G, whereby X can 
be any amino acid 385 386 387. Site-directed mutagenesis and active site-labelling 
elucidated the invariant cysteine residue as essential for PTP activity 388 389 390. 
Several studies show PTPs, including SHP2, have a conserved catalytic 
mechanism involving a two-step process in which substrate binding is followed 
by phosphate monoester hydrolysis as shown in figure 6.1 387 391 392 393 394 395. 
The active site within the PTP domain of SHP2 forms a ‘pocket’ consisting of 
three loops; P, Q and WDP. The catalytic cysteine of SHP2, Cys459, resides within 
the P-loop of the active site along with a critical arginine 43. The pKa of this 
cysteine thiol is low, which facilitates the nucleophilic attack of the thiolate 
towards protein phosphate groups. This low pKa is maintained through 
electrostatic interactions between the negatively charged thiolate and the 
positively charged side chains of the critical arginine 43. H bonding has also been 
shown to stabilize the proton-dissociated state of the reactive cysteine residue to 
maintain the low pKa. This was demonstrated by Chigadze et al, who showed the 
side chains of Asp61 within the WDP-loop form multiple H bonds, including with 
Ser460 from the catalytic P-loop, a water-mediated H bond with the catalytic 
Cys459, two water-mediated H bonds with Arg465 and another water-mediated H 
bond with Asp425 392 397. The orientation of the positively charged critical arginine 
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within the P-loop facilitates correct binding of the phosphorylated substrate by 
coordinating with negatively charged oxygens of the phosphate group 398 399 400. 
The first step of the reaction involves nucleophilic attack of the catalytic cysteine 
thiolate towards the phosphorus atom 390 392 401. Concurrently with cleavage of 
this ester bond, an adjacent aspartic acid residue residing in the proteins WPD-
loop donates a proton to the leaving group oxygen upon the substrate 391 399 402 
403. This results in a cysteinyl-phosphorus intermediate covalently bound via a 
thioester linkage, which is stabilised by the P-loop arginine, and release of the 
dephosphorylated substrate 387 403. The second rate-limiting step involves 
positioning of a water molecule within the phosphatase domain by coordination 
with a glutamate in the Q-loop 404. The catalytic aspartate now acts as a general 
base by accepting a proton from the water molecule and facilitating hydrolysis of 
the scissile phosphorous-sulfur bond 402 405 406 407. This generates free-phosphate 
and also restores the reactive thiolate, allowing the PTP to engage in a new 
reaction cycle. As outlined in chapters 3 and 5, SFN inhibited SHP2 phosphatase 
activity in vitro and in vivo. Interestingly, the in vitro studies showed SFN 
adduction to SHP2 was followed by the loss of a detectable adduct, even though 
inhibition of the phosphatase was maintained. A possible explanation for this was 
that loss of the adduct was coupled with the formation of a residual modification 
within the active site that prevents the catalytic mechanism described above. 
Here I sought to investigate this incompletely understood mechanism of inhibition 
of SHP2 by SFN which unexpectedly and intriguingly cannot be accounted for by 






















Figure 6.1. Catalytic mechanism of cysteine-based PTPs, including SHP2. 
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6.2 Materials and methods 
6.2.1 SDS-PAGE and western immunoblotting  
SDS-PAGE and western immunoblotting were performed as outlined in the 








Table 6.1. List of primary antibodies used for western immunoblotting in chapter 
6. 
 
6.2.2 Immunoprecipitation  
Immunoprecipitation of proteins from tissue was performed as outlined in the 
general methods. For this chapter, the capture antibody was agarose-conjugated 
anti-SHP2 (Rabbit, Santa Cruz, #sc-7384 AC).  
6.2.3 H2O2 treatment of recombinant SHP2  
10 ng of recombinant SHP2 in 20 µl of PBS containing 0-250 µM H2O2 was 
incubated at room temperature for 15 minutes. 20 µl of 2X SDS-PAGE sample 
buffer was then added and western immunoblotting was performed as described 
in the general methods.   
6.2.4 Polyethylene glycol (PEG)-switch method 
The PEG-switch method was used to assess potential reversible oxidative 
modification of SHP2 following treatment with SFN. SHP2 was 
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immunoprecipitated from cardiac tissue of control WT or NS mice or following 
treatment with 2.5 mg/ml SFX-01 for 4 days in their drinking water and 
resuspended in 50 µl PBS. 50 µl of a maleimide containing buffer (100 mM 
maleimide, 100 mM Tris-HCl, 1 % SDS, pH 7.4) was then added to each SHP2 
containing mixture and incubated at 50 ˚C for 25 minutes. 200 mM TCEP was 
then added, and the mixture was incubated at room temperature for 30 minutes. 
Each reaction mixture was desalted using a 7 kDa cut-off 0.5 ml Zeba Spin 
desalting column (Thermo Fisher) and 20 µl of a PEG-maleimide containing 
buffer (70 mM PEG-maleimide, 500 mM Tris-HCl, 7 % SDS, pH 7.4) was added 
followed by incubation at room temperature for 2 hours rotating at 20 rpm. An 
equal volume of 2X SDS-PAGE sample buffer containing 50 mM maleimide was 
then added to quench the reaction. Samples were analysed under non-reducing 
conditions by SDS-PAGE and western immunoblotting using an anti-SHP2 
antibody. PEG-maleimide specifically reacts with free cysteine thiols and carries 
a pegylated tail with a molecular weight of 5 kDa. This method therefore 
potentially allows determination of the number of cysteines within SHP2 which 
had been subjected to reversible oxidative modification by analysis of the 
proteins banding pattern following western immunoblotting.   
6.2.5 Biotinylated iodoacetamide (BIAM) labelling method 
The BIAM labelling method was used to identify if the catalytic cysteine within 
SHP2 was post-translationally modified following treatment with SFN. SHP2 was 
immunoprecipitated from cardiac tissue of control WT or NS mice or following 
treatment with 2.5 mg/ml SFX-01 for 4 days in their drinking water and 
resuspended in 50 µl PBS, pH 6.4. 2 µl of a 10 mM BIAM stock (400  
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µM final concentration) was then added and the reaction mixture was incubated 
at room temperature for 30 minutes followed by addition of an equal volume 2X 
SDS-PAGE sample buffer containing 100 mM maleimide to quench the reaction. 
Samples were analysed under non-reducing conditions by SDS-PAGE and 
western immunoblotting. PVDF membranes were probed using HRP-conjugated 
streptavidin (1:10,000 in 5 % BSA in PBS-T) which was detected using ECL. If 
the catalytic cysteine is post-translationally-modified, BIAM is unable to adduct 
and loss of labelling is seen.  
6.2.6 Phenylarsinic acid (PAA) labelling method 
The PAA labelling method was used to identify if two vicinal thiols within the 
catalytic domain of SHP2 had been post-translationally-modified following 
treatment with SFN. SHP2 was immunoprecipitated from cardiac tissue of control 
WT or NS mice or following treatment with 2.5 mg/ml SFX-01 for 4 days in their 
drinking water and resuspended in 50 µl PBS followed by an equal volume of 2X 
SDS-PAGE sample buffer. Samples were analysed under non-reducing 
conditions by SDS-PAGE and far-western blotting. PVDF membranes were 
incubated with 1 mM biotinylated-PAA (Synlnnova) in 40 ml 5 % BSA in PBS-T 
for 1-hour at room temperature. Membranes were then washed for 5X 15 minutes 
with PBS-T and incubated for a further hour with HRP-conjugated streptavidin 
(1:10,000 in 5 % BSA in PBS-T) which was detected using ECL. If two vicinal 
thiols are post-translationally-modified, PAA is unable to adduct and loss of 
labelling is seen.  
6.2.7 Amplification and purification of WT and Cys459Ser SHP2 plasmid  
WT or Cys459Ser SHP2 plasmids were purchased from Addgene (plasmid #8381 
and #8382 respectively). Both plasmids comprised a cytomegalovirus (pCMV) 
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vector backbone with ampicillin resistance and human SHP2 inserted (with or 
without mutation). The WT plasmid can be visualised in figure 6.2. Plasmids were 
received in transformed bacteria in an agar stab. 5 ml Luria-Bertani (LB) broth 
supplemented with 100 mg/ml ampicillin was inoculated with the transformed 
bacteria and incubated for 7 hours at 37 ˚C shaking at 100 rpm. Transformed LB 
broth was then added to 245 ml fresh LB broth supplemented with 100 mg/ml 
ampicillin and incubated overnight at 37 ˚C shaking at 100 rpm. The following 
morning, the plasmid was extracted from the bacterial cells using a plasmid maxi-
prep kit (QIAGEN) following the manufacturer’s instructions. DNA was then 







6.2.8 Site-directed mutagenesis of SHP2 plasmid 
Multiple cysteine to serine single or double SHP2 mutants, as named in table 6.2, 










Table 6.2. List of primers used to generate cysteine to serine SHP2 mutants. 
 
Site-directed mutagenesis was achieved via polymerase chain reaction (PCR) 
using a Q5 High-Fidelity DNA Polymerase kit (New England Biolabs), the 
oligonucleotide primers stated in table 6.2 and the PCR protocol stated in table 
6.3. 
 
Step Temperature Time 
Initial denaturation 98 ˚C 30 seconds 






Final extension 72 ˚C 15 minutes 
Holding 4 ˚C Until removed 
 
Table 6.3. PCR protocol used for site-directed mutagenesis. 
Following PCR, 1 µl of the restriction enzyme DpnI (New England Biolabs) was 





Forward primer for PCR Reverse primer for 
PCR 
Cys333Ser SHP2  
WT 
5’ – ACACAAGGCTCCCTG 
CAAAAC - 3’ 
5’ - GGCAATGTAACT 
CTTTTTGG - 3’ 
Cys367Ser SHP2  
WT 
5’ - AAGAGTAAATCTGTC 
AAATACTGGC - 3’ 
5’ - TCCTCTCTCCAC 
TTCTTTC- 3’ 
Cys333/367Ser SHP2  
Cys333Ser 
5’ - AAGAGTAAATCTGTC 
AAATACTGGC - 3’ 
5’ – TCCTCTCTCCAC 
TTCTTTC - 3’ 
Cys333/459Ser SHP2  
Cys459Ser 
5’ - ACACAAGGCTCCCTG 
CAAAAC - 3’ 
5’ - GGCAATGTAACT 
CTTTTTGG - 3’ 
198 
 
6.2.9 Transformation of Escherichia coli and plasmid purification following 
mutagenesis 
Following incubation of the PCR mixture with Dpn1, 5 µl of PCR mix was added 
to one vial of 5-α competent Escherichia coli cells (New England Biolabs), 
incubated on ice for 30 minutes, heat shocked at 42 ˚C for 30 seconds followed 
by a final incubation on ice for 5 minutes. 500 µl of super optimal broth with 
catabolite repression (SOC) medium was added to the competent cells, 
incubated at 37 ˚C for 1-hour shaking at 300 rpm. 100 µl of the transformed 
competent cells were then spread evenly onto a LB agar plate supplemented with 
100 mg/ml ampicillin and incubated at 37 ˚C overnight. 5 ml of LB broth 
supplemented with 100 mg/ml ampicillin was then inoculated with single bacterial 
colonies which grew on the LB agar plate and incubated at 37 ˚C overnight 
shaking at 100 rpm. The following morning, the plasmid was extracted from the 
bacterial cells using a plasmid mini-prep kit (QIAGEN) following the supplied 
instructions. DNA was then sequenced by Eurofins Genomics and sequencing 
results were analysed using ApE software.  
6.2.10 Transfection of HEK293 cells with SHP2 plasmids 
For each well of a 6-well plate, the following was prepared; 4 µl Lipofectamine 
2000 (Thermo Fischer) was added to 100 µl opti-MEM reduced serum media in 
a microcentrifuge tube. In a separate tube, 0-500 ng of SHP2 plasmid was added 
to 100 µl Lipofectamine. Both tubes were incubated separately for 5 minutes at 
room temperature. The contents of the tubes were then combined and incubated 
for a further 15 minutes. During this time media was replenished upon HEK293 
cells. The DNA-containing transfection solution was then added drop-wise to 
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each well. Cells were placed back into the incubator and experiments were 
carried out 24 hours post-transfection.  
6.2.11 Cell treatment with SFX-01 
Media from HEK293 cells seeded into 6-well plates, either with or without prior 
transfection with an SHP2 plasmid was replaced with 2 ml warmed, serum-free 
media (DMEM plus GlutaMAX-I supplemented with penicillin/streptomycin (1 
unit/ml;1 µg/ml)). Cells were treated with varying amounts of SFX-01, 0-250 µM, 
and placed back into the incubator for 0.5-4 hours. Following this, if western 
immunoblotting was required, 200 µl of 2X SDS-PAGE sample buffer was added 
to each well. When immunoprecipitation of SHP2 was required, 200 µl of PBS 
was added instead. Cells were then detached from the well using a cell scraper, 
moved into a microcentrifuge tube and lysed via sonication for 7 seconds at 30 
kHz and 40 % amplitude. Western immunoblotting or immunoprecipitation 
protocols previous outlined were then followed. 
6.2.12 Generation of 5-thio-2-nitrobenzoic acid (TNB)  
To generate TNB, 0.5 g 5, 5-dithio-bis-2-nitrobenzoic acid (dTNB, Ellman’s 
reagent) was dissolved in 25 ml 0.5 M Tris-HCl pH 8.8 containing 2.5 ml β-
mercaptoethanol. The pH of the solution was adjusted to 1.5 with 6 M HCl. The 
solution was rotated at 4 ˚C to aid TNB crystal formation. The following morning, 
the bright orange TNB crystals were filtered and washed with 2 L cold 0.1 M HCl 
to remove β-mercaptoethanol. The crystals could be stored indefinitely at room 
temperature.   
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6.2.13 Treatment of TNB and analysis by HPLC 
1 mg of TNB crystals were dissolved in 200 µl deionised water followed by a 
further 1:500 dilution in water to make a 50 µM TNB solution which was incubated 
with or without 5 µM SFX-01 for 1-hour or overnight. An equivalent amount of 
dissolved TNB was also incubated with 100 µM H2O2 for 1-hour. The solutions 
were analysed by HPLC using the protocol outlined in the general methods but 
with the UV detector set to 320 nm to aid detection of TNB. A deionised water-
only sample was used as a negative control followed by TNB, dTNB alone or 
SFX-01 alone standards to determine their retention time.  
6.2.14 Liquid chromatography-mass spectrometry analysis of GSH 
following treatment with SFX-01 
LC-MS/MS was carried out by Dr Francesca Mazzacuva (Franklin-Wilkins 
Building, King’s College London). 10 or 100 µM of reduced GSH was incubated 
with 10 µM L-SFN (dissolved in DMSO) and incubated for 0.5-24 hours. 
Immediately prior to analysis, samples were diluted 1:50 with 1:1 H2O/1,1′-
azobis(cyclohexanecarbonitrile) + 0.1 % formic acid. 5 µl of sample was first 
separated by LC using a reverse-phase column (Luna Omega, C18, 1.6 µM, 100 
Å, 100 mm x 2.1 mm inner diameter, Thermo Fisher). An atomic absorption 
spectrometer was incorporated into the LC system which monitored the 
absorption of light (atomic absorbance), which was produced by a hollow cathode 
lamp, to measure the amount of each reaction product in the solution.  
Separated reaction products were then applied to an interfacing linear ion trap 
mass spectrometer with an electron transfer dissociation source (LTQ Orbitrap 
XL, Thermo Fisher) and collected from the analyser using full ion scan mode over 
an m/z range of 100-1000. MS conditions used were: capillary voltage 14 V, 
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capillary temperature 350 ˚C, tube lens 35 V. During the 15-minute run time the 
machine simultaneously performed several experiments: 
1) MS scan in positive ion mode, range 100-1000 m/z 
2) MS2 in positive ion mode of 613.3 m/z, collision energy 17, range 300-650 m/z 
for GSSG 
3) MS2 in positive ion mode of 308.3 m/z, collision energy 15, range 150-310 m/z 
for GSH 
4) MS2 in positive ion mode of 178.6 m/z, collision energy 15, range 50-150 m/z 
for SFN 
5) MS3 in positive ion mode of 485.2 m/z, collision energy 23, and then of 356 













6.3 Results  
6.3.1 An SFN adduct is not detected upon inhibited cardiac SHP2  
As outlined in figure 3.12 of chapter 3, immunoprecipitation of cardiac SHP2 from 
WT or NS mice revealed inhibition of the protein’s phosphatase activity following 
4-day treatment with 2.5 mg/ml SFX-01 in their drinking water. Re-analysis of 
immunocaptured SHP2 by SDS-PAGE followed by immunoblotting unexpectedly 
revealed the absence of an SFN adduct upon the inhibited phosphatase from WT 







6.3.2 Recombinant SHP2 migrates faster by SDS-PAGE following H2O2 
treatment 
To investigate if oxidative modification induced an intramolecular disulfide within 
SHP2, recombinant protein was incubated with 0-500 µM H2O2 for 15 minutes. 
Immunoblotting revealed a proportion of the recombinant SHP2 protein migrated 
Figure 6.3. An SFN adduct is not detected upon SHP2 following chronic in vivo 
treatment with SFX-01. 
A representative immunoblot showing the absence of an SFN adduct upon 
immunocaptured cardiac SHP2 from WT or NS mice following 4-day treatment with 2.5 
mg/ml SFX-01 in their drinking water. 
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faster on a polyacrylamide gel following H2O2 treatment in a concentration-








6.3.3 SFN treatment induces a non-reducible molecular weight shift of 
SHP2 in vivo  
Immunoprecipitation of SHP2 from cardiac tissue of WT mice that received 2.5 
mg/ml SFX-01 in their drinking water for 4-10 days followed by western 
immunoblotting identified two lower molecular weight protein bands following 
drug treatment (as shown by the red arrows in figure 6.5). These bands were still 
present when the protein was incubated with 5 mM of the reducing agent DTT, 
indicating these molecular weight shifts are unlikely to result from SFN inducing 




Figure 6.4. H2O2-treated recombinant SHP2 migrates faster on a polyacrylamide 
gel.  
A representative immunoblot showing a proportion of recombinant SHP2 protein 
migrated faster on a polyacrylamide gel in a concentration dependent manner following 














6.3.4 SFN-induced inhibition of cardiac SHP2 is not reversed by treatment 
with DTT  
A fluorescence-based phosphatase activity assay showed cardiac SHP2 
immunoprecipitated from WT or NS mice was inhibited following 4-10-day 
treatment with 2.5 mg/ml SFX-01 in their drinking water (figure 6.6). Subsequent 
analyses with this assay revealed treatment of the inhibited SHP2 protein with 5 




Figure 6.5. A small portion of cardiac SHP2 migrates faster a polyacrylamide gel 
following SFX-01 treatment.  
A representative immunoblot showing SFN induces two molecular weight shifts in a 
small proportion of cardiac SHP2 (indicated by red arrows) following in vivo treatment of 
WT mice with 2.5 mg/ml SFX-01 in their drinking water for 4-10 days. Lower molecular 
weight protein bands were still present following treatment of immunoprecipitated SHP2 










6.3.5 SFN treatment induces a small mobility shift of cardiac SHP2 
following the PEG-switch assay 
PEG-maleimide treatment of SHP2 immunoprecipitated from cardiac tissue of 
WT or NS mice that received 2.5 mg/ml SFX-01 in their drinking water for 4 days 
induced a mobility shift in a small but detectable proportion of the protein on a 
polyacrylamide gel, as detected by a 5 kDa increase in molecular weight by 
western immunoblotting (Figure 6.7).  
 
Figure 6.6. SFX-01 treatment inhibits SHP2 phosphatase activity in vivo, which is 
not recovered by DTT.  
A fluorescence-based assay using cardiac SHP2 immunoprecipitated from WT or NS 
mice following 4-10-day treatment with 2.5 mg/ml SFX-01 in their drinking water revealed 

























6.3.6 In vivo treatment with SFX-01 reduces BIAM labelling of SHP2  
SHP2 immunoprecipitated from cardiac tissue of WT or NS mice following 4-day 
treatment with 2.5 mg/ml SFX-01 in their drinking water was incubated with BIAM. 
Figure 6.7. Analysis of the oxidative modification of cardiac SHP2 following in vivo 
treatment with SFX-01 using the PEG-switch method.  
An immunoblot showing a small but detectable increase in molecular weight of cardiac 
SHP2 immunoprecipitated from WT or NS mice who had received 2.5 mg/ml SFX-01 in 
their drinking water for 4 days when incubated with PEG-maleimide. (n = 4, *p<0.05 
versus untreated control). 
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Immunoblotting revealed reduced binding of BIAM to SHP2 in samples derived 




















6.3.7 In vivo SFX-01 treatment reduces PAA labelling of SHP2  
SHP2 immunoprecipitated from cardiac tissue of WT or NS mice following 4-day 
treatment with 2.5 mg/ml SFX-01 in their drinking water was incubated with 
Figure 6.8. BIAM labelling of cardiac SHP2 is reduced following SFN-induced 
inhibition of the protein.  
An immunoblot showing reduced binding of BIAM to SHP2 immunoprecipitated from 
cardiac tissue of WT or NS mice following 4-day treatment with 2.5 mg/ml SFX-01 in 
their drinking water. (n = 4, *p<0.05 versus water only control). 
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biotinylated-PAA. Far-western blotting revealed reduced binding of PAA to SHP2 


















6.3.8 Cysteine to serine SHP2 mutants were successfully generated  
Using site-directed mutagenesis to exchange a guanine for a cytosine, two single 
mutants and two double mutants in which cysteine (TGC (Cys333) or TGT 
(Cys367)) was changed to serine (TCC (Cys333) or TCT (Cys367)) in an SHP2 
Figure 6.9. PAA labelling of cardiac SHP2 is reduced following SFN-induced 
inhibition of the protein.  
A far-western blot showing reduced binding of PAA to SHP2 immunoprecipitated from 
cardiac tissue of WT or NS mice following 4-day treatment with 2.5 mg/ml SFX-01 in 
their drinking water. (n = 4, *p<0.05 versus water only control). 
209 
 
expression plasmid were generated. These included: Cys333Ser and Cys367Ser 
(generated from the WT plasmid) Cys333/367Ser (made from Cys333Ser plasmid) 
and Cys333/459Ser (made from Cys459Ser plasmid). Successful mutagenesis was 
confirmed using nucleotide sequencing and a subsequent alignment comparison 








Figure 6.10. Nucleotide sequence alignment of Cys333Ser SHP2 mutant with WT 
plasmid.   
Alignment of nucleotide sequences from WT SHP2 plasmid purchased from Addgene 
(top line) with Cys333Ser SHP2 plasmid generated by site-directed mutagenesis. The 
red highlighted # at position 998 represents exchange of a guanine for a cytosine, 
showing successful mutation of this cysteine (TGC) to a serine (TCC). The red sections 




Figure 6.11. Nucleotide sequence alignment of Cys367Ser SHP2 mutant with WT 
plasmid.   
Alignment of nucleotide sequences from WT SHP2 plasmid purchased from Addgene 
(top line) with Cys367Ser SHP2 plasmid generated by site-directed mutagenesis. The red 
highlighted # at position 1100 represents exchange of a guanine for a cytosine, showing 
successful mutation of this cysteine (TGT) to a serine (TCT). The red sections at the 




Figure 6.12. Nucleotide sequence alignment of Cys333/367Ser SHP2 mutant with WT 
plasmid.  
Alignment of nucleotide sequences from WT SHP2 plasmid purchased from Addgene 
(top line) with Cys333/367Ser SHP2 plasmid generated by site-directed mutagenesis. The 
red highlighted # at positions 998 and 1100 represents exchanges of guanine for 
cytosine, showing successful mutation of these cysteines (TGC or TGT) to serines (TCC 
or TCT). The red sections at the beginning and end of the Cys333/367Ser sequence 




Figure 6.13. Nucleotide sequence alignment of Cys333/459Ser SHP2 mutant with WT 
plasmid.  
Alignment of nucleotide sequences from WT SHP2 plasmid purchased from Addgene 
(top line) with Cys333/459Ser SHP2 plasmid generated by site-directed mutagenesis. The 
red highlighted # at positions 998 and 1388 & 1389 represents exchanges of cysteines 
to serines. The red sections at the beginning and end of the Cys333/459Ser sequence 
represent areas of primer binding. 
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6.3.9 SFN adducts proteins in a concentration-dependent manner in 
HEK293 cells  
To establish if SFN could adduct protein targets in a cultured cell line, HEK293 
cells were treated with 0-250 µM SFX-01 for 30 minutes. An increase in SFX-01 
concentration correlated with an increased abundance of protein-SFN adducts 


















Figure 6.14. SFN adducts proteins in HEK293 cells in a concentration-dependent 
manner.  
A representative immunoblot showing multiple proteins adducted by SFN in a 




6.3.10 Cellular transfection with SHP2 plasmid increases protein 
expression in an amount-dependent manner  
To determine if cellular transfection with increasing amounts of SHP2 plasmid 
correlated to an increase in the protein’s expression, HEK293 cells were 
transfected with 0-500 ng WT SHP2 plasmid and protein expression was 
analysed 24 hours later. Western immunoblotting revealed transfection with 
increasing amounts of SHP2 plasmid correlated with increased expression of the 

















Figure 6.15. Cellular transfection with higher amounts of SHP2 plasmid generates 
increased protein expression.  
A representative immunoblot showing increased expression of SHP2 protein in HEK293 
cells 24 hours post-transfection with increasing amounts of WT plasmid.   
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6.3.11 Cys459Ser SHP2 mutation does not affect plasmid transfection 
efficiency or protein expression  
Western immunoblotting showed SHP2 protein expression was comparable 24 
hours following transfection of HEK293 cells with 0-500 ng of plasmid regardless 
of whether WT or Cys459Ser plasmid was used, suggesting transfection efficiency 













6.3.12 The phosphatase activity of SHP2 is lost following mutation of the 
protein’s catalytic cysteine  
I next assessed if site-directed mutagenesis of cysteines within the active site of 
SHP2 affected the phosphatase’s activity. To do so, HEK293 cells were 
transfected with 500 ng of WT, Cys459Ser, Cys333Ser, Cys367Ser, Cys333/367Ser or 
Cys333/459Ser SHP2 plasmid followed by protein immunoprecipitation 24 hours 
Figure 6.16. SHP2 protein expression is unaffected by a Cys459Ser mutation.  
A representative immunoblot showing comparable SHP2 protein expression in HEK293 
cells 24 hours after transfection with WT or Cys459Ser SHP2 plasmid. 
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later. Western immunoblotting identified comparable protein expression in input 
samples as well as captured protein between all plasmids (figure 6.17 A). A 
subsequent fluorescence-based activity assay revealed that mutants which did 
not contain Cys459Ser, such as Cys333Ser, Cys367Ser or Cys333/367Ser, had 
comparable phosphatase activity to WT SHP2. However, mutation of Cys459 to 





























Figure 6.17. Cys459Ser SHP2 protein has no phosphatase activity  
 A) An immunoblot showing comparable SHP2 protein expression in HEK293 cells 24 
hours following transfection with 500 ng of WT, Cys459Ser, Cys333Ser, Cys367Ser, 
Cys333/367Ser or Cys333/459Ser plasmid. The amount of SHP2 protein immunocaptured 
from cells was also comparable between all plasmids. B) A fluorescence-based assay 
showing comparable SHP2 phosphatase activity between WT SHP2 and Cys333Ser, 
Cys367Ser and Cys333/367Ser mutants. The phosphatase activity of SHP2 was lost 
following mutation of the catalytic cysteine to a serine. (n = 5, *p<0.05 versus WT 
control).         
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6.3.13 Mutation of any cysteine pair within the active site of SHP2 results in 
retention of the SFN adduct  
I next explored if SFN that adducts to SHP2 in HEK293 cells can be removed 
from the phosphatase in a similar fashion to that observed in in vitro experiments. 
I hypothesised that retention of the electrophile upon SHP2 might be achieved if 
two of the triadic vicinal thiols in the catalytic domain of the phosphatase were 
mutated to serine. To assess this idea, HEK293 cells were transfected with 500 
ng WT, Cys333/367Ser or Cys333/459Ser SHP2 plasmid and 24 hours later cells were 
treated with 10 µM SFX-01.  Immunocapture followed by western immunoblotting 
revealed SFN adduction to WT, Cys333/367Ser or Cys333/459Ser SHP2 protein 2 
hours post-treatment with SFX-01 (figure 6.18). Whilst an SFN adduct was not 
detected 4 hours post-treatment on WT SHP2, adduction of the electrophile to 
SHP2 was observed at this time point on Cys333/367Ser or Cys333/459Ser protein. 
Immunoblotting also revealed comparable SHP2 protein expression 28 hours 






























Figure 6.18. SFN adduct upon SHP2 is stabilised following mutation of two active 
site cysteines.   
An immunoblot showing SFN adducted to WT, Cys333/367Ser or Cys333/459Ser SHP2 
immunoprecipitated from HEK293 cells 2 hours post-treatment with 10 µM SFX-01. The 
SFN adduct was not detected on WT SHP2 immunoprecipitated from HEK293 cells 4 
hours post-treatment with SFX-01 but was retained at this time point on Cys333/367Ser or 
Cys333/459Ser SHP2. (n = 3, *p<0.05 versus WT plasmid following 2-hour treatment with 
SFX-01).    
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6.3.14 dTNB is formed following incubation of TNB with SFX-01  
HPLC analysis following incubation of 50 µM TNB with 100 µM H2O2 identified a 
chromatographic peak at 11.27 minutes (figure 6.20 A), which was highly likely 
dTNB as this retention time was very similar to the retention time of an authentic 
standard, which was 11.21 minutes (figure 6.19 A). This showed oxidative 
modification of TNB by H2O2 could induce a disulfide between two TNB 
molecules. Further HPLC analysis identified a peak on the chromatogram at 
11.24 minutes following treatment of 50 µM TNB with 5 µM SFX-01 for 1-hour 
(figure 6.20 B). Again, this product was highly likely dTNB, as this retention time 
was very similar to the retention time of an authentic standard. The area under 
the hypothesised dTNB peak following incubation of SFX-01 with TNB increased 
following 24-hour incubation, whilst a peak at ~1.08 minutes, corresponding to 
TNB decreased (figure 6.20 C). A peak corresponding to SFN alone was also 
present on chromatograms from both the 1-hour and 24-hour incubation time 
points, as well as one at 10.87 minutes, which may represent TNB-SFN, although 
this could not be confirmed due to the lack of an authentic standard (figure 6.20 





































Figure 6.19. HPLC chromatograms of standards used for analysis.  
A) A dTNB standard. B) A TNB standard. C) A TNB standard left at room temperature 
for 24 hours. D) An SFX-01 standard. mAU represents absorbance using a UV detector 















Figure 6.20. HPLC chromatograms showing SFN incubation with TNB inducing 
dTNB formation.  
A) 50 µM TNB incubated with 100 µM H2O2 for 1-hour. B, C) 50 µM TNB incubated with 
5 µM SFX-01 for 1- or 24-hours respectively. mAU represents absorbance using a UV 
detector set at a wavelength of 320 nm. 
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6.3.15 The identification of a dithiolethione was not achieved by mass 
spectrometry following incubation of GSH with SFN  
To identify if SFN could induce dithiolethione formation between two GSH 
molecules, 10 µM L-SFN was incubated with 10 µM GSH for 8 hours or 100 µM 
GSH for 0.5, 3, 18 or 24 hours and the resultant reaction products were analysed 
by LC-MS/MS. Chromatograms from LC of experiments containing 100 µM GSH  
are shown here which identified 4 major products within all reaction mixtures with 
retention times of 5.94, 1.46, 1.35 and 2.86 minutes (figure 6.21). LC 
chromatograms were the same for experiments using 10 µM GSH. Following 
injection into the linear ion trap mass spectrometer, subsequent MS2 analysis 
performed on the first three peaks identified base peaks of 114.09, 179.03 + 
308.15 and 484.18 m/z which correspond to SFN, GSH and GSSH respectively 
as calculated from standards (figure 6.22 A-C). MS3 was performed on the final 
peak identifying a base peak of 136.03 m/z (figure 6.22 D). Analysis of the base 
peaks formed following MS2 and MS3 of this latter peak strongly suggest this 
reaction product was GSH-SFN (figure 6.23-6.25).  Analysis of atomic 
absorbance (AA) of LC peaks identified a time-dependent increase in the amount 
of GSH-SFN or GSSG formed (figure 6.26 and 6.27 A). A time-dependent 
increase in AA of GSSG was also seen following incubation of 10 µM GSH alone 
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Figure 6.21. Representative chromatograms from LC performed prior to linear ion 
trap MS.  
A) 10 µM L-SFN incubated with 100 µM GSH for 24 hours. B-E) Optimisation of 
chromatogram A showing peaks for different reaction products. B) A product with a 
retention time (RT) of 5.94 minutes. C) A product with a RT of 1.46 minutes. D) A product 
with a RT of 1.35 minutes. E) A product with a RT of 2.86 minutes. AA = atomic 
absorbance which represents amount of each product in the reaction. BP = 
corresponding base peak when analysed by MS which represents the most intense peak 
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Figure 6.22. Representative mass spectrums from linear ion trap tandem MS 
performed following the incubation of GSH with L-SFN. 
A-D) Mass spectrums from linear ion trap MS performed after LC following 24-hour 
incubation of 10 µm L-SFN with 100 µm GSH. A) MS2 performed at an m/z range of 50-
150 identifying a base peak of 114.09 m/z which corresponds to SFN. B) MS2 performed 
at an m/z range of 150-310 identifying base peaks of 179.03 m/z and 308.15 m/z which 
correspond to GSH. C) MS2 performed at an m/z range of 300-650 identifying a base 
peak of 484.14 m/z which corresponds to GSSG. D) MS3 performed at an m/z range of 




























Figure 6.23. Full MS performed following the incubation of GSH with L-SFN. 
A representative MS mass spectrum performed after LC following 24-hour incubation of 10 
µm L-SFN with 100 µm GSH at an m/z range of 100-1000. Peaks were identified which 
corresponded to SFN, GSH and GSSG as well as a new peak, circled in red, formed at an 

























Figure 6.24. MS2 performed following the incubation of GSH with L-SFN.  
A representative MS2 mass spectrum performed at an m/z range of 130-1000 following 
fragmentation of an unidentified MS mass spectrum peak formed at an m/z of 485.14 
after LC following 24-hour incubation of 10 µm L-SFN with 100 µm GSH. A new base 
peak was formed at an m/z of 356.07, likely SFN adducted to fragmented GSH. Two 
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Figure 6.25. MS3 performed following the incubation of GSH with L-SFN. 
A representative MS3 mass spectrum performed at an m/z range of 95-1000 following 
fragmentation of a base peak formed at an m/z of 356.07 following MS2 after LC following 
24-hour incubation of 10 µm L-SFN with 10 µm GSH. A new base peak was formed at an 
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Figure 6.26. The amount GSH-SFN formed following incubation of GSH with L-SFN 
increases in a time-dependent manner.  
AA of GSH-SFN calculated from LC performed following 24-hour incubation of 10 µm 
SFN with 100 µm GSH identified a time-dependent increase in abundance of GSH-SFN. 
Figure 6.27. The amount of GSSG formed following the incubation of GSH at room 
temperature increases in a time-dependent manner.  
A) AA of GSSG calculated from LC performed following 24-hour incubation of 10 µm 
SFN with 100 µm GSH identified a time-dependent increase in abundance of GSSG. B) 
AA of GSSG calculated from LC performed following 8-hour incubation of 10 µm SFN 




SFN can react with nucleophilic biomolecules and covalently adduct to them. 
Typically, covalent interactions are stable and permanent or only slowly reversed. 
Chapters 3 and 5 explained and characterised in detail the inhibition of 
recombinant or cardiac SHP2 phosphatase activity by SFN. Although 
unexpected, the in vitro studies showed that SFN initially forms an adduct with 
the recombinant SHP2, but over time the modification was lost. However, despite 
this loss of the electrophilic adduct, the phosphatase itself remained inhibited. 
Additional biochemical analyses outlined in this chapter showed that SFX-01 
treatment in vivo also induced inhibition of SHP2 phosphatase activity without a 
detectable SFN adduct. In this chapter, I sought to investigate the molecular 
mechanism of inhibition of SHP2 by SFN which occurs despite the absence of a 
stable covalent adduct that is initially observed when the phosphatase 
encounters this electrophile.  
As described in the general introduction, quantitative MS analysis of proteins 
immunocaptured with a pan-specific anti-SFN-protein antibody identified cardiac 
SHP2 as a significant target of the electrophile in vivo. For SHP2 to be 
immunocaptured, prior to its subsequent identification by MS, this required the 
presence of an SFN adduct to which the capture antibody binds. These initial 
studies involved an acute, large bolus dose of SFN being administered orally to 
mice, before isolation of the heart for analysis 3 hours later. The large dose and 
the relatively short exposure time would account for the presence of an SFN-
adduct, as it is likely a time point which captures the initial adduction of the 
electrophile. In the follow-up studies outlined above, this adduct was shown to be 
prone to removal or alteration such that is cannot be detected on SHP2 by the 
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anti-SFN antibody, depending on the conditions assessed. For example, the in 
vivo studies outlined in this chapter as well as those in chapter 3 were conducted 
using chronic 4-10-day exposure of mice to SFX-01 in their drinking water, which 
resulted in SHP2 inhibition, but no SFN adduct was detected. Considering the 
reversal of the adduct observed in the in vitro studies and the fact that the 
immunocapture-MS studies identified SHP2 as a target of the electrophile, it is 
rational to conclude SFN initially adducts, with the electrophile then somehow 
altered such that it cannot be detected but maintains the inhibition of the 
phosphatase. 
In line with the observations and considerations made in chapter 4, perhaps the 
loss of the adduct was achieved via trans-thiolation of the electrophile from SHP2 
to another cellular protein. Although this is considered unlikely, as typically this 
mechanism would result in phosphatase activity being regained as the catalytic 
thiolate would be reformed, whereas SHP2 remains inhibited following the loss 
of detectable SFN.  
Several studies have shown RTK stimulation is associated with an increase in 
cellular H2O2, which is necessary for maximal phosphorylation of the receptor 408. 
As H2O2 inhibits PTP activity, including SHP2, it has been strongly suggested this 
increase in oxidant levels serve as a regulatory mechanism to inhibit PTPs and 
optimise receptor phosphorylation 409 410 411 412 413. Indeed, H2O2-induced 
oxidative modification of SHP2 is observed following cellular stimulation with 
PDGF 414. PTPs with only one cysteine in their active domain, such as PTP1B, 
undergo oxidative modification of this residue forming a sulfenic acid intermediate 
415 416. To prevent higher irreversible oxidation to a sulfinic or sulfonic acid, the 
oxygen is rapidly eliminated via formation of a cyclic sulfenamide; a 5-atom ring 
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structure whereby a covalent bond is formed between the cysteine sulfur and the 
main chain nitrogen of an adjacent serine residue 417. This cysteine-serine link 
induces structural changes within the active site, exposing the oxidative 
modification to cellular reducing agents such as GSH and Trx, regenerating the 
active form of the enzyme 418. Some PTPs, on the other hand, have a second 
thiol within their active domain which is vicinal to their catalytic cysteine, including 
the cell cycle cdc25 phosphatases, low molecular weight-PTP and tensin 
homologue (PTEN). These are often termed ‘backdoor’ cysteines, and protect 
against irreversible oxidation of the sulfenic acid intermediate by facilitating the 
formation of an intramolecular disulfide 419 420 421. Again, the S-S bond can be 
readily reduced enabling reversibility of this inhibitory oxidative modification and 
so providing a mechanism of regulation. Crystallographic studies showed the 
active site of SHP2 contains two of these ‘backdoor’ cysteines at positions 333 
and 367, which are vicinal not only to the catalytic cysteine, Cys459, but also each 
other 43 422. The proximity of these cysteines was visualised using the computer 
software PyMol, as shown in figure 6.28. As mentioned, oxidative modification of 
the catalytic cysteine of SHP2 acts as an inhibitory mechanism to regulate 
downstream signalling pathways, such as MAPK and endothelin 1 423 424 425. 
Through biochemical and structural analysis, Machado et al propose a sulfenic 
acid intermediate forms upon Cys459, inhibiting the phosphatases catalytic 
activity, which is quickly resolved by Cys367 to form an intramolecular disulfide, 
maintaining inhibition of the protein as the catalytic cysteine is still unavailable 
426. A similar mechanism has been demonstrated for MAP kinase phosphatase 
3, whereby oxidative modification of its catalytic cysteine by H2O2 induces 
disulfide formation with one of the multiple cysteines distributed within the 
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proteins N- and C-terminal domains 427. Through kinetic and MS analysis, the 
Rudolph group demonstrate H2O2 treatment of SHP2 results in an inhibitory 
intramolecular disulfide between Cys333 and Cys367 142. Further to this, disulfide 
formation was not achieved following H2O2 treatment of Cys459Ser mutant protein 
142. They conclude a sulfenic acid intermediate is first formed upon Cys459 which 
is then resolved by the formation of an intramolecular disulfide with either Cys333 
or Cys367, with this S-S bond itself resolved by formation of a subsequent 
intramolecular disulfide between both of the ‘backdoor’ cysteines. They propose 
the resultant intramolecular disulfide acts as a protective mechanism to block 
Cys459 from further oxidative modification until itself is resolved by cellular 
disulfide reductases. Kinetic studies by the Gates group also support that SHP2 
phosphatase activity can be inhibited by an oxidant-induced intramolecular 
disulfide within the active domain of the protein 428.  
As demonstrated in chapter 3, in vitro treatment of recombinant SHP2 with low 
amounts of SFX-01 resulted in the formation of SHP2-SFN, followed by a loss in 
the detection of the electrophile adduct, even though inhibition of the 
phosphatase was maintained. With this in mind, I hypothesised that an SFN 
adduct may behave akin to a sulfenic acid intermediate, with this oxidative-like 
modification chemically transitioning to a secondary modification with resultant 
loss of the adduct, for example, an intramolecular disulfide. As shown in figure 
6.29, perhaps adduction of SFN at Cys459 causes initial inhibition of the 
phosphatase, with subsequent loss of the adduct due to a resolving 
intramolecular disulfide between Cys459 and Cys333 or Cys367 and maintaining 
inhibition as the catalytic cysteine remains unavailable. These ‘backdoor’ 
cysteines are also maintained in a reduced state and reside near the opening of 
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the active site pocket of SHP2. Perhaps due to its reactive nature, SFN can also 
adduct here. If so, inhibition of the phosphatase may occur due to reduced 
access of phosphorylated substrates to the catalytic cysteine of SHP2, firstly by 
the presence of an SFN adduct and subsequently due to a resolving intra-
disulfide between the backdoor cysteine (figure 6.29).  
Notably, in vitro treatment with high amounts of SFX-01 inhibited SHP2 
phosphatase activity with SFN adduction maintained over time. It was likely at 
such high abundance, SFN adducted the catalytic thiol as well as both ‘backdoor’ 
cysteines, making induction of an intramolecular disulfide within the active 










Figure 6.28. A PyMol image of the active site of SHP2.  
The catalytic cysteine of SHP2, Cys459, can be visualised as vicinal to Cys333 and Cys367 
separated by 12.47 Å and 9.93 Å respectively. Cys333 and Cys367 are also vicinal to each 
other, separated by 4.98 Å. 
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However, SFN-induced intramolecular disulfide formation would require a 
concomitant reductive modification of the electrophile, which has not been 
reported and chemically is considered an unlikely reaction. Further to this, H2O2-
treated recombinant SHP2 migrated faster on an acrylamide gel, consistent with 
intra-disulfide formation, whilst inhibited cardiac SHP2 immunoprecipitated 
following in vivo SFX-01 treatment did not. Lower molecular weight protein bands 
were detected by immunoblotting following in vivo treatment with SFX-01, 
however, the shift in molecular weight was much greater than would be 
anticipated for the formation of an intra-disulfide and was perhaps more likely a 
result of protein degradation. Also, as SFN-induced inhibition of cardiac SHP2 
could not be reversed following treatment with DTT, this helps to rule out the 
formation of a disulfide by the direct reaction of the electrophile with the 
phosphatase. The PEG-switch method utilises a step in which oxidised thiols are 
chemically reduced to generate free-thiols which are then labelled with PEG-
maleimide 429. Only minimal amounts of inhibited cardiac SHP2 became labelled 
with PEG-maleimide following in vivo treatment with SFX-01, indicating further 
the inhibitory modification induced by SFN was not reducible. These observations 
together are consistent with SHP2 inhibition by SFN not being mediated by an 
active site intramolecular disulfide.  
However, whilst cardiac SHP2 from control mice was labelled by the thiol-reactive 
BIAM reagent 430, it failed to label the protein when mice were administered SFX-
01 for 4 days. BIAM-labelling was carried out under acidic conditions, driving 
protonation of thiols with a higher pKa whilst maintaining the reduced, 
deprotonated state of the catalytic cysteine. The loss of BIAM labelling, therefore, 
indicates the catalytic cysteine was likely covalently modified, although to 
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reiterate, this is unlikely to be a disulfide or a simple SFN adduct. Further analysis 
showed that the cardiac SHP2 that was inhibited following 4-day exposure to 
SFX-01 was also no longer able to bind PAA, a dithiol cross-linking reagent which 
can form stable dithioarsine rings with protein vicinal thiols 431. This suggests 
SFN-induced inhibition of SHP2 was most probably driven by an oxidative-like 
modification of two cysteines within its active domain. To explore this further, 
cysteine to serine double SHP2 mutants were generated, Cys333/367Ser and 
Cys333/459Ser, leaving only one available cysteine within the catalytic domain. As 
expected, catalytic activity was maintained in the former mutant and diminished 
in the latter. Following a 2-hour treatment of cells with SFX-01, SFN was detected 
upon WT, Cys333/367Ser or Cys333/459Ser SHP2. This is consistent with SFN 
adducting not only to the catalytic cysteine, but also one or both of the ‘backdoor’ 
cysteines. In line with in vitro experiments, the WT SHP2-SFN adduct was lost 
over time. In contrast, a stable adduct was maintained upon either double mutant. 
Again, this is consistent with SFN adducting and inhibiting SHP2, but with this 
modification subsequently reacting with an adjacent cysteine to form another 
oxidative modification that underlies the sustained inhibition of the phosphatase. 
The chemical nature of this inhibitory modification is an important consideration 
and the subject of the discussion below. 
Zhang et al have demonstrated a cyclocondensation reaction between ITCs and 
the vicinal dithiol-containing compound 1,2-benzenedithol 432. This results in the 
formation of a 1,3-dithiole-2-thione cyclic dithiolethione compound, with this 
stable and non-reducible modification occurring between the two vicinal thiols of 
1,2-benzenedithol and release of R-substituted nitrogen as an amine. In addition, 
this group showed ITC metabolites, including GSH-SFN, cysteinylglycine-, 
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cysteine- as well as N-acetylcysteine-conjugates can also undergo the same 
cyclocondensation reaction with 1,2-benzenedithol and produce a dithiolethione 
433. Perhaps SFN or its metabolites induced dithiolethione formation, which is 
characterised by two sulfur atoms linked by a C=S group, between two of the 
vicinal thiols in the active domain of SHP2 as shown in figure 6.30. Such an 
adduct would likely not be detectable by the anti-SFN antibody developed in-
house and used throughout these studies, as the dithiolethione is markedly 
different than an SFN adduct from a structural standpoint. This would initially 
involve adduction of SFN at Cys459 or either of the ‘backdoor’ cysteines, followed 
by nucleophilic attack by a second vicinal thiol at the same carbon atom of SFN 
as outlined in figure 6.31. A resulting sulfur-containing dithiolethione 
condensation product would then be formed between either Cys459 and a 
backdoor cysteine, driving inhibition as the catalytic cysteine is unavailable, or 
between the backdoor cysteines themselves, likely preventing access of 






Figure 6.29. A proposed scheme of SFN-induced intra-disulfide formation.        
Following adduction of SFN to the catalytic cysteine of SHP2, or either of the proteins 
‘backdoor’ cystines, resolution of the adduct by an intramolecular disulfide would 
maintain inhibition of the phosphatase. This considered mechanism is unlikely to occur 




The premise that SFN may induce such a dithiolethione ‘chemical bridge’ 
between two thiols is supported by the generation of dTNB following incubation 
of TNB with L-SFN. However, MS analysis is required to confirm this idea, which 
was underway at the time of writing.  
Incubation of SFN with GSH resulted in a time-dependent increase in the 
formation of a compound which did not correspond to SFN, GSH or GSSG 
standards when analysed by MS. Subsequent MS3 analysis of this compound 
and review of resultant base peaks strongly suggested the formation of GSH-
SFN and not two GSH molecules linked via a dithiolethione. Nevertheless, the 
formation of GSH-SFN is the first step required for dithiolethione formation. A 
higher relative abundance of GSH or longer incubation times may increase the 
probability that a second tripeptide would contact and react with GSH-SFN to 
facilitate dithiolethione formation. Although perhaps generation of such a 
chemical structure between two thiol-containing proteins is unlikely and requires 
two thiols to be in close vicinal proximity, such as those found within the active 
domain of SHP2.  
Enzymatic digestion and analysis by MS of SHP2 exposed to SFN would be a 
rational way of assessing whether a dithiolethione condensation product does 
indeed form within the active site of the protein to causatively mediate 
phosphatase inhibition by this electrophile. The presence of a mass correlating 
to two peptide chains each containing Cys459, Cys333 or Cys367 linked by the 




















Figure 6.30. A proposed scheme for SFN-induced dithiolethione formation 
between two vicinal thiols within the active site of SHP2.                
Following the adduction of SFN to either the catalytic cysteine of SHP2 or either of the 
‘backdoor’ cysteines, a cyclocondensation reaction may occur which forms a 
dithiolethione product, which may be responsible for maintaining the SFN-induced 
inhibition of the phosphatase.  
Figure 6.31. A possible cyclocondensation reaction of an SFN adduct with vicinal 
thiols within the active site of SHP2. 
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7 Summary and Conclusion 
7.1 Summary  
This thesis reports a comprehensive investigation of the inhibition of the PTP 
SHP2 by the electrophilic ITC SFN. Specific focus is given to how this inhibition 
may prevent the development and progression of phenotypes that NS patients 
present with.  
Cysteine thiols with a low pKa value, meaning they can ionise and so become 
reactive at cellular pH, are often involved in the catalytic activity of a protein, 
either through regulation of tertiary structure or conducting the catalytic events 
themselves. These thiolate moieties are susceptible to modification by oxidants, 
with their negative charge also enabling nucleophilic reactions with electrophilic 
compounds such as SFN, which mediates covalent adduction of such 
compounds that potentially modulates the activity and function of the protein.  
It is established SFN adducts to cysteines of multiple proteins and the biological 
effects of these interactions accumulatively contribute to the cancer prevention 
activity of the electrophile, which has sparked an increase in studies investigating 
this ITC 25 33 209 434 435. A comprehensive review of these events is not in the 
scope of this thesis; however, they include the induction of anti-inflammatory and 
pro-apoptotic responses 436. Data also suggest that SFN may alter epigenetic 
changes which occur in some cancers, which reverse aberrant changes in gene 
transcription through mechanisms of histone deacetylase inhibition, global 
demethylation, and microRNA modulation 437.  
SFN can also induce an antioxidant response by adducting cysteines within 
KEAP1 32 438 439. Upregulation of antioxidants in non-pathological conditions can 
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prevent homeostatic failures caused by an increase in cellular oxidants 440 441. 
Cancer cells, on the other hand, can activate the Warburg effect, which increases 
the conversion of glucose-6-phosphate into ribulose-5-phosphate and generates 
NADPH 442 443 444. NADPH is required for GSH production as well as some 
disulfide reductase systems and protects tumour cells from apoptosis by 
counteracting oxidative stress and facilitating DNA damage repair 445. Therefore, 
whilst cancer has been considered a result of increased oxidative stress, its 
treatment with antioxidants would contribute to the already increased reducing 
conditions of these cells. Indeed, successful cancer therapies such as 
radiotherapy or doxorubicin induce oxidant production 446 447 448 449. Although 
SFN induces an antioxidant response, the electrophile also adducts proteins at 
moieties which are otherwise modified by oxidants and therefore can mimic them. 
Further to this, whilst SFN rapidly conjugates with GSH which delineates the drug 
from modifying other cellular proteins, this interaction also prevents the reductive 
capabilities of the GSH 22. Therefore, even though SFN upregulates the 
production of antioxidants, their own adduction by the electrophile may alleviate 
this antioxidant response. Indeed, a number of human clinical trials have been 
performed with rigour using SFN with published study results indicating potential 
therapeutic benefit 450 451. The electrophile is structurally simple and small which 
underlies the ability of SFN to interact with and adduct to a large number of 
protein targets, some of which likely remain unknown, and may induce multiple 
biological events. Nevertheless, human clinical trials using SFN as well as SFX-
01, a chemically stabilised variant of SFN in which it is encapsulated in α-
cyclodextrin ring structure, to our knowledge, have shown little, if any, undesired 
biological outcomes at the therapeutic concentrations used 91 92 93 94 95 104 105. 
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Therefore, despite SFN adducting multiple cellular proteins, as can be observed 
with the anti-SFN antibody used throughout this study, the electrophile is 
tolerated and is considered a tractable therapeutic. 
Identifying protein targets of SFN may help define the impact of the electrophile 
on biological systems. For example, if SFN attenuates the development of a 
specific pathology, its adduction to one of the protein targets identified may 
mediate, at least in part, its therapeutic actions. Another prospect following target 
identification is it may highlight proteins which are functionally altered during 
pathological conditions, and perhaps their adduction by SFN may be therapeutic 
by modifying their function.  
Indeed, as reported herein, immunoprecipitation of SFN adducted to protein 
cysteines following in vivo treatment with SFX-01 and subsequent proteomic 
analysis identified cardiac SHP2 as a significant target. This then leads to the 
rational hypothesis, as considered below, that SFN likely adducts to the catalytic 
cysteine in SHP2 to inhibit it and so may prove therapeutic in pathologies 
mediated by hyperactivation of this phosphatase.  
Point mutations in Ptpn11, the gene which encodes SHP2, are causative of all 
phenotypes present in the multisymptomatic developmental disorder NS, 
including abnormal facial features, short stature and in some cases 
myeloproliferative disease 65 69 137 452. NS is also the most common non-
chromosomal pathology associated with congenital heart defects, which include 
pulmonary valve stenosis and atrial and ventricular septal defects, among others 
66 67. 12 missense, germline mutations of the Ptpn11 gene have been identified 
in NS patients, which all cause hyperactivation of SHP2 phosphatase activity. 
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Hyperactivation of the phosphatase, either because of a gain-of-function 
mutation in Ptpn11, or other dysregulated signalling events, have also been 
characterised in multiple cancers. Hyperactive SHP2 phosphatase activity is 
therefore associated with the initiation and progression of both pathologies. This 
has driven significant pharmacological programmes developing inhibitors of 
SHP2. Whilst some of these compounds are potent inhibitors of the phosphatase, 
their interaction with other off-target proteins has been observed which may 
cause undesired biological functions, and studies are still needed to evaluate 
potential side-effects of these interactions in vivo 79 82 83.  
Due to the electrophilicity of SFN, it was logical to assume its adduction to SHP2 
was occurring at the proteins negatively charged thiolate moiety of its catalytic 
cysteine, Cys459. This nucleophilic thiolate is required for the phosphatase activity 
of SHP2, so it was anticipated that adduction of SFN would inhibit its ability to 
dephosphorylate substrates. Consistent with this, incubation of recombinant 
SHP2 with SFX-01 resulted in adduction of SFN and concentration-dependent 
inhibition of the phosphatase’s activity. A rational implication was that SFN may 
be therapeutic in scenarios in which hyperactive SHP2 activity contributes to 
pathogenesis, such as NS. A logical next step was, therefore, investigating SFN-
mediated inhibition of the phosphatase in an NS mouse model engineered to 
express a heterozygous gain-of-function mutation, D61G/+, found to cause the 
highest level of SHP2 activation in human patients 452.  
Biochemical analysis showed multiple proteins had been adducted by SFN in a 
variety of tissue types in WT or NS mice that received an acute (30-minute) bolus 
dose of high amounts of SFX-01. This data provided evidence of successful 
absorption of SFN and transport into tissue cells when SFX-01 was used as the 
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source of the electrophile. Even so, western immunoblot analysis of SHP2 
immunoprecipitated from cardiac tissue of WT or NS mice following this 30-
minute treatment with SFX-01 did not show an SFN adduct upon the protein. 
Follow-up assays also revealed no inhibition of the phosphatase’s activity. 
Perhaps 30-minute post-treatment with SFX-01 was too short to allow adduction 
of the electrophile to cardiac SHP2, as initial identification of SFN as a target of 
the phosphatase in vivo was achieved using MS analysis 3-hours post-treatment 
with the drug.  
Data from biochemical analysis of SHP2 phosphatase activity following 
incubation of recombinant protein with varying concentrations of SFX-01 for 
different lengths of time showed chronic treatment with lower amounts of the 
electrophile caused the same level of inhibition of the phosphatase as when 
incubated with higher amounts of the drug for a much shorter duration. This 
corroborated studies by the Darley-Usmar group which show continual treatment 
with low amounts of an electrophilic compound over time caused its accumulative 
adduction to target proteins which was not achieved through short-term treatment 
regimens 144. Indeed, immunoprecipitation of cardiac SHP2 and analysis of its 
activity revealed the phosphatase was inhibited following chronic 4-, 7- or 10-day 
treatment with low amounts of SFX-01 continually in the drinking water of WT or 
NS mice, which otherwise was not seen following acute treatment with a high 
bolus amount of the drug. 
An increase in the phosphorylation of STAT5, an essential protein of the GH 
signalling pathway which acts downstream of SHP2 was also seen, which was 
logically assumed as a direct effect of SFN-induced inhibition of the phosphatase. 
The Ras/ERK pathway is another signalling event which occurs downstream of 
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SHP2, with activation of the phosphatase leading to increased phosphorylation 
of the kinase. It was therefore anticipated that inhibition of SHP2 by SFN would 
decrease phosphorylation of ERK, which has previously been observed with 
other inhibitors of the phosphatase 79 82 83. In fact, chronic in vivo SFX-01 
treatment caused an increase in ERK phosphorylation in cardiac tissue of WT 
mice, even though SHP2 was inhibited. This was perhaps a consequence of 
adduction of SFN to proteins other than SHP2 and this data corroborates 
previous studies showing an increase in ERK phosphorylation following 
treatment with the electrophile in a variety of cell types 151 152 153 154. Therefore, 
whilst SFN-induced inhibition of the phosphatase may reduce SHP2-mediated 
stimulation of the Ras/ERK signalling pathway, this might be outweighed by the 
electrophile adducting and modifying the activity of other proteins also 
responsible for regulating ERK activity, such as MAPK phosphatase 1, a 
phosphatase known to dephosphorylate ERK.  
As SFN-induced inhibition of SHP2 in vivo had been characterised it was rational 
to explore if this was therapeutic in the D61G/+ NS mouse model. Although the 
underlying mechanism remains unclear, NS patients and this mouse model often 
present with different phenotypes which can also be present with different 
severities 73. For example, short stature, cranial defects and myeloproliferative 
disease are present in 100 % of D61G/+ offspring, however, the severity of these 
phenotypes differs between mice. On the other hand, 100 % of homozygous foeti 
and 50 % of those that are heterozygous for this mutation die mid-gestation due 
to severe cardiac complications, as well as skeletal defects and liver necrosis, 
whilst the remainder are born with no cardiac phenotype. As these developmental 
defects are caused by a single gain-of-function SHP2 mutation, it was rational to 
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assume a reduction of the phosphatase’s activity by SFN could improve cardiac, 
skeletal and liver development in foeti with NS that would otherwise succumb to 
embryonic lethality. To address this, foeti were exposed to SFN via treatment of 
heterozygous parents with SFX-01 in their drinking water before and throughout 
pregnancy. Whilst foeti from WT/WT breeding pairs were unaffected, the number 
of homozygous or heterozygous neonates born from NS breeding pairs following 
treatment with SFX-01 was unfortunately decreased compared to water only 
controls. Analysis of the activity of SHP2 immunoprecipitated from NS neonates 
which were born from these studies revealed no inhibition of the phosphatase. 
Further biochemical analysis showed SFX-01 increased foetal ERK 
phosphorylation. As SHP2 is a positive regulator of the Ras/ERK signalling 
pathway, hyperactivation of the phosphatase causes an increase in 
phosphorylation of the kinase. Thorough studies conducted by the Neel group 
allowed the conclusion that this basal increase in ERK phosphorylation in the 
D61G/+ NS mouse model is causative of the majority of developmental defects 
occurring in these mice 78. It was, therefore, logical to assume that SFN increased 
ERK phosphorylation even higher in NS foeti which may have exacerbated 
developmental defects. Therefore, this may be responsible for the decreased 
number of heterozygous offspring born following foetal treatment with the 
electrophile. Nevertheless, it remains rational that reduction of SHP2 
phosphatase activity would improve the embryonic development of NS foeti and 
further studies of this nature should be conducted using inhibitors of the protein 
that do not result in elevated ERK phosphorylation.  
Activation of ERK leads to the stimulation of downstream transcription factors 
which positively regulate cell growth and proliferation. Although SFN-induced 
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increases in ERK phospho-activation induces undesired biological events during 
the embryonic development of NS foeti, perhaps this increase in the activity of 
this kinase in neonates would be therapeutic towards the growth retardation 
these patients present with. SFN-induced increase in STAT5 phosphorylation, 
which positively regulates the GH signalling pathway, may also contribute to an 
increase in growth of these patients post-birth.  
SHP2 regulates multiple stages of white blood cell production 345 346 347. It is 
therefore unsurprising that some children with NS develop JMML, characterised 
by increased myeloid and monocyte cell count which can sometimes escalate 
into leukaemia 68 69. Similarly, adult NS mice presented with elevated white blood 
cell count, myeloid cell count (myeloproliferative disease) and splenomegaly. As 
well as regulating the proliferation and survival of white blood cell progenitor cells, 
SHP2 has more specific roles in granulocyte lineage determination i.e. the 
differentiation of premature white blood cells into neutrophils, basophils or 
eosinophils 352 353. Flow cytometry analysis lead to the novel observation that 
increased myeloid cell count in the blood, spleen and bone marrow of NS mice 
was predominantly an increase in the number of neutrophils. As this 
myeloproliferative phenotype was caused by a single gain-of-function mutation 
in SHP2, it was logical to determine if SFN-induced inhibition of the phosphatase 
would prevent increased myeloid cell production and assess if this could be 
sustained over time. To do so, adult NS mice were treated with SFX-01 for a 
prolonged 10-week period which indeed reduced the phosphatase activity of the 
protein and fewer mice developed a myeloproliferative phenotype of the blood, 
spleen and bone marrow. Further analysis of this data showed that neutrophils 
were the predominant cell-type that was lower in SFX-01-treated NS mice 
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compared to water only controls. A reduction in the growth of the spleen of NS 
mice, which was monitored using ultrasound, was also observed when mice were 
treated with the drug. As the splenomegaly observed in NS mice is attributed in 
part to an increase in spleen-residing myeloid cells, it is logical that the reduced 
spleen growth observed when treated with SFX-01 was due to fewer circulating 
and spleen-residing myeloid cells. Perhaps if children with NS were treated with 
SFN or SFX-01 from birth this may prevent the hyperproliferation of myeloid cells 
and lower the incidence of JMML and leukaemia in these juvenile patients.  
The electrophilicity of SFN allows covalent interaction of the electrophile with 
nucleophilic moieties. Therefore, it was rationally anticipated that inhibition of 
SHP2 following 4-day or 10-week treatment with SFX-01 was caused by a stable 
SFN adduct upon the protein, likely at its negatively charged catalytic cysteine. 
However, immunoprecipitation of SHP2 and biochemical analysis showed that 
whilst the electrophile induced inhibition of the phosphatase’s activity, an SFN 
adduct was not seen upon the protein. It was logical to assume SFN did adduct 
SHP2 which inhibited the protein, due to its identification as a target of the 
electrophile being achieved by MS following immunoprecipitation of proteins with 
an SFN adduct. However, perhaps this adduction was followed by loss or 
chemical modification of SFN, which maintained the inhibition of the 
phosphatase.   
Spontaneous reversal of thiol-SFN adducts has previously been documented 176 
177. The Uchida group have also shown using MS analysis that as well as the 
spontaneous reversal of a GSH-SFN interaction, the electrophile can actively 
transfer directly from GSH to a second thiol-containing protein 182, a mechanism 
termed ‘trans-thiolation’ in this document. Data presented herein also shows 
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trans-thiolation of SFN can occur and perhaps this mechanism enables the 
electrophile to exert biological effects on multiple proteins in vivo. 
It is likely spontaneous reversal of a thiol-SFN interaction or trans-thiolation of 
the adduct regenerates a reactive form of the thiol that the electrophile was 
initially adducted to and as a result, the protein would regain its activity. As 
inhibition of SHP2 phosphatase activity was maintained following the loss of the 
SFN adduct it was perhaps unlikely removal of the electrophile occurs via either 
of these mechanisms. Indeed, biochemical assays carried out using the 
alkylating agent iodoacetamide, which readily adducts cysteine thiolates, showed 
chronic in vivo treatment with SFX-01 inhibited the phosphatase activity of SHP2 
and although no SFN adduct was detected, iodoacetamide could no longer 
adduct at the protein’s catalytic cysteine. To our knowledge, this is the first 
evidence that functional modifications of a protein’s activity induced by adduction 
of SFN can be maintained following the loss of the adduct. To reiterate, these 
data supported the hypothesis that loss of the SFN adduct from SHP2 was not 
achieved by spontaneous reversal of the electrophile-protein interaction or trans-
thiolation, as these mechanisms would regenerate a reactive thiolate at the 
protein’s catalytic cysteine.  
Analysis of the crystal structure of SHP2 showed the catalytic cysteine within its 
phosphatase domain is in proximity to two other vicinal cysteines, creating a triad 
of reactive thiols. Cellular oxidants can modify the catalytic cysteine of SHP2 and 
inhibit its phosphatase activity. One of the two other cysteines which reside 
nearby form an intramolecular disulfide with the catalytic cysteine which reduces 
the oxidative modification and prevents further irreversible oxidation. The 
catalytic cysteine remains unreactive as its thiolate moiety is participating in the 
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intramolecular disulfide and the proteins phosphatase activity remains inhibited 
until the bond itself is reduced by cellular disulfide reductases. PAA is a dithiol 
cross-linking agent which can only bind to proteins when two protein vicinal thiols 
are in a reduced and reactive state. Biochemical analysis utilizing this compound 
showed it could no longer adduct to cardiac SHP2 from mice following 4-day 
treatment with SFX-01, suggesting at least two of the three vicinal thiols within 
the phosphatase domain of SHP2 were impeded, which to reiterate was not by 
stable SFN adducts. To our knowledge, we have shown the novel observation 
that SFN can induce an oxidative-like modification between two vicinal thiols 
when adduction of the electrophile occurs at a cysteine which resides close to at 
least one other reactive thiol.  
 Whilst induction of an inhibitory intramolecular disulfide within the active domain 
of SHP2 following adduction of the electrophile to the proteins catalytic cysteine 
was a logical assumption, this would require a reductive modification of the 
electrophile upon its resolution from the catalytic cysteine, which chemically is 
unlikely. Data produced from biochemical assays carried out following the 
reduction of protein disulfide bonds, including the PEG-switch, also suggested 
that SFN-induced inhibitory modification of at least two of the three vicinal thiols 
within the phosphatase domain of SHP2 was not an intramolecular disulfide.  
It has been shown that a dithiolethione can be formed by a series of condensation 
reactions following adduction of SFN to a dithiol containing compound, which is 
characterised by two sulfur atoms linked by a C=S chemical structure  433.  It is 
rational to suggest SFN adducts the catalytic cysteine of SHP2, with a second 
vicinal thiol within the protein’s phosphatase domain subsequently attacking the 
electrophile, which results in the formation of a dithiolethione condensation 
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product between two of the vicinal thiols within the proteins active domain. 
Inhibition of SHP2 would, therefore, be induced by initial adduction of the 
electrophile at the catalytic cysteine, with the resolution of the adduct to a 
dithiolethione maintaining the inhibition of the phosphatase as the catalytic 
cysteine remains unreactive. The resultant dithiolethione epitope would be 
undetectable by the antibody developed in-house against SFN adducted to 
protein cysteines and may explain why no SFN adduct is detected upon inhibited 
SHP2 following chronic in vitro and in vivo treatment with the electrophile.  
Biochemical data collected following the treatment of different SHP2 cysteine to 
serine mutants in HEK293 cells with SFX-01 suggested SFN can adduct at the 
two thiols vicinal to the catalytic cysteine, as well as Cys459 itself. Further to this, 
when two of the three cysteines within the phosphatase domain of SHP2 were 
mutated to a serine, a stable SFN adduct was seen following treatment with SFX-
01, which was otherwise resolved when two reactive thiols were present. This 
data suggests SFN can also adduct SHP2 at one of the two non-catalytic vicinal 
thiols within its phosphatase domain, with either the catalytic cysteine or the 
second vicinal thiol inducing dithiolethione formation. If the latter were to occur, 
inhibition of SHP2 would be achieved as this chemical structure would prevent 
access of phosphorylated substrates to the catalytic cysteine of the protein.  
7.2 Conclusion 
Sulforaphane, or a formulation in clinical development called SFX-01, inhibits the 
catalytic activity of SHP2; a protein-tyrosine phosphatase which when 
hyperactivate causatively mediates multiple cancers as well as Noonan 
syndrome. Sulforaphane-mediated inhibition of SHP2 is not achieved by a stable 
adduct but likely by induction of a chemical modification of two vicinal thiols within 
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the protein’s catalytic domain, perhaps the formation of a dithiolethione. SFN-
induced inhibition of the phosphatase reduced the incidence of myeloproliferative 
disease and splenomegaly in a mouse model for Noonan syndrome which is 
genetically engineered with a single gain-of-function SHP2 mutation, D61G/+. 
Chronic treatment with SFN is well tolerated in adult mice and is a promising 
candidate to utilize as a therapy regarding not only Noonan syndrome but also 
cancers which are driven by hyperactivation of SHP2.  
7.3 Future work  
It is evident from published studies and data presented herein that SFN 
modulates multiple biological effects in vivo, due to the electrophile adducting 
many cell signalling proteins. An increase in ERK phosphorylation in NS embryos 
may have contributed to their embryonic lethality following foetal treatment with 
SFX-01. Therefore, identifying how SFN induced an increase in ERK 
phosphorylation may be beneficial if the electrophile is to be pursued as a therapy 
for this pathology. It was rational to speculate the increase in ERK 
phosphorylation occurred due to adduction of SFN to MAPK phosphatase 1 
which would inhibit its ability to dephosphorylate ERK. This could be assessed 
using the same biochemical techniques utilised to analyse the activity of SHP2 
and its adduction by SFN throughout this research project. It has also been 
shown SFN can increase the levels of cellular ROS, which in turn can promote 
ERK phosphorylation in an IGF1 dependent manner. Assays such as with 
dichlorodihydrofluorescein diacetate 453, dihydroethidium 454 or the HyPer probe 
455 could be used to analyse cellular levels of ROS following treatment with SFN.  
Perhaps treatment of NS foeti post-gastrulation would inhibit SHP2 phosphatase 
activity and allow correct development of the later stages of embryogenesis, 
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whilst the anticipated increase in ERK phosphorylation may not compromise key 
stages of foetal development as they would have already occurred. Although 
preliminary data suggested treatment of NS foeti post-gastrulation also 
decreased the number of NS neonates born, a definitive conclusion should not 
be taken from these studies. The date of conception was predicted by the 
presence of a vaginal plug and these studies should be repeated whereby 
gastrulation is confirmed using ultrasound, as perhaps SFN was administered 
before gastrulation was fully completed.  
During this research project, the pharmaceutical company Novartis documented 
a potent (IC50 = 71 nM), highly selective and orally bioavailable small-molecule 
SHP2 inhibitor named SHP099 456. SHP099 stabilises the closed and auto-
inhibited conformation of SHP2 by concurrently binding the interface of the N- 
and C-terminal SH2 domains and the PTP domain, thereby driving inhibition 
through an allosteric mechanism. Not only does SHP099 suppress downstream 
Ras/ERK signalling, but the drug has no significant effect on the biological activity 
of a panel of PTPs or kinases tested. However, subsequent studies by Sun et al 
identified SHP2 with gain-of-function mutations within the N- or C-SH2 domains, 
including D61G/+, were resistant to inhibition by SHP099 in cultured GM-CSF-
dependent TF 1 myeloid cells 457. Nevertheless, in vivo treatment with the drug 
has not been documented. Treatment of NS foeti with SHP099 may inhibit SHP2 
with no off-target biological effects, which may prevent the defects in embryonic 
development which are caused by hyperactivation of the phosphatase.  
NS patients are born with short stature and this growth retardation continues into 
adulthood. Studies reported herein showed that combined treatment of SFN and 
GH potentiated activation of the JAK/STAT GH signalling pathway compared to 
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GH alone, which is currently the only therapy available for NS patients. Therefore, 
as activation of ERK stimulates cell growth and proliferation, perhaps 
upregulation of this pathway as well as GH signalling using a combined SFN/GH 
therapy post-birth would be therapeutic in increasing the growth of NS patients 
and reducing the incidence of short stature.  
Proteomic analysis showed SFN adducted to Cys93 of Hgb β during chronic in 
vivo exposure to SFX-01. Published studies showed NO also readily adducts at 
Cys93 223 224. Although elucidation of the role and mechanism of NO binding at 
this reactive cysteine is still ongoing, it is suggested this interaction aids 
regulation of NO-mediated vessel relaxation and therefore blood pressure 225 226 
227. SFN adduction to Cys93 may impede binding and transport of NO to areas 
where vascular relaxation is required which could prevent NO-mediated 
regulation of blood pressure, and such physiological changes could be monitored 
in mice treated with SFX-01 using telemetry probes. However, the stoichiometry 
of the SFN modification at Hgb β Cys93 may be very low that it is functionally 
insignificant. 
Finally, observations from biochemical studies suggest SFN adduction at the 
catalytic cysteine of SHP2 inhibits its phosphatase activity, which is maintained 
by the induction of an oxidative-like modification between at least one other 
vicinal thiol, with resultant loss of a detectable adduct. This SFN-induced 
modification may be the formation of a dithiolethione condensation product and 
proteomic analysis using LC-MS/MS could be used to look for this theoretical 
modification. Following in vivo treatment with SFN, immunoprecipitation of SHP2 
and enzymatic digestion of the protein may preserve a dithiolethione between 
two peptides that each contain one of the discussed vicinal thiols. The 
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identification of a product with a mass that corresponds to two of these thiol-
containing peptides plus the mass of the dithiolethione would strongly suggest 
SFN induced such a chemical structure between two vicinal thiols within the 
phosphatase domain of SHP2. Such an analysis would also allow the 
identification of the two protein cysteines involved in this potential post-
translational modification that may mediate inhibition of SHP2 in vivo during 
chronic exposure to SFX-01. If a dithiolethione is indeed present, the generation 
of an antibody to detect this specific epitope may aid identification of other vicinal 
thiol-containing proteins which are also inhibited or activated by this chemical 
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